

AE

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/69, C07F 5/02, 5/04	A1	(11) International Publication Number: WO 95/09634 (43) International Publication Date: 13 April 1995 (13.04.95)
(21) International Application Number: PCT/US94/11280 (22) International Filing Date: 6 October 1994 (06.10.94)	(74) Agents: KERR, Don, M. et al.; The du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).	
(30) Priority Data: 08/133,251 7 October 1993 (07.10.93) US 08/139,445 20 October 1993 (20.10.93) US	(81) Designated States: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).	Published <i>With international search report.</i>	
(72) Inventors: GALEMMO, Robert, Anthony, Jr.; 3039 Stump Hall Road, Collegeville, PA 19426 (US); ABELMAN, Matthew, Mark; Apartment 3312, 873 Stevens Avenue, Solana Beach, CA 92075 (US); AMPARO, Eugene, Cruz; 107 Garfield Avenue, West Chester, PA 19380-4509 (US); FEVIG, John, Matthew; 987 Church Road, Lincoln University, PA 19352-9349 (US); KNABB, Robert, Madara; 14 Sullivan Chase Drive, Avondale, PA 19311-9349 (US); MILLER, William, Henry; 1909 Coventry Lane, Glen Mills, PA 19342 (US); PACOPSKY, Gregory, James; 510 Polk Street, Raleigh, NC 27604 (US); WEBER, Patricia, Carol; 107 Marshall Bridge Road, Kennett Square, PA 19348-2705 (US).		
(54) Title: ELECTROPHILIC PEPTIDE ANALOGS AS INHIBITORS OF TRYPSIN-LIKE ENZYMES		
(57) Abstract		
This invention relates to electrophilic dipeptide analogs conjugated to an <i>N,N</i> disubstituted α -amino acid as inhibitors of trypsin-like serine protease enzymes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Title

Electrophilic Peptide Analogs As Inhibitors of Trypsin-Like Enzymes

5 Cross-reference to Earlier Filed Applications

This application is a continuation-in-part of U.S. Patent Application Serial Number 08/139,445 filed October 20, 1993.

10

Field of the Invention

This invention relates generally to electrophilic peptide analogs as inhibitors of trypsin-like serine
15 proteases. These compounds are dipeptides in which an electrophilic derivative of an α -amino acid is conjugated with an *N,N*-disubstituted α -amino acid. The *N,N*-disubstituted α -amino acid conjugates of the electrophilic amino acid analog are derivatives of an amino acid where
20 the α -amino group is alkylated and acylated or diacylated to give alicyclic or cyclic substituents. The electrophilic functional groups used to derivatize these peptide analogs are: boronic acids and their esters, α -mono- and α -perhaloketones, aldehydes, vicinal di- and
25 tricarbonyl compounds, α -mono- and α -dihalo- β -ketoesters.

Background of the Invention

Electrophilic tripeptide analogs
30 containing the ((D-phenylalanyl)prolyl)- arginyl- sequence are well known as effective inhibitors of the trypsin-like serine protease thrombin. H-(D)Phe-Pro-ArgCH₂Cl was first reported by Kettner and Shaw (*Thromb. Res.* 14, 969 (1979)) to be a selective but irreversible inhibitor of human
35 thrombin. A number of studies looking for alternatives to the electrophilic P₁ argininechloromethylketones that would

yield a reversible protease inhibitor have been reported. Bajuez et al. (*Folia Haematol.* 109, s. 16 (1982)) found the corresponding aldehyde, D-phenylalanyl-prolyl-arginal, to be a reversible thrombin inhibitor with a $K_i = 75$ nM for human thrombin. The nitrile analog, D-phenylalanyl-prolyl-NHCH((CH₂)₃NHC(=NH)NH₂)-CN, was found to be substantially less potent with a $K_i = 700$ nM (Kaiser et al., *Pharmazie* 46, 128 (1991)). A retroamide inhibitor, with the D-phenylalanyl-prolyl- sequence and 2-(4-guanidinophenylalanyl)-N-acetyl-2,2-difluoroethylamine substituting for an electrophilic arginine derivative, is a good inhibitor with a K_i of 70 nM for thrombin (Altenburger and Schirlin, *Tetrahedron Lett.* 32, 7255 (1991)). Cheng et al. claim that the substitution of racemic diphenyl 1-amino-4-methoxybutylphosphonate for an electrophilic arginine derivative gives very good inhibitors with a $K_i = 4.8$ nM (*Tetrahedron Lett.* 32, 7333 (1991)). Iwanowicz et al. (*Bioorgan. Med. Chem. Lett.* 2, 1607 (1992)) has studied the efficacy of (D-phenylalanine)prolyl- conjugated to -NHCH((CH₂)₄NH₂)CH(OH)CO₂Me and -NHCH((CH₂)₄NH₂)C(=O)CO₂Me derivatives. The most effective inhibitor of human thrombin reported to date is the boropeptide acetyl-D-phenylalanyl-prolyl-boro arginine with a $K_i = 0.041$ nM (Kettner et al., *J. Biol. Chem.* 265, 18289 (1990)). Walker et al. (*Biochem. J.* 230, 645 (1985)) published a comparative study of irreversible thrombin inhibitors based on the D-phenylalanyl-prolyl-argininyl sequence confirming the earlier report by Kettner and Shaw (1979). H-(D)Phe-Pro-ArgCH₂Cl was found to be the most effective inhibitor ($K_i = 25$ nM) while replacing the D-phenylalanine with 4-amino-D-phenylalanine or ω -benzoyl-D-lysine gave less active analogs. Compounds in development include -(prolyl)arginal derivatives with a variety of unusual P₃ amino acids including D-N-methylphenylglycine, Boc-D-fluorophenylglycine as well as constrained cyclized

derivatives of D-phenylglycine and D-phenylalanine (Shuman et. al., J. Med. Chem. 36, 314 (1993)). Balasubramanian et al. (J. Med. Chem. 36, 300 (1993)) has reported an extensive study of replacements for the P₃ D-phenylalanine
5 of D-phenylalanyl-prolyl-arginal and found the dihydrocinnamoyl group to be effective, although somewhat less potent.


Patent disclosures in this area have centered around suitably protected peptides composed of natural and
10 unnatural amino acids. In U.S. Patent No. 5,187,157 DuPont Merck has disclosed peptides comprised of C-terminal boronic acid derivatives of lysine, ornithine and arginine as reversible inhibitors of trypsin-like serine proteases, as well as a series of boropeptides active as elastase
15 inhibitors in U.S. Patent No. 4,499,082. In European Patent Application EP 471 651 A2 Sandoz disclosed borolysine and boroarginine peptide analogs containing at least one unnatural hydrophobic α -amino acid substituted with groups such as the trimethylsilyl- or naphthyl-. In
20 U.S. Patent No. 5,106,948 was disclosed a series of boropeptides that are effective as cytotoxic agents. In PCT Application WO 92/07869, Thrombosis Research Institute has disclosed tripeptide analogs containing a P₂ proline and an unnatural disubstituted amino acid at P₃. A variety
25 of electrophilic and non-electrophilic α -amino acid analogs were claimed as suitable P₁ substituents. Tripeptide antithrombotic agents limited to α -alkyl and α -aryl or heteroaryl substituted glycines at P₃ conjugated to -(prolyl)arginal were been disclosed by Lilly (European
30 Patent Application EP 479 489 A2). Marion Merrell Dow disclosed a series of activated electrophilic ketone analogs of peptidase substrates useful for inhibiting serine-, carboxylic acid- and metallo- proteolytic enzymes; compounds are peptides composed of suitably protected α -
35 amino acids conjugated to an electrophilic ketone

derivative of an α -amino acid (European Patent Applications EP 417 721 A2, EP 364 344 A2, EP 363 284 A2, EP 195 212 A2). Astra has disclosed a series of α -((trifluoroethyl)oxymethyl)-arginine tripeptides (European Patent Application EP 0 530 167 A). Georgia Tech Research Corporation disclosed peptidyl ketoamides, -ketoacids and -ketoesters as inhibitors of serine and cysteine proteases (WO 92/12140). Boehringer Ingelheim disclosed a series of trifluoromethyl- and α,α -difluoromethyl- β -ketoesterpeptide derivatives as elastase inhibitors (EP 0 369 391 A2).

The present invention concerns dipeptides which contain an electrophilic derivative of an α -amino acid at P_1 conjugated with an N,N -disubstituted α -amino acid at P_2 . The electrophilic functional groups used to derivatize the P_1 amino acid analog are: boronic acids and their esters, α -mono- and α -perhaloketones, vicinal di- and tricarbonyl compounds, and α,α -dihalo- β -ketoesters. The N,N -disubstituted α -amino acids are derivatives of an amino acid other than proline where the α -amino group is alkylated and acylated or diacylated to give alicyclic or cyclic substituents. As a result these compounds are found to have the advantage of an improved toxicological profile as well as the selectivity and inhibition activity for thrombin required for a useful therapeutic agent.

Summary of the Invention

[1] There is provided by this invention a compound of the formula (I):




(I)

or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein:

R¹ is

- a) -(C₁-C₁₂ alkyl)-X,
- b) -(C₁-C₁₂ alkenyl)-X, or
- c)



X is

- a) halogen,
- 15 b) -CN,
- c) -NO₂,
- d) -CF₃,
- e) -NH₂,
- f) -NHR²,
- 20 g) -NHC(=NH)R²,
- h) -NHC(=NH)NHOH,
- i) -NHC(=NH)NHNH₂,
- j) -NHC(=NH)NHCN,
-) -NHC(=NH)NHR²,
- 25 j) -NHC(=NH)NHCOR²,
- k) -C(=NH)NHR²,
- l) -C(=NH)NHCOR²,
- m) -C(=O)NHR²,


- n) $-\text{CO}_2\text{R}^2$,
- o) $-\text{OR}^2$,
- p) $-\text{OCF}_3$,
- q) $-\text{S}(\text{O})_r\text{R}^2$,
- 5 r) $-\text{SC}(=\text{NH})\text{NHR}^2$, or
- s) $-\text{SC}(=\text{NH})\text{NHC}(=\text{O})\text{R}^2$;

R^2 is

- a) hydrogen, or
- 10 b) $\text{C}_1\text{-C}_4$ alkyl;


R^3 is:

- a) $-\text{C}(=\text{O})\text{-aryl}$,
- b) $-\text{C}(=\text{O})\text{-(CH}_2)_p\text{-CR}^6\text{R}^7\text{-(CH}_2)_q\text{-aryl}$,
- 15 c) $-\text{C}(=\text{O})\text{-(C}_2\text{-C}_5\text{ alkenyl)}\text{-aryl}$,
- d) $-\text{C}(=\text{O})\text{-W-CR}^8\text{R}^9\text{-aryl}$, with the proviso that W cannot be a bivalent oxygen atom,
- e) $-\text{C}(=\text{O})\text{-CR}^8\text{R}^9\text{-W-(CH}_2)_r\text{-aryl}$, with the proviso that W cannot be $-\text{NR}^4\text{-}$ or $-\text{NC}(=\text{O})\text{R}^4\text{-}$,
- 20 f) $-\text{C}(=\text{O})\text{-heteroaryl}$,
- g) $-\text{C}(=\text{O})\text{-(CH}_2)_p\text{-CR}^6\text{R}^7\text{-(CH}_2)_q\text{-heteroaryl}$,
- h) $-\text{C}(=\text{O})\text{-(C}_2\text{-C}_5\text{ alkenyl)}\text{-heteroaryl}$,
- i) $-\text{C}(=\text{O})\text{-W-CR}^8\text{R}^9\text{-heteroaryl}$,
- j) $-\text{C}(=\text{O})\text{-CR}^8\text{R}^9\text{-W-(CH}_2)_r\text{-heteroaryl}$, with the proviso
- 25 that W cannot be $-\text{NR}^4\text{-}$ or $-\text{NC}(=\text{O})\text{R}^4\text{-}$,
- k) $-\text{C}(=\text{O})\text{-heterocycle}$,
- l) $-\text{C}(=\text{O})\text{-(CH}_2)_p\text{-CR}^6\text{R}^7\text{-(CH}_2)_q\text{-heterocycle}$,
- m) $-\text{C}(=\text{O})\text{-(C}_2\text{-C}_5\text{ alkenyl)}\text{-heterocycle}$,
- n) $-\text{C}(=\text{O})\text{-W-CR}^8\text{R}^9\text{-heterocycle}$,
- 30 o) $-\text{C}(=\text{O})\text{-CR}^8\text{R}^9\text{-W-(CH}_2)_r\text{-heterocycle}$, with the proviso that W cannot be $-\text{NR}^4\text{-}$ or $-\text{NCOR}^4\text{-}$,
- p) $-\text{C}(=\text{O})\text{-(CH}_2)_t\text{-adamantyl}$,
- q) $-\text{C}(=\text{O})\text{-(CH}_2)_t\text{-(C}_5\text{-C}_7\text{ cycloalkyl)}$,
- r) $-\text{C}(=\text{O})\text{-(CH}_2)_t\text{-W-(C}_5\text{-C}_7\text{ cycloalkyl)}$,
- 35 s)



(CH₂)_t-aryl, wherein aryl is limited to phenyl,


t)



5


(CH₂)_p-W-(CH₂)_q-aryl, wherein aryl is limited to phenyl,

u)




10


v)



w)




x)




5 with the proviso that R^{13} cannot be $-N(C_1-C_4 \text{ alkyl})_2$
when A is $-C(=O)R^{14}$,

y)




10


z)



aa)




bb)




5

cc)




dd)




10

ee)




ff)




5

gg)




hh)




10

ii)




CH=CH-aryl, wherein aryl is limited to phenyl;

- jj) $-(C(=O)-(CR^8R^9)-NR^{11'})_v-R^{11}$;
 5 kk) $-(C(=O)-(CR^8R^9)-NR^{11'})_v-C(=O)R^{11}$;
 ll) $-(C(=O)-(CR^8R^9)-NR^{11'})_v-C(=S)R^{11}$;
 mm)




nn)




10

- oo) $-C(=O)-(CR^8R^9)-NHS(O)_xR^8$;
 pp)



15

qq)



R^4 and R^5 are independently selected at each occurrence from the group consisting of:

- a) hydrogen,
- b) C₁-C₄ alkyl,
- c) -(C₁-C₄ alkyl)-aryl, or
- d) C₅-C₇ cycloalkyl;

5

R⁶, R⁷, R⁸ and R⁹ are independently selected at each occurrence from the group consisting of:

- a) hydrogen,
- b) C₁-C₄ alkyl,
- 10 c) C₁-C₄ alkoxy,
- d) aryl,
- e) -(C₁-C₄ alkyl)-aryl,
- f) -(C₁-C₄ alkyl)-heterocycle,
- g) -O-aryl,
- 15 h) -(CH₂)_p-CO₂R⁴,
- i) R⁶ and R⁷ can be taken together to form a (C₂-C₇) alkyl, or
- j) R⁸ and R⁹ can be taken together to form a (C₂-C₇) alkyl;

20


R¹⁰ is:

phenyl, wherein phenyl is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₇-C₁₅ alkylaryl, C₇-C₁₅ alkoxyaryl, methylenedioxy, 25 -NO₂, -CF₃, -SH, -S(O)_r-(C₁-C₄ alkyl), CN, -OH, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -NHCOR⁴, -(CH₂)_p-CO₂R⁴, -C(=NH)NHR⁴, -NHC(=NR⁴)R⁴, -NHC(=NH)NHR⁴;


30 R¹¹ is:

- a) C₁-C₄ alkyl,
- b) C₃-C₆ cycloalkyl,
- c) -OR⁴,
- d) -NR¹⁵R¹⁶,
- 35 e) -NC(=O)R¹⁵R¹⁶,


- f) $-\text{NR}^{15}\text{C}(=\text{O})\text{OR}^4$,
 g) aryl,
 h) $-(\text{C}_1\text{-C}_4 \text{ alkyl})\text{-aryl}$,
 i) heteroaryl,
 5 j) $-(\text{C}_1\text{-C}_4 \text{ alkyl})\text{-heteroaryl}$,
 k) $-(\text{C}_1\text{-C}_4 \text{ alkyl})\text{-CO}_2\text{R}^4$,
 l) heterocycle,
 m) $-(\text{C}_1\text{-C}_4 \text{ alkyl})\text{heterocycle}$,
 n)




o)



p)




q)



r)


, or




R³ and R¹¹, when taken together to form a ring bonded to the nitrogen:

5

a)




b)





10



c)



d)




5



10





R¹¹ is independently selected at each occurrence from the group consisting of:

- 5 a) hydrogen;
- b) C₁-C₄ alkyl
- c) -OR⁴
- d) -NR¹⁵R¹⁶
- e) -NC(=O)R¹⁵R¹⁶
- 10 f) -NR¹⁵C(=O)OR⁴
- g) aryl,
- h) -(C₁-C₄ alkyl)-aryl,
- i) heteroaryl,
- j) -(C₁-C₄ alkyl)-heteroaryl,
- 15 k) -(C₁-C₄ alkyl)-CO₂R⁴,
- l) heterocycle,
- m) -(C₁-C₄ alkyl)heterocycle,

20 R¹³ is independently selected at each occurrence from the group consisting of:

- a) hydrogen
- b) halogen,
- c) C₁-C₄ alkyl,
- 25 d) C₁-C₄ alkoxy,
- e) methylenedioxy,
- f) -NO₂,
- g) -CF₃,
- h) -SH,
- 30 i) -S(O)_r-(C₁-C₄ alkyl),

- j) -CN,
k) -OH,
l) -NH₂,
m) -NH(C₁-C₄ alkyl),
5 n) -N(C₁-C₄ alkyl)₂,
o) -NHC(=O)R⁴, or
p) -(CH₂)_p-CO₂R⁴;
q) -C(=NH)NHR⁴
r) -NHC(=NR⁴)R⁴
10 s) -NHC(=NH)NHR⁴

R¹⁴ is:

- a) -CF₃,
b) -CHF₂,
15 c) -CH₂F,
d) -CH₂Cl,
e) -C(=O)OR⁴,
f) -C(=O)NR¹⁵R¹⁶,
g) -C(=O)R⁴,
20 h) -C(=O)COOR⁴,
i) -C(=O)C(=O)NR¹⁵R¹⁶,
j) -C(=O)C(=O)R⁴,
k) -CY³Y⁴COOR⁴,
l) -CY³Y⁴C(=O)NR¹⁵R¹⁶, or
25 m) -CY³Y⁴C(=O)R⁴;


R¹⁵ and R¹⁶ are independently selected at each occurrence from the group consisting of:

- a) hydrogen,
30 b) C₁-C₄ alkyl,
c) -(C₁-C₄ alkyl)-aryl, where aryl is defined above,
d) C₅-C₇ cycloalkyl, or
e) phenyl, unsubstituted or substituted by R¹³,
f) C₁-C₄ alkoxy;


35

R¹⁵ and R¹⁶ taken together to form a ring can also include:

a)



b)



5

R¹⁷ is:

a) hydrogen,

b) C₁-C₄ alkyl,

10 c) aryl, wherein aryl is defined above,

d) -(C₁-C₄ alkyl)-aryl, wherein aryl is defined above,

or

e) C₅-C₇ cycloalkyl;

15 R¹⁸ is:

a) hydrogen,

b) -(C₁-C₅) alkyl, or

c) -(C₁-C₅) haloalkyl,

d) -(C₁-C₅) alkoxy;

20

R¹⁹ is:

a) hydrogen,

b) -(C₁-C₅) alkyl,

c) halo, or

25 d) -(C₁-C₅) haloalkyl,

e) -NO₂,

f) -NR⁴R⁵,

g) -CN,

h) -(C₁-C₅) alkoxy;

30

R²⁰ is

- a) hydrogen; or
- b) $-N^2$ with amine protecting;

A is:

- 5 a) $-BY^1Y^2$, or
- b) $-C(=O)R^{14}$,
- c) $C(OH)R^{14}R^{18}$;

W is:

- 10 a) $-O-$,
- b) $-S(O)_r-$,
- c) $-NR^4-$, or
- d) $-NC(=O)R^4-$;

15 Y^1 and Y^2 are:

- a) $-OH$,
- b) $-F$,
- c) $-NR^4R^5$,
- d) C_1-C_8 alkoxy, or

20 when taken together Y^1 and Y^2 form:

- e) a cyclic boron ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O,
- 25 f) a cyclic boron amide where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O,
- g) a cyclic boron amide-ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O;
- 30

Y^3 and Y^4 are

- 35 a) $-OH$ or

b) -F;

n is 0 or 1;

p is 0 to 3;

5 q is 0 to 4;

r is 0 to 2;

t is 1 to 3;

u is 1 to 4;

v is 1 to 17.

10

Specifically preferred compounds of this invention include:

Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn-C10H16 HCl

15 Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn(CH=NH)-C10H16 HCl

Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn(CH=NH)-OH HCl

Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroArg(CH3)-C10H16 HCl

Hydrocinnamoyl-[N-(N(CH3)2)-Gly]-boroLys-C10H16 HCl

20 Hydrocinnamoyl-[N-(N(CH3)2)-Gly]-boroLys-OH HCl

Hydrocinnamoyl-[N-(N(CH3)2)-Gly]-boroOrn-C10H16 HCl

Hydrocinnamoyl-[N-(N(CH3)2)-Gly]-boroOrn(CH=NH)-C10H16 HCl

Methanesulfonyl-Sar-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl

Methanesulfonyl-Sar-[N-(Phenethyl)-Gly]-boroLys-OH HCl

25 Methanesulfonyl-Gly-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl

Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl

Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-boroLys-OH HCl

30 Hydrocinnamoyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl

Hydrocinnamoyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-OH HCl

Succinyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl

- Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroLys-
OH HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroLys-
C10H16 HCl
- 5 Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroLys-
OH HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-
boroOrn(CH=NH)-OH HCl
- Hydrocinnamoyl-[N-(2,2-(Diethyl)-Phenethyl)-Gly]-boroLys-
10 C10H16 HCl
- Hydrocinnamoyl-Sar-Lys[C(=O)-C(=O)-OH]
(2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH2]3-Br]-
C10H16
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH2]4-Br]-
15 C10H16
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroIrg-C10H16 HBr
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH2]3-N3]-
C10H16
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-borohomoIrg-C10H16 HBr
- 20 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH2]4-N3]-
C10H16
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroOrn-C10H16 HCl
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-borohomoArg-C10H16 HCl
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroArg-C10H16 HCl
- 25 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroOrn(CH=NH)-C10H16
HCl
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroLys(CH=NH)-C10H16
HCl
- 2-Benzyl-(N-Benzyl)-Sar-boroLys-C10H16 HCl
- 30 2-Thiophenyl-Benzoyl-Sar-boroLys(CH=NH)-C10H16
- 2-(Thiophenyl)-Benzoyl-Sar-boroIrg-C10H16 HBr
- 2-(Thiophenyl)-Benzoyl-Sar-boroOrn-C10H16 HCl
- 2-(Thiophenyl)-Benzoyl-Sar-boroOrn(CH=NH)-C10H16 HCl
- Pinanediol N-{N-methyl-N-[2-(Thiophenyl)-Benzoyl]Sar}-1-
35 amido-5-thiocyanatobutane boronate

- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroLys-C10H16 HCl
 Acetyl-Gly[N-(2-(Benzyl)-Benzyl)]-boroLys-C10H16 HCl
 Pinanediol N-(N-methyl-N-[2-(pyrrol-1-ylmethyl)-Benzyl]glycyl)-1-amido-5-aminopentaneboronate,
 5 hydrochloride salt
 N-(N-methyl-N-[2-(pyrrol-1-ylmethyl)-Benzyl]glycyl)-1-amido-5-aminopentaneboronic acid, hydrochloride salt
 2-(2-(Trifluoromethyl)-Benzyl)-Benzoyl-Sar-Lys-C(=O)-NHNH2 2 HCl
 10 2-(Benzyl)-Benzoyl-Sar-Lys-C(=O)-NHNH2 2 HCl
 [3-(Trifluoromethyl)-Benzyl]-Benzoyl-Sar-boroLys-C10H16 HCl
 3-(3-(Chloro)-Benzyl)-Benzoyl-Sar-boroLys-C10H16 HCl
 Hydrocinnamoyl-Sar-Lys(Z)-C(=O)-O-(CH2)2-NH(Z)
 Hydrocinnamoyl-Sar-Lys-C(=O)-O-(CH2)2-NH2 2 HCl
 15 Hydrocinnamoyl-Sar-Lys(Z)-C(=O)-OCH3
 Hydrocinnamoyl-Sar-Lys-C(=O)-OCH3 HCl
 Hydrocinnamoyl-Sar-Lys-C(=O)-CH3 HCl
 Hydrocinnamoyl-Sar-Lys(Z)-H
 Hydrocinnamoyl-Sar-NHCH(CH2OH)(CH2)4-NH(Z)
 20 Hydrocinnamoyl-Sar-NHCH(CH2OH)(CH2)4-NH2
 Hydrocinnamoyl-Sar-Lys[CH(OH)(OCH3)-C(=O)-OCH3] HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn-C10H16 HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys-OH HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn(CH=NH)-OH HCl
 25 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn(CH=NH)-C10H16 HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys(CH=NH)-C10H16 HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys(CH=NH)-OH HCl
 30 Phenoxyacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl
 Thiophenacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl
 Phenoxyacetyl-[N-(Cyclopropyl)-Gly]-boroLys-OH HCl
 Thiophenacetyl-[N-(Cyclopropyl)-Gly]-boroLys-OH HCl
 Hydrocinnamoyl-[N-(N-(Methyl)-Phenyl)-Gly]-boroLys-C10H16
 35 HCl

- Hydrocinnamoyl-[N-(N-(Methyl)-Phenyl)-Gly]-boroLys-OH HCl
 Hydrocinnamoyl-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-ClO₂H₁₆
 HCl
 Glutaryl-[N-(Phenethyl)-Gly]-boroLys-OH HCl
 5 Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-ClO₂H₁₆
 Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-
 ClO₂H₁₆ HCl
 Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-OH
 Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-
 10 OH HCl
 Boc-Asp-[N-(Phenethyl)-Gly]-boroLys-ClO₂H₁₆
 Boc-Glu-[N-(Phenethyl)-Gly]-boroLys-ClO₂H₁₆
 Boc-Glu(OCH₃)-[N-(Phenethyl)-Gly]-boroLys-ClO₂H₁₆ HCl
 Boc-Glu-[N-(Phenethyl)-Gly]-boroLys-OH
 15 Hydrocinnamoyl-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-OH HCl
 Methanesulfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-
 ClO₂H₁₆ HCl
 Methanesulfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-OH
 HCl
 20 Hydrocinnamoyl-[N-(Succinyl)-Gly]-boroLys-ClO₂H₁₆
 Hydrocinnamoyl-[N-(Methyl Succinyl)-Gly]-boroLys-ClO₂H₁₆ HCl
 Succinyl-[N-(Phenethyl)-Gly]-boroLys-OH
 Methyl Succinyl-[N-(Phenethyl)-Gly]-boroLys-OH HCl
 Glutaryl-[N-(Phenethyl)-Gly]-boroLys-ClO₂H₁₆
 25 Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys-ClO₂H₁₆ HCl
 Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys-OH HCl
 Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroArg-
 ClO₂H₁₆ HCl
 Hydrocinnamoyl-[N-(2-(Cyclopentyl)-Phenethyl)-Gly]-boroLys-
 30 ClO₂H₁₆ HCl
 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroArg-OH HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroLys-
 ClO₂H₁₆ HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroOrn-
 35 ClO₂H₁₆ HCl

- Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroArg-C10H16 HCl
- Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroOrn(CH=NH)-C10H16 HCl
- 5 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroArg-OH HCl
- Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroOrn(CH=NH)-OH HCl
- Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroOrn-C10H16 HCl
- 10 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-[2-(3,5-dimethylphenyl)-ethyl]-Gly]-boroOrn-C10H16 HCl
- 15 Hydrocinnamoyl-[N-[2-(3,5-dimethylphenyl)-ethyl]-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-[2,2-(Dimethyl)-2-(3,5-dimethylphenyl)-ethyl]-Gly]-boroArg-C10H16 HCl
- Hydrocinnamoyl-[N-[2,2-(Dimethyl)-2-(3,5-dimethylphenyl)-ethyl]-Gly]-boroOrn(CH=NH)-C10H16 HCl
- 20 Hydrocinnamoyl-[N-[2-(3,5-dimethylphenyl)-ethyl]-Gly]-boroArg-C10H16 HCl
- Hydrocinnamoyl-[N-[2-(3,5-dimethylphenyl)-ethyl]-Gly]-boroOrn(CH=NH)-C10H16 HCl
- 25 Hydrocinnamoyl-[N-(Cyclohexyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(Cyclohexyl)-Gly]-boroLys-OH HCl
- Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn(CH=NH)-C10H16 HCl
- 30 Hydrocinnamoyl-[N-(2-(Cyclopentyl)-Phenethyl)-Gly]-boroOrn(CH=NH)-C10H16 HCl
- Hydrocinnamoyl-[N-(2-(Cyclopentyl)-Phenethyl)-Gly]-boroArg-C10H16 HCl
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₃)]Gly-boroLys-OH
- 35 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂)₂Ph]Gly-boroLys-OH

- [N-(C(O)(CH₂)₂Ph)-N-Ph]Gly-boroLys-OH
 [N-(C(O)N(CH₃)CH₂Ph)-N-Ph]Gly-boroLys-OH
 [N-(C(O)Ph-3-CH=CHPh)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)Ph-3-CH₂CH₂Ph)-N-(CH₃)]Gly-boroLys-OH
 5 [N-(C(O)Ph-3-SPh-2-OCH₃)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)Ph-2-CH₂Ph-2-Ph)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)Ph-4-CH₂Ph)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)Ph-2-CH₂Ph)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-boroLys-OH
 10 [N-(C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)CH₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph)-N-(i-C₃H₇)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph)-N-(N(CH₃)₂)]Gly-boroLys-OH
 15 [N-(C(O)CH₂Ph)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₃Ph)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)Ph)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph)-N-CH₂Ph]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-boroLys-OH
 20 [N-(C(O)(CH₂)₂Ph-4-Cl)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-4-CH₃)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-4-OCH₃)-N-(CH₃)]Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)(CH₂)₂Ph)-N-(CH₂)₂Ph]Gly-boroLys-C₁₀H₁₆
 25 [N-(C(O)(CH₂)₂Ph)-N-Ph]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)N(CH₃)CH₂Ph)-N-Ph]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)Ph-3-CH=CHPh)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)Ph-3-CH₂CH₂Ph)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)Ph-3-SPh-2-OCH₃)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 30 [N-(C(O)Ph-2-CH₂Ph-2-Ph)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)Ph-4-CH₂Ph)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)Ph-2-CH₂Ph)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 [N-(C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆
 35 [N-(C(O)CH₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-boroLys-C₁₀H₁₆

- $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
5 $[N-(C(O)Ph)-N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
10 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)CH_3)(D)-Phe[N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(SO_2CH_3)(D)-Phe[N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-boroArg-OH$
15 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-OH$
20 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroOrn(N-$
 $\text{methylamidino})-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-$
 $C_{10}H_{16}$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroOrn(N-$
25 $\text{methylamidino})-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-boroOrn(formamidino)-OH$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroOrn(formamidino)-OH$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-boroOrn(formamidino)-OH$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-boroOrn(formamidino)-$
30 OH
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-boroOrn(formamidino)-C_{10}H_{16}$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroOrn(formamidino)-$
 $C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-boroOrn(formamidino)-C_{10}H_{16}$

- [N-(-C(O)(CH₂)₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH(i-C₃H₇)Ph)]-Gly-boroLys-OH
 5 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3-CH₃)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3-CH₃)]-Gly-boroLys-OH
 10 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3-NO₂)]-Gly-boroLys-OH
 15 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3-NO₂)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph-3,5-(CH₃)₂)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3,5-(CH₃)₂)]-Gly-boroArg-OH
 20 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroOrn(formamidino)-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3-CH₃)]-Gly-boroOrn(formamidino)-OH
 25 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3-CH₃)]-Gly-boroOrn(formamidino)-OH

Illustrative of the preferred compounds of this invention are the following:

- 30 [N-(-C(O)(CH₂)₂Ph)-N-(C₂H₅)]Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(N-C₃H₇)]Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(OH)]Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-boroLys-OH
 35 [N-(-C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-boroLys-OH

- $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-boroLys-OH$
5 $[N-(C(O)(OCH_2)Ph)](D)-Phe[N-(CH_3)]Gly-boroLys-OH$
 $[N-(C(O)(OCH_2)Ph)](D)-Phe[N-(CH_3)]Ala-boroLys-OH$
 $[N-(C(O)(OCH_2)Ph)](D)-Phe[N-(Ph)]Gly-boroLys-OH$
 $[N-(C(O)(OCH_2)Ph)](D)-Phe[N-(CH_2Ph)]Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-boroLys-C_{10}H_{16}$
10 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-boroLys-C_{10}H_{16}$
15 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-boroLys-C_{10}H_{16}$
 $(N-CO_2CH_2Ph)[Leu-Ser(O^tBu)-Asn]_4-[N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
[Sequence No. 1]
20 $(H)-[Leu-Ser(O^tBu)-Asn]_4-[N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
[Sequence No. 2]
 $(H)-[Leu-Ser-Asn]_4-[N-(CH_3)]Gly-boroLys-C_{10}H_{16}$ [Sequence No. 3]
 $[N-(C(O)(OCH_2)Ph)](D)-Phe[N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
25 $[N-(C(O)(CH_3)](D)-(\beta\text{-cyclohexyl})Ala[N-(CH_3)]Gly-boroLys-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Lys-CF_3$
30 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Lys-CF_3$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Lys-CF_3$
35 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Lys-CF_3$

- $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Lys-CF_3$
5 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Lys-CF_3$
10 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBOc)]Gly-Lys-CF_3$
15 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Lys-CF_3$
20 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Lys-CF_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Lys-CF_3$
25 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Lys-OCH_3$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Lys-OCH_3$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Lys-OCH_3$
30 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Lys-OCH_3$
35 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Lys-OCH_3$

- $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Lys-OCH_3$
5 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Lys-OCH_3$
10 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Lys-OCH_3$
15 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Lys-OCH_3$
20 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Lys-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Lys-CO_2CH_3$
25 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
30 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Lys-CO_2CH_3$
35 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Lys-CO_2CH_3$

- $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Lys-CO_2CH_3$
5 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-Lys-CO_2CH_3$
10 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Lys-CO_2CH_3$
15 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Lys-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Lys-CO_2CH_3$
20 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-boroArg-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-boroArg-OH$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-boroArg-OH$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-boroArg-OH$
25 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-boroArg-OH$
30 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-boroArg-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-boroArg-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-boroArg-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-boroArg-OH$
35 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-boroArg-OH$

- $[N-(-C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-boroArg-OH$
5 $[N-(-C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-boroArg-OH$
 $[N-(-C(O)CH_2Ph)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-boroArg-OH$
10 $[N-(-C(O)Ph)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-boroArg-OH$
15 $[N-(-C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-boroArg-OH$
 $[N-(-C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-Ph]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
20 $[N-(-C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
25 $[N-(-C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-boroArg-C_{10}H_{16}$
30 $[N-(-C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(OH)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-boroArg-C_{10}H_{16}$
35 $[N-(-C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-boroArg-C_{10}H_{16}$

- $[N-(-C(O)(CH_2)_2Ph)-N-(NHBOc)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)CH_2Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
5 $[N-(-C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)Ph)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-CH_2Ph)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
10 $[N-(-C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)CH_3)(D)-Phe[N-(CH_3)]]Gly-boroArg-C_{10}H_{16}$
 $[N-(-C(O)CH_3)(D)-Phe[N-(CH_3)]]Gly-boroIrg-C_{10}H_{16}$
 $[N-(-C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Arg-CF_3$
15 $[N-(-C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-Ph]Gly-Arg-CCF_3$
 $[N-(-C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Arg-CF_3$
 $[N-(-C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Arg-CF_3$
20 $[N-(-C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Arg-CF_3$
25 $[N-(-C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Arg-CF_3$
30 $[N-(-C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-(OH)]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Arg-CF_3$
 $[N-(-C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Arg-CF_3$
35 $[N-(-C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Arg-CF_3$

- $[N-(C(O)(CH_2)_2Ph)-N-(NHBOc)]Gly-Arg-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Arg-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Arg-CF_3$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Arg-CF_3$
5 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph)]Gly-Arg-CF_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Arg-CF_3$
10 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Arg-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Arg-OCH_3$
15 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Arg-OCH_3$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Arg-OCH_3$
20 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Arg-OCH_3$
25 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Arg-OCH_3$
30 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Arg-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBOc)]Gly-Arg-OCH_3$
35 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Arg-OCH_3$

- $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(CH}_2\text{CO}_2\text{CH}_3)]\text{Gly-Arg-OCH}_3$
 $[N-(\text{-C(O)CH}_2\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-OCH}_3$
 $[N-(\text{-C(O)(CH}_2)_3\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-OCH}_3$
 $[N-(\text{-C(O)Ph})\text{-N-(CH}_3)]\text{Gly-Arg-OCH}_3$
5 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-CH}_2\text{Ph)]Gly-Arg-OCH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-3,4-Cl}_2)\text{-N-(CH}_3)]\text{Gly-Arg-OCH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-Cl})\text{-N-(CH}_3)]\text{Gly-Arg-OCH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-CH}_3)\text{-N-(CH}_3)]\text{Gly-Arg-OCH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-OCH}_3)\text{-N-(CH}_3)]\text{Gly-Arg-OCH}_3$
10 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(CH}_2)_2\text{Ph)]Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-Ph)]Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)N(CH}_3)\text{CH}_2\text{Ph})\text{-N-Ph)]Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)Ph-3-CH=CHPh})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
15 $[N-(\text{-C(O)Ph-3-CH}_2\text{CH}_2\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)Ph-3-SPh-3-OCH}_3)\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)Ph-2-CH}_2\text{Ph-2-Ph})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)Ph-4-CH}_2\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)Ph-2-CH}_2\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
20 $[N-(\text{-C(O)Ph-3-CH}_2\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)Ph-3-CH}_2\text{Ph-2-CF}_3)\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)CH}_2\text{Ph-3,4-Cl}_2)\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(C}_2\text{H}_5)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(n-C}_3\text{H}_7)]\text{Gly-Arg-CO}_2\text{CH}_3$
25 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(i-C}_3\text{H}_7)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(C}_6\text{H}_{12})]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(OH)}]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(OCH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(OCH}_2\text{Ph)}]\text{Gly-Arg-CO}_2\text{CH}_3$
30 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(NH}_2)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(N(CH}_3)_2)]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(NHBOc)}]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(CH}_2\text{CO}_2\text{H)}]\text{Gly-Arg-CO}_2\text{CH}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})\text{-N-(CH}_2\text{CO}_2\text{CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$
35 $[N-(\text{-C(O)CH}_2\text{Ph})\text{-N-(CH}_3)]\text{Gly-Arg-CO}_2\text{CH}_3$

- $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Arg-CO_2CH_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Arg-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Arg-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Arg-CO_2CH_3$
5 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Arg-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Arg-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Arg-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-boroPhe(mCN)-OH$
10 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
15 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
20 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-boroPhe(mCN)-OH$
25 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-boroPhe(mCN)-OH$
30 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$
35 $[N-(C(O)Ph)-N-(CH_3)]Gly-boroPhe(mCN)-OH$

- $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph] Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)] Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)] Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)] Gly-boroPhe(mCN)-OH$
 5 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)] Gly-boroPhe(mCN)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph] Gly-boroPhe(mCN)-C_{10}H_{16}$
 10 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 15 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 20 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 25 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 30 $[N-(C(O)CH_2Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)Ph)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph] Gly-boroPhe(mCN)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$
 35 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)] Gly-boroPhe(mCN)-C_{10}H_{16}$

- $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-CH}_3)-N-(\text{CH}_3)]\text{Gly-boroPhe(mCN)-C}_{10}\text{H}_{16}$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-OCH}_3)-N-(\text{CH}_3)]\text{Gly-boroPhe(mCN)-C}_{10}\text{H}_{16}$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{CH}_2)_2\text{Ph}]\text{Gly-Phe(mCN)-CF}_3$
5 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-\text{Ph}]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)N(CH}_3)\text{CH}_2\text{Ph})-N-\text{Ph}]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)Ph-3-CH=CHPh})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)Ph-3-CH}_2\text{CH}_2\text{Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)Ph-3-SPh-3-OCH}_3)-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
10 $[N-(\text{-C(O)Ph-2-CH}_2\text{Ph-2-Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)Ph-4-CH}_2\text{Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)Ph-2-CH}_2\text{Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)Ph-3-CH}_2\text{Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)Ph-3-CH}_2\text{Ph-2-CF}_3)-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
15 $[N-(\text{-C(O)CH}_2\text{Ph-3,4-Cl}_2)-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{C}_2\text{H}_5)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(n\text{-C}_3\text{H}_7)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(i\text{-C}_3\text{H}_7)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{C}_6\text{H}_{12})]\text{Gly-Phe(mCN)-CF}_3$
20 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{OH})]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{OCH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{OCH}_2\text{Ph})]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{NH}_2)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{N(CH}_3)_2)]\text{Gly-Phe(mCN)-CF}_3$
25 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{NHBoc})]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{CH}_2\text{CO}_2\text{H})]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-(\text{CH}_2\text{CO}_2\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)CH}_2\text{Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_3\text{Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
30 $[N-(\text{-C(O)Ph})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph})-N-\text{CH}_2\text{Ph}]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-3,4-Cl}_2)-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-Cl})-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-CH}_3)-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$
35 $[N-(\text{-C(O)(CH}_2)_2\text{Ph-4-OCH}_3)-N-(\text{CH}_3)]\text{Gly-Phe(mCN)-CF}_3$

- $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Phe(mCN)-OCH_3$
5 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
10 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Phe(mCN)-OCH_3$
15 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Phe(mCN)-OCH_3$
20 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Phe(mCN)-OCH_3$
25 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Phe(mCN)-OCH_3$
30 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Phe(mCN)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
35 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Phe(mCN)-CO_2CH_3$

- $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
5 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
10 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Phe(mCN)-CO_2CH_3$
15 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Phe(mCN)-CO_2CH_3$
20 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
25 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
30 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Phe(mCN)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-boroOrn(N-methylamidino)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-boroOrn(N-methylamidino)-OH$
35 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-boroOrn(N-methylamidino)-OH$

- [N-(-C(O)Ph-3-CH=CHPh)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)Ph-3-CH₂CH₂Ph)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- 5 [N-(-C(O)Ph-3-SPh-3-OCH₃)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)Ph-2-CH₂Ph-2-Ph)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)Ph-4-CH₂Ph)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- 10 OH
- [N-(-C(O)Ph-2-CH₂Ph)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- OH
- [N-(-C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- OH
- 15 [N-(-C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(C₂H₅)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(n-C₃H₇)]Gly-boroOrn(N-methylamidino)-OH
- OH
- 20 [N-(-C(O)(CH₂)₂Ph)-N-(i-C₃H₇)]Gly-boroOrn(N-methylamidino)-OH
- OH
- [N-(-C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(OH)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-boroOrn(N-methylamidino)-OH
- 25 [N-(-C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-boroOrn(N-methylamidino)-OH
- OH
- [N-(-C(O)(CH₂)₂Ph)-N-(NH₂)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(N(CH₃)₂)]Gly-boroOrn(N-methylamidino)-OH
- 30 [N-(-C(O)(CH₂)₂Ph)-N-(NHBoc)]Gly-boroOrn(N-methylamidino)-OH
- OH
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂H)]Gly-boroOrn(N-methylamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂CH₃)]Gly-boroOrn(N-methylamidino)-OH
- 35

- $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-OH$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-OH$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-boroOrn(N-methylamidino)-OH$
5 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-OH$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-OH$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-boroOrn(N-$
10 $methylamidino)-OH$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-boroOrn(N-methylamidino)-C_{10}H_{16}$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-boroOrn(N-methylamidino)-$
15 $C_{10}H_{16}$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-C_{10}H_{16}$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-C_{10}H_{16}$
20 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-C_{10}H_{16}$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-C_{10}H_{16}$
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-$
25 $C_{10}H_{16}$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-$
 $C_{10}H_{16}$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-boroOrn(N-methylamidino)-$
 $C_{10}H_{16}$
30 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-boroOrn(N-$
 $methylamidino)-C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-boroOrn(N-methylamidino)-$
 $C_{10}H_{16}$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-boroOrn(N-methylamidino)-$
35 $C_{10}H_{16}$

- [N-(-C(O)(CH₂)₂Ph)-N-(*i*-C₃H₇)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- 5 [N-(-C(O)(CH₂)₂Ph)-N-(OH)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- 10 [N-(-C(O)(CH₂)₂Ph)-N-(NH₂)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph)-N-(N(CH₃)₂)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- 15 [N-(-C(O)(CH₂)₂Ph)-N-(NHBoc)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂H)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- 20 [N-(-C(O)CH₂Ph)-N-(CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₃Ph)-N-(CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)Ph)-N-(CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- 25 [N-(-C(O)(CH₂)₂Ph)-N-CH₂Ph)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph-4-Cl)-N-(CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- 30 [N-(-C(O)(CH₂)₂Ph-4-CH₃)-N-(CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- [N-(-C(O)(CH₂)₂Ph-4-OCH₃)-N-(CH₃)]Gly-boroOrn(*N*-methylethylamidino)-C₁₀H₁₆
- 35 [N-(-C(O)(CH₂)₂Ph)-N-(CH₃)]Gly-Orn(*N*-methylethylamidino)-CF₃

- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($-\text{CH}_2)_2\text{Ph}$]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-Ph]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})\text{N}(\text{CH}_3)\text{CH}_2\text{Ph}$)-N-Ph]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})\text{Ph}-3-\text{CH}=\text{CHPh}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
 5 [N-($-\text{C}(\text{O})\text{Ph}-3-\text{CH}_2\text{CH}_2\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-
 CF₃
 [N-($-\text{C}(\text{O})\text{Ph}-3-\text{SPh}-3-\text{OCH}_3$)-N-(CH₃)]Gly-Orn(N-methylamidino)-
 CF₃
 10 [N-($-\text{C}(\text{O})\text{Ph}-2-\text{CH}_2\text{Ph}-2-\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-
 CF₃
 [N-($-\text{C}(\text{O})\text{Ph}-4-\text{CH}_2\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})\text{Ph}-2-\text{CH}_2\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})\text{Ph}-3-\text{CH}_2\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})\text{Ph}-3-\text{CH}_2\text{Ph}-2-\text{CF}_3$)-N-(CH₃)]Gly-Orn(N-
 15 methylamidino)-CF₃
 [N-($-\text{C}(\text{O})\text{CH}_2\text{Ph}-3,4-\text{Cl}_2$)-N-(CH₃)]Gly-Orn(N-methylamidino)-
 CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(C₂H₅)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(n-C₃H₇)]Gly-Orn(N-methylamidino)-CF₃
 20 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(i-C₃H₇)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(C₆H₁₂)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(OH)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(OCH₃)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(OCH₂Ph)]Gly-Orn(N-methylamidino)-CF₃
 25 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(NH₂)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(N(CH₃)₂)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(NHBoc)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(CH₂CO₂H)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-(CH₂CO₂CH₃)]Gly-Orn(N-methylamidino)-
 30 CF₃
 [N-($-\text{C}(\text{O})\text{CH}_2\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_3\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})\text{Ph}$)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-CH₂Ph)]Gly-Orn(N-methylamidino)-CF₃

- [N-(-C(O)(CH₂)₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
- [N-(-C(O)(CH₂)₂Ph-4-Cl)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
- 5 [N-(-C(O)(CH₂)₂Ph-4-CH₃)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
- [N-(-C(O)(CH₂)₂Ph-4-OCH₃)-N-(CH₃)]Gly-Orn(N-methylamidino)-CF₃
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- 10 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂)₂Ph]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)(CH₂)₂Ph)-N-Ph]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)N(CH₃)CH₂Ph)-N-Ph]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)Ph-3-CH=CHPh)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- 15 [N-(-C(O)Ph-3-CH₂CH₂Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)Ph-3-SPh-3-OCH₃)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)Ph-2-CH₂Ph-2-Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- 20 [N-(-C(O)Ph-4-CH₂Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)Ph-2-CH₂Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- 25 [N-(-C(O)CH₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(C₂H₅)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(n-C₃H₇)]Gly-Orn(N-methylamidino)-OCH₃
- 30 [N-(-C(O)(CH₂)₂Ph)-N-(i-C₃H₇)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(OH)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-Orn(N-methylamidino)-OCH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-Orn(N-methylamidino)-OCH₃
- 35 [N-(-C(O)(CH₂)₂Ph)-N-(NH₂)]Gly-Orn(N-methylamidino)-OCH₃

- $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Orn(N-methylamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBOc)]Gly-Orn(N-methylamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Orn(N-methylamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Orn(N-methylamidino)-$
 5 OCH_3
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-OCH_3$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-OCH_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Orn(N-methylamidino)-OCH_3$
 10 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Orn(N-$
 $methylamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 OCH_3
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 15 OCH_3
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 OCH_3
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Orn(N-methylamidino)-$
 20 CO_2CH_3
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Orn(N-methylamidino)-CO_2CH_3$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Orn(N-methylamidino)-CO_2CH_3$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 CO_2CH_3
 25 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 CO_2CH_3
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 CO_2CH_3
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 30 CO_2CH_3
 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 CO_2CH_3
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Orn(N-methylamidino)-$
 CO_2CH_3

- [N-(-C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- 5 [N-(-C(O)CH₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(C₂H₅)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(n-C₃H₇)]Gly-Orn(N-methylamidino)-CO₂CH₃
- 10 [N-(-C(O)(CH₂)₂Ph)-N-(i-C₃H₇)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(OH)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- 15 [N-(-C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(NH₂)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(N(CH₃)₂)]Gly-Orn(N-methylamidino)-CO₂CH₃
- 20 [N-(-C(O)(CH₂)₂Ph)-N-(NHBOC)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂H)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- 25 [N-(-C(O)CH₂Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₃Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)Ph)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-CH₂Ph)]Gly-Orn(N-methylamidino)-CO₂CH₃
- 30 [N-(-C(O)(CH₂)₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph-4-Cl)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph-4-CH₃)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- 35

- [N-(-C(O)(CH₂)₂Ph-4-OCH₃)-N-(CH₃)]Gly-Orn(N-methylamidino)-CO₂CH₃
- [N-(-C(O)(CH₂)₂Ph)-N-Ph]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)N(CH₃)CH₂Ph)-N-Ph]Gly-boroOrn(formamidino)-OH
- 5 [N-(-C(O)Ph-3-CH=CHPh)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)Ph-3-CH₂CH₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)Ph-3-SPh-3-OCH₃)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)Ph-2-CH₂Ph-2-Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- 10 OH
- [N-(-C(O)Ph-4-CH₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)Ph-2-CH₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- 15 boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(C₂H₅)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(n-C₃H₇)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(i-C₃H₇)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-boroOrn(formamidino)-OH
- 20 [N-(-C(O)(CH₂)₂Ph)-N-(OH)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(NH₂)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(N(CH₃)₂)]Gly-boroOrn(formamidino)-OH
- 25 [N-(-C(O)(CH₂)₂Ph)-N-(NHBoc)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂H)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₃Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- 30 [N-(-C(O)(CH₂)₂Ph)-N-CH₂Ph)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph-4-Cl)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- [N-(-C(O)(CH₂)₂Ph-4-CH₃)-N-(CH₃)]Gly-boroOrn(formamidino)-OH
- 35 OH

- [N-(-C(O)(CH₂)₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂)₂Ph]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-Ph]Gly-boroOrn(formamidino)-C₁₀H₁₆
 5 [N-(-C(O)N(CH₃)CH₂Ph)-N-Ph]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)Ph-3-CH=CHPh)-N-(CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)Ph-3-CH₂CH₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 10 [N-(-C(O)Ph-3-SPh-3-OCH₃)-N-(CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)Ph-2-CH₂Ph-2-Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 15 [N-(-C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-
 boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(C₂H₅)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(n-C₃H₇)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 20 [N-(-C(O)(CH₂)₂Ph)-N-(i-C₃H₇)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 25 [N-(-C(O)(CH₂)₂Ph)-N-(NH₂)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(N(CH₃)₂)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(NHBoc)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 30 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂H)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CO₂CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(-C(O)CH₂Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 35 [N-(-C(O)(CH₂)₃Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-C₁₀H₁₆

- [N-(C(O)Ph)-N-(CH₃)]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(C(O)(CH₂)₂Ph)-N-CH₂Ph]Gly-boroOrn(formamidino)-C₁₀H₁₆
 [N-(C(O)(CH₂)₂Ph-4-Cl)-N-(CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 5 [N-(C(O)(CH₂)₂Ph-4-CH₃)-N-(CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(C(O)(CH₂)₂Ph-4-OCH₃)-N-(CH₃)]Gly-boroOrn(formamidino)-
 C₁₀H₁₆
 [N-(C(O)(CH₂)₂Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 10 [N-(C(O)(CH₂)₂Ph)-N-(CH₂)₂Ph]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-Ph]Gly-Orn(formamidino)-CF₃
 [N-(C(O)N(CH₃)CH₂Ph)-N-Ph]Gly-Orn(formamidino)-CF₃
 [N-(C(O)Ph-3-CH=CHPh)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)Ph-3-CH₂CH₂Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 15 [N-(C(O)Ph-3-SPh-3-OCH₃)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)Ph-2-CH₂Ph-2-Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)Ph-4-CH₂Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)Ph-2-CH₂Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)Ph-3-CH₂Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 20 [N-(C(O)Ph-3-CH₂Ph-2-CF₃)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)CH₂Ph-3,4-Cl₂)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(C₂H₅)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(n-C₃H₇)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(i-C₃H₇)]Gly-Orn(formamidino)-CF₃
 25 [N-(C(O)(CH₂)₂Ph)-N-(C₆H₁₂)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(OH)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(OCH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(OCH₂Ph)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(NH₂)]Gly-Orn(formamidino)-CF₃
 30 [N-(C(O)(CH₂)₂Ph)-N-(N(CH₃)₂)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(NHBOC)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(CH₂CO₂H)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)(CH₂)₂Ph)-N-(CH₂CO₂CH₃)]Gly-Orn(formamidino)-CF₃
 [N-(C(O)CH₂Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃
 35 [N-(C(O)(CH₂)₃Ph)-N-(CH₃)]Gly-Orn(formamidino)-CF₃

- $[N-(C(O)Ph)-N-(CH_3)]Gly-Orn(formamidino)-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Orn(formamidino)-CF_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Orn(formamidino)-CF_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Orn(formamidino)-CF_3$
5 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Orn(formamidino)-CF_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Orn(formamidino)-CF_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Orn(formamidino)-OCH_3$
10 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
15 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
20 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Orn(formamidino)-OCH_3$
25 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Orn(formamidino)-OCH_3$
30 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
35 $[N-(C(O)Ph)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$

- $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
5 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Orn(formamidino)-OCH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2)_2Ph]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-Ph]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)N(CH_3)CH_2Ph)-N-Ph]Gly-Orn(formamidino)-CO_2CH_3$
10 $[N-(C(O)Ph-3-CH=CHPh)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)Ph-3-SPh-3-OCH_3)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)Ph-2-CH_2Ph-2-Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
15 $[N-(C(O)Ph-4-CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)Ph-2-CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)Ph-3-CH_2Ph-2-CF_3)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
20 $[N-(C(O)CH_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(C_2H_5)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(n-C_3H_7)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(i-C_3H_7)]Gly-Orn(formamidino)-CO_2CH_3$
25 $[N-(C(O)(CH_2)_2Ph)-N-(C_6H_{12})]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OH)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(OCH_2Ph)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NH_2)]Gly-Orn(formamidino)-CO_2CH_3$
30 $[N-(C(O)(CH_2)_2Ph)-N-(N(CH_3)_2)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(NHBoc)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2H)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CO_2CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
35 $[N-(C(O)CH_2Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$

- $[N-(C(O)(CH_2)_3Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)Ph)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph)-N-CH_2Ph]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-3,4-Cl_2)-N-(CH_3)]Gly-Orn(formamidino)-$
 5 CO_2CH_3
 $[N-(C(O)(CH_2)_2Ph-4-Cl)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-CH_3)-N-(CH_3)]Gly-Orn(formamidino)-CO_2CH_3$
 $[N-(C(O)(CH_2)_2Ph-4-OCH_3)-N-(CH_3)]Gly-Orn(formamidino)-$
 CO_2CH_3
 10 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(prop\text{-}1,3\text{-}diyl)Ph)]-Gly-$
 $boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CH(i-C_3H_7)Ph-3-CH_3)]-Gly-$
 $boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(ethanediyl)Ph-3-CH_3)]-Gly-$
 15 $boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(prop\text{-}1,3\text{-}diyl)Ph-3-CH_3)]-$
 $Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(but\text{-}1,4\text{-}diyl)Ph-3-CH_3)]-$
 $Gly-boroLys-OH$
 20 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(CH_2CH_3)_2Ph-3,5-(CH_3)_2)]-Gly-$
 $boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CH(i-C_3H_7)Ph-3,5-(CH_3)_2)]-Gly$
 $boroLys-OH$
 25 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(ethanediyl)Ph-3,5-(CH_3)_2)]-$
 $Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(prop\text{-}1,3\text{-}diyl)Ph-3,5-$
 $(CH_3)_2)]-Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(but\text{-}1,4\text{-}diyl)Ph-3,5-(CH_3)$
 30 $_2)]-Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CH_2Ph-3-NH_2)]-Gly-boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(CH_3)_2Ph-3-NH_2)]-Gly-boroLys-$
 OH
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2C(CH_2CH_3)_2Ph-3-NH_2)]-Gly-$
 35 $boroLys-OH$
 $[N-(C(O)(CH_2)_2Ph)-N-(CH_2CH(i-C_3H_7)Ph-3-NH_2)]-Gly-$

- boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3-NH₂)]-Gly-
 boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph-3-NH₂)]-
 5 Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3-NH₂)]-
 Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph-3-NO₂)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3-NO₂)]-Gly-
 10 boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3-NO₂)]-Gly-
 -boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph-3-NO₂)]-
 Gly-boroLys-OH
 15 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3-NO₂)]-
 Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-boroArg-OH
 20 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph-3-CH₃)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3-CH₃)]-Gly-boroArg-
 OH
 25 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3-CH₃)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3-CH₃)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3-CH₃)]-Gly-
 30 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph-3-CH₃)]-
 Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3-CH₃)]-
 Gly-boroArg-OH
 35 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3,5-(CH₃)₂)]-Gly-

- boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3,5-(CH₃)₂)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3,5-(CH₃)₂)]-
 5 Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,4-diyl)Ph-3,5-
 (CH₃)₂)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3,5-(CH₃)
 2)]-Gly-boroArg-OH
 10 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph-3-NH₂)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3-NH₂)]-Gly-boroArg-
 OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3-NH₂)]-Gly-
 boroArg-OH
 15 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3-NH₂)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3-NH₂)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph-3-NH₂)]-
 20 Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3-NH₂)]-
 Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph-3-NO₂)]-Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3-NO₂)]-Gly-boroArg
 25 -OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3-NO₂)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3-NO₂)]-Gly-
 boroArg-OH
 30 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3-NO₂)]-Gly-
 boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph-3-NO₂)]-
 Gly-boroArg-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3-NO₂)]-
 35 Gly-boroArg-OH

- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroOrn
(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-boroOrn
(formamidino)-OH
- 5 [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph)]-Gly-
boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph-3-CH₃)]-Gly-boroOrn
(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3-CH₃)]-Gly-
10 boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3-CH₃)]-Gly-
boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,4-diyl)Ph-3-CH₃)]-
Gly-boroOrn(formamidino)-OH
- 15 [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3-CH₃)]-
Gly-boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph-3,5-(CH₃)₂)]-Gly-
boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph-3,5-(CH₃)₂)]-Gly-
20 boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3,5-(CH₃)₂)]-Gly-
boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3,5-(CH₃)₂)]-Gly-
boroOrn(formamidino)-OH
- 25 [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph-3,5-(CH₃)₂)]-
Gly-boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(propane-1,3-diyl)Ph-3,5-
(CH₃)₂)]-Gly-boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(butane-1,4-diyl)Ph-3,5-(CH₃)
30 2)]-Gly-boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂C(CH₂CH₃)₂Ph-3-NH₂)]-Gly-
boroOrn(formamidino)-OH
- [N-(C(O)(CH₂)₂Ph)-N-(CH₂CH(*i*-C₃H₇)Ph-3-NH₂)]-Gly-
boroOrn(formamidino)-OH

- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{ethanediy1})\text{Ph}-3-\text{NH}_2$)]-Gly-
 boroOrn(formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{propane-1,3-diyl})\text{Ph}-3-\text{NH}_2$)]-
 Gly-boroOrn(formamidino)-OH
- 5 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{butane-1,4-diyl})\text{Ph}-3-\text{NH}_2$)]-
 Gly-boroOrn(formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{CH}_2\text{Ph}-3-\text{NO}_2$)]-Gly-boroOrn
 (formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{CH}_3)_2\text{Ph}-3-\text{NO}_2$)]-Gly-
 10 boroOrn(formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{CH}_2\text{CH}_3)_2\text{Ph}-3-\text{NO}_2$)]-Gly-
 boroOrn(formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{CH}(\text{i-C}_3\text{H}_7)\text{Ph}-3-\text{NO}_2$)]-Gly-
 boroOrn(formamidino)-OH
- 15 [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{ethanediy1})\text{Ph}-3-\text{NO}_2$)]-Gly-
 boroOrn(formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{propane-1,3-diyl})\text{Ph}-3-\text{NO}_2$)]-
 Gly-boroOrn(formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2\text{Ph}$)-N-($\text{CH}_2\text{C}(\text{butane-1,4-diyl})\text{Ph}-3-\text{NO}_2$)]-
 20 Gly-boroOrn(formamidino)-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -2-pyridyl)-N-($\text{CH}_2\text{CH}_2\text{Ph}$)]-Gly-boroLys-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -2-pyridyl)-N-($\text{CH}_2\text{C}(\text{CH}_3)_2\text{Ph}$)]-Gly-
 boroLys-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -2-pyridyl)-N-($\text{CH}_2\text{C}(\text{CH}_2\text{CH}_3)_2\text{Ph}$)]-Gly-
 25 boroLys-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -2-pyridyl)-N-($\text{CH}_2\text{CH}(\text{i-C}_3\text{H}_7)\text{Ph}$)]-Gly-
 boroLys-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -2-pyridyl)-N-($\text{CH}_2\text{C}(\text{ethanediy1})\text{Ph}$)]-Gly-
 boroLys-OH
- 30 [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -2-pyridyl)-N-($\text{CH}_2\text{C}(\text{propane-1,3-diyl})\text{Ph}$)
]-Gly-boroLys-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -2-pyridyl)-N-($\text{CH}_2\text{C}(\text{butane-1,4-diyl})\text{Ph}$)]
 -Gly-boroLys-OH
- [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -3-pyridyl)-N-($\text{CH}_2\text{CH}_2\text{Ph}$)]-Gly-boroLys-OH
- 35 [N-($-\text{C}(\text{O})(\text{CH}_2)_2$ -3-pyridyl)-N-($\text{CH}_2\text{C}(\text{CH}_3)_2\text{Ph}$)]-Gly-

- boroLys-OH
 [N-(-C(O)(CH₂)₂-3-pyridyl)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-
 boroLys-OH
 [N-(-C(O)(CH₂)₂-3-pyridyl)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-
 5 boroLys-OH
 [N-(-C(O)(CH₂)₂-3-pyridyl)-N-(CH₂C(ethanediyl)Ph)]-Gly-
 boroLys-OH
 [N-(-C(O)(CH₂)₂-3-pyridyl)-N-(CH₂C(propane-1,3-diyl)Ph)]-Gly-boroLys-OH
 10 [N-(-C(O)(CH₂)₂-3-pyridyl)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OH)-N-(CH₂CH₂Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OH)-N-(CH₂C(CH₃)₂Ph)]-Gly-boroLys-OH
 15 [N-(-C(O)(CH₂)₂Ph-3-OH)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OH)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OH)-N-(CH₂C(ethanediyl)Ph)]-Gly-boroLys-OH
 20 [N-(-C(O)(CH₂)₂Ph-3-OH)-N-(CH₂C(propane-1,3-diyl)Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OH)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OMe)-N-(CH₂CH₂Ph)]-Gly-boroLys-OH
 25 [N-(-C(O)(CH₂)₂Ph-3-OMe)-N-(CH₂C(CH₃)₂Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OMe)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OMe)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-boroLys-OH
 30 [N-(-C(O)(CH₂)₂Ph-3-OMe)-N-(CH₂C(ethanediyl)Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OMe)-N-(CH₂C(propane-1,3-diyl)Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph-3-OMe)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroLys-OH
 35

- [N-(C(O)(CH₂)₂Ph-3-NO₂)-N-(CH₂CH₂Ph)]-Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-NO₂)-N-(CH₂C(CH₃)₂Ph)]-Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-NO₂)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroLys-
 5 OH
 [N-(C(O)(CH₂)₂Ph-3-NO₂)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-boroLys-
 OH
 [N-(C(O)(CH₂)₂Ph-3-NO₂)-N-(CH₂C(ethanediyl)Ph)]-Gly-
 boroLys-OH
 10 [N-(C(O)(CH₂)₂Ph-3-NO₂)-N-(CH₂C(propane-1,3-diyl)Ph)]-Gly-
 boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-NO₂)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-
 boroLys-OH
 15 [N-(C(O)(CH₂)₂Ph-3-CO₂H)-N-(CH₂CH₂Ph)]-Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂H)-N-(CH₂C(CH₃)₂Ph)]-Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂H)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroLys-
 OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂H)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-boroLys-
 20 OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂H)-N-(CH₂C(ethanediyl)Ph)]-Gly-
 boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂H)-N-(CH₂C(propane-1,3-diyl)Ph)]-
 Gly-boroLys-OH
 25 [N-(C(O)(CH₂)₂Ph-3-CO₂H)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-
 boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂Me)-N-(CH₂CH₂Ph)]-Gly-boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂Me)-N-(CH₂C(CH₃)₂Ph)]-Gly-boroLys-OH
 30 [N-(C(O)(CH₂)₂Ph-3-CO₂Me)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-
 boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂Me)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-
 boroLys-OH
 [N-(C(O)(CH₂)₂Ph-3-CO₂Me)-N-(CH₂C(ethanediyl)Ph)]-Gly-
 35 boroLys-OH

- [N-(-C(O)(CH₂)₂Ph-3-CO₂Me)-N-(CH₂C(propane-1,3-diyl)Ph)]-Gly-boroLys-OH
- [N-(-C(O)(CH₂)₂Ph-3-CO₂Me)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroLys-OH
- 5 [N-(-C(O)(CH₂)₂Ph-3-NH₂)-N-(CH₂CH₂Ph)]-Gly-boroLys-OH
- [N-(-C(O)(CH₂)₂Ph-3-NH₂)-N-(CH₂C(CH₃)₂Ph)]-Gly-boroLys-OH
- [N-(-C(O)(CH₂)₂Ph-3-NH₂)-N-(CH₂C(CH₂CH₃)₂Ph)]-Gly-boroLys-OH
- [N-(-C(O)(CH₂)₂Ph-3-NH₂)-N-(CH₂CH(*i*-C₃H₇)Ph)]-Gly-boroLys-OH
- 10 [N-(-C(O)(CH₂)₂Ph-3-NH₂)-N-(CH₂C(ethanediy1)Ph)]-Gly-boroLys-OH
- [N-(-C(O)(CH₂)₂Ph-3-NH₂)-N-(CH₂C(propane-1,4-diyl)Ph)]-Gly-boroLys-OH
- 15 [N-(-C(O)(CH₂)₂Ph-3-NH₂)-N-(CH₂C(butane-1,4-diyl)Ph)]-Gly-boroLys-OH

This invention also provides compositions comprising one or more of the foregoing compounds and methods of using such compositions in the treatment of aberrant proteolysis such as thrombosis in mammals.

20

Detail Description of the Invention

25 As used throughout the specifications, the following abbreviations for amino acid residues or amino acids apply:


- Ala = L-alanine
- Arg = L-arginine
- 30 Asn = L-asparagine
- Asp = L-aspartic acid
- Cys = L-cysteine
- Gln = L-glutamine
- Glu = L-glutamic acid
- 35 Gly = glycine

	His	=	L-histidine
	Ile	=	L-isoleucine
	Leu	=	L-leucine
	Lys	=	L-lysine
5	Met	=	L-methionine
	Phe	=	L-phenylalanine
	Pro	=	L-proline
	Ser	=	L-serine
	Thr	=	L-threonine
10	Trp	=	L-tryptophan
	Tyr	=	L-tyrosine
	Val	=	L-valine
	Sar	=	L-sarcosine
15	Irg	=	L-arginine where the guanidine is replaced with an isothiuronium (-SC(=NH)NH ₂)

The "D" prefix for the foregoing abbreviations indicates the amino acid is in the D-configuration. "D,L" indicates the amino is present in mixture of the D- and the L-configuration. The prefix "boro" indicates amino acid residues where the carboxyl is replaced by a boronic acid or a boronic acid ester. For example, if R¹ is isopropyl and Y¹ and Y² are OH, the C-terminal residue is abbreviated "boroVal-OH" where "-OH" indicates the boronic acid is in the form of the free acid. The pinanediol boronic acid ester and the pinacol boronic acid ester are abbreviated "-C₁₀H₁₆" and "-C₆H₁₂", respectively. Examples of other useful diols for esterification with the boronic acids are 1,2-ethanediol, 1,3-propanediol, 1,2-propanediol, 2,3-butanediol, 1,2-diisopropylethanediol, 5,6-decanediol, and 1,2-dicyclohexylethanediol. Other abbreviations are: formamidino, HC(=NH)-; N-methylamidino, CH₃NHC(=NH)-; Z, benzyloxycarbonyl; BSA, benzene sulfonic acid; THF, tetrahydrofuran; Boc-, t-butoxycarbonyl-; Ac-, acetyl; pNA, p-nitro-aniline; DMAP, 4-N,N-dimethylaminopyridine; Tris,


- Tris(hydroxymethyl)aminomethane; MS, mass spectrometry; FAB/MS, fast atom bombardment mass spectrometry. LRMS(NH₃-CI) and HRMS(NH₃-CI) are low and high resolution mass spectrometry, respectively, using NH₃ as an ion source.
- 5 Thus, an example of the chemical structure based on the nomenclature used herein is:

[N-(-C(O)(CH₂)₂Ph)-N-(CH₃)]Gly-Orn(formamidino)-CO₂CH₃
represents



10

and [N-(-C(O)(CH₂)₂Ph-4-OCH₃)-N-(CH₃)]Gly-borophe(mCN)-OH
represents



- 15 It is understood that many of the compounds of the present invention contain one or more chiral centers and that these stereoisomers may possess distinct physical and biological properties. The present invention comprises all of the stereoisomers or mixtures thereof. If the pure
- 20 enantiomers or diastereomers are desired, they may be prepared using starting materials with the appropriate stereochemistry, or may be separated from mixtures of undesired stereoisomers by standard techniques, including

chiral chromatography and recrystallization of diastereomeric salts.

The term "amine-blocking group" or "amine-protecting group" as used herein, refers to various acyl, thioacyl, alkyl, sulfonyl, phosphoryl, and phosphinyl groups comprised of 1 to 20 carbon atoms. Substituents on these groups maybe either alkyl, aryl, alkaryl which may contain the heteroatoms, O, S, and N as a substituent or as inchain component. A number of amine-blocking groups are recognized by those skilled in the art of organic synthesis. Examples of suitable groups include formyl, acetyl, benzoyl, trifluoroacetyl, and methoxysuccinyl; aromatic urethane protecting groups, such as, benzyloxycarbonyl; and aliphatic urethane protecting groups, such as t-butoxycarbonyl or adamantyloxycarbonyl. Gross and Meienhofer, eds., *The Peptides*, Vol 3; 3-88 (1981), Academic Press, New York, and Greene and Wuts *Protective Groups in Organic Synthesis*, 315-405 (1991), J. Wiley and Sons, Inc., New York disclose numerous suitable amine protecting groups and they are incorporated herein by reference for that purpose.

"Amino acid residues" as used herein, refers to natural or unnatural amino acids of either D- or L- configuration. Natural amino acids residues are Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val. Roberts and Vellaccio, *The Peptides*, Vol 5; 341-449 (1983), Academic Press, New York, discloses numerous suitable unnatural amino acids and is incorporated herein by reference for that purpose.

"Amino acids residues" also refers to various amino acids where sidechain functional groups are coupled with appropriate protecting groups known to those skilled in the art. "The Peptides", Vol 3, 3-88 (1981) discloses numerous suitable protecting groups and is incorporated herein by reference for that purpose.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.

5 "Alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge.

"Cycloalkyl" is intended to include saturated ring groups, including mono-, bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and cyclooctyl, and so forth.

10 "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.

15 "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo.

The term "aryl" is defined as phenyl, fluorenyl, biphenyl and naphthyl, which may be unsubstituted or include optional substitution with one to three
20 substituents.

The term "heteroaryl" is meant to include 5-, 6-, 9-, or 10-membered mono- or bicyclic aromatic rings which can optionally contain from 1 to 3 heteroatoms selected from the group consisting of O, N, and S; said ring(s) may be
25 unsubstituted or include optional substitution with one to three substituents. Included in the definition of the group heteroaryl, but not limited to, are the following: 2-, or 3-, or 4-pyridyl; 2- or 3-furyl; 2- or 3-benzofuranyl; 2-, or 3-thiophenyl; 2- or 3-benzo[b]thiophenyl; 2-, or 3-,
30 or 4-quinolinyl; 1-, or 3-, or 4-isoquinolinyl; 2- or 3-pyrrolyl; 1- or 2- or 3-indolyl; 2-, or 4-, or 5-oxazolyl; 2-benzoxazolyl; 2- or 4- or 5-imidazolyl; 1- or 2-benzimidazolyl; 2- or 4- or 5-thiazolyl; 2-benzothiazolyl; 3- or 4- or 5-isoxazolyl; 3- or 4- or 5-pyrazolyl; 3- or 4-
35 or 5-isothiazolyl; 3- or 4-pyridazinyl; 2- or 4- or 5-

pyrimidinyl; 2-pyrazinyl; 2-triazinyl; 3- or 4- cinnolinyl;
1-phthalazinyl; 2- or 4-quinazolinyl; or 2-quinoxaliny
ring. Particularly preferred are 2-, 3-, or 4-pyridyl; 2-,
or 3-furyl; 2-, or 3-thiophenyl; 2-, 3-, or 4-quinolinyl;
5 or 1-, 3-, or
4-isoquinolinyl.

The term "heterocycle" is meant to include 5-, 6-, 9-,
or 10-membered mono- or bicyclic rings which can optionally
contain from 1 to 3 heteroatoms selected from the group
10 consisting of N, O, or S, with the proviso that proline is
excluded from this group; said ring(s) may be unsubstituted
or include optional substitution with one to three
substituents. Included in the definition of the group
heterocycle, but not limited to, are
15 tetrahydroisoquinoline, tetrahydroquinoline,
tetrahydrofuran, tetrahydrothiophene, piperidine,
piperazine, morpholine. Particularly preferred are 1-, 3-,
or 4-tetrahydroisoquinolinyl.

Unless otherwise specified, the substituents that may
20 be attached to the aryl, heteroaryl or heterocycle ring(s)
may be independently selected at each occurrence from the
group consisting of:

halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, methylenedioxy,
-NO₂, -CF₃, -SH, -S(O)_r-(C₁-C₄ alkyl), CN, -OH, -NH₂,
25 -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(=NH)NHR⁴,
-NHC(=NR⁴), -NHC(=NH)NHR⁴, -NHC(=O)R⁴, -(CH₂)_p-CO₂R⁴,
-NHCO C₁-C₄ alkoxy), -NH(C₁-C₄ alkoxy)₂, -N(C₁-C₄
alkoxy), phenyl which may be unsubstituted or
substituted with R¹³.

30 By "stable compound" or "stable structure" is meant
herein a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction
mixture, and formulation into an efficacious therapeutic
agent.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound of formula (I) is modified by making acid or base salts of the compound of formula (I). Examples of
5 pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.

"Prodrugs" are considered to be any covalently bonded
10 carriers which release the active parent drug according to formula (I) *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of formula (I) are prepared by modifying functional groups present in the compounds in such a way that the modifications are
15 cleaved, either in routine manipulation or *in vivo*, to the parent compounds. Prodrugs include compounds of formula (I) wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or
20 sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I); and the like.


Pharmaceutically acceptable salts of the compounds of
25 the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or
30 acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

35

Synthesis

The compounds of Formula (I) can be prepared using the reactions and techniques described below, in addition to
5 synthetic procedures described in Applicant's Assignee's commonly assigned patent applications USSN 08/010,731 (filed January 29, 1993), USSN 08/036,378 (filed March 24, 1993), and USSN 08/052,835 (filed April 27, 1993), all of which are hereby incorporated by reference. The reactions
10 are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the
15 transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the
20 planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained
25 practitioner is Greene and Wuts, *Protective Groups In Organic Synthesis*, Wiley and Sons (1991).

Scheme 1



M is a carboxylic acid protecting group

5 The preparation of the required *N,N*-disubstituted amino acid subunit can be accomplished by the sequence outlined in Scheme 1. A variety of methods for the asymmetric synthesis of the amino acids required for the amino acid ester substrate (II) is reviewed by Morrison and Moshier (*Asymmetric Organic Reactions*, American Chemical Society, 297-334 (1976) and references there in). The appropriate ester (II), where M is the ester residue, can be conjugated to give the *N*-substituted intermediate (III) by *N*-monoalkylation with an alkyl halide related to R¹¹. 10 Typical conditions for *N*-monoalkylation include the admixture of an excess of (II), the required alkyl bromide or iodide and a base in an anhydrous polar aprotic solvent, such as acetone, acetonitrile, *N,N*-dimethylformamide or methyl sulfoxide. The option exists for stirring this mixture at room temperature or heating at temperatures up to the reflux point of the selected solvent. The base added is chosen so that it will not interfere with the ester functionality of (II); among those recommended are non-nucleophilic bases such as sodium hydride or potassium carbonate. 15 Another general route for the preparation of compounds of this type is the reductive amination of (II) with a selected aldehyde related to R¹¹. In this procedure, a mixture of (II) and the aldehyde are heated in an anhydrous non polar solvent, such as benzene, toluene or xylene, with continuous removal of evolved water by drying 20

agents or azeotropic distillation. This process causes condensation of the aldehyde with amine (II). The condensation product is reduced to monoalkylated (III) by treatment with a selective hydride reducing agent such as sodium cyanoborohydride or sodium borohydride, according to the method of Getson et. al., *J. Heterocycl. Chem.* 1, 300 (1964), or by catalytic hydrogenation with platinum, palladium, nickel or Raney nickel in an alcohol solvent like propanol, ethanol or methanol, according to the method of Hudlicky, *Reductions In Organic Synthesis*, John Wiley and Sons, pp. 134 (1984).


While a number of coupling or acylation methods can be contemplated for the preparation of the disubstituted derivative (IV) from (III), (see Bodanszky and Bodanszky, *The Practice of Peptide Synthesis*, Springer-Verlag, p. 87-150 (1984)), three methods are preferred. In the first, a solution of (III) in an anhydrous non polar solvent, such as tetrahydrofuran or dichloromethane, at -78°C or higher is treated sequentially with a selected acid chloride related to R³ followed by a trialkylamine base. This mixture is allowed to warm to ambient temperature over several hours if required. The second method is the mixed anhydride procedure of Anderson et al. reported in *J. Am. Chem. Soc.* 89, 5012 (1967). In this procedure the alkyl mixed anhydride is generated by dissolving a selected carboxylic acid related to R³ in non-polar anhydrous solvent, such as tetrahydrofuran or dichloromethane, and adding one equivalent of a trialkylamine base. The solution is stirred at -78°C or higher and one equivalent of an alkylchloroformate is added. After formation of the mixed anhydride is complete, a solution of one equivalent each of intermediate (III) and a trialkylamine base is added dropwise. The mixture is stirred with or without cooling until the reaction is complete. The third method preferred for amide formation is the hydroxybenzotriazole /

dialkylcarbodiimide method of Koenig and Geiger in *Chem. Ber.* 103, 788 (1970). Thus, to (III) and a selected carboxylic acid related to R^3 , dissolved in an aprotic solvent like *N,N*-dimethylformamide, dichloromethane or
5 tetrahydrofuran, at -78°C or higher, is added dialkylcarbodiimide, hydroxybenzotriazole and a trialkylamine base. If necessary, the stirred solution is allowed to thaw to ambient temperature over several hours.

An alternative preparation of *N,N*-disubstituted amino
10 acids uses α -halo- or α -sulfonate acylesters such as (V) of Scheme 2. Compound (V) can be treated with a primary amine related to R^{11} in the presence of a variety of bases like potassium carbonate, triethyl amine or sodium hydride and in solvents such as ethyl ether, acetone or
15 dimethylformamide at temperatures ranging from -78°C to the reflux point of the solvent selected. From this reaction can be isolated the *N*-alkyl aminoacid ester (III) of Scheme 1; the *N*-alkyl-*N*-acylamino acid ester (IV) can be prepared from compound (III) by any of the methods outlined
20 in Scheme 1 and the related discussion hereafter.

The preparation of intermediates which will lead to compounds where R^3 and R^{11} may be taken together to form a cyclic amide or phthalimide is described in Scheme 2. *N,N*-Disubstituted α -amino acid subunits (VI) which lead to
25 compounds of this type are best derived by reaction of an appropriate α -haloester (V), where $J = \text{Cl, Br, I}$.

Scheme 2




with the alkali metal salt of an amide or phthalimide
 5 related to the desired cyclized combination of R³ and R¹¹
 in a polar aprotic solvent according to the method of Daly
 et. al. in *J. Med. Chem.* 33, 2818 (1990); Neuberger and
 Scott, *J. Chem. Soc.* p 1820 (1954). In a typical
 preparation the alkali metal salt of the required cyclic
 10 amide or phthalimide is generated by adding one equivalent
 of a strong non-nucleophilic base such as sodium or
 potassium hydride, a lithium dialkylamine, or lithium
 trimethyl- or lithium triphenylmethane to a solution of the
 amide or phthalimide in an anhydrous inert solvent, such as
 15 tetrahydrofuran or 1,2-dimethoxyethane, at -78° C or
 higher. When the salt formation is complete, the solvent
 is removed by distillation and replaced by the appropriate
 polar aprotic solvent such as acetonitrile, *N,N*-
 dimethylformamide or methylsulfoxide. The appropriate α -
 20 chloro- or α -bromoester is introduced and the mixture
 stirred at room temperature or with heating until the
 haloester is consumed.

It will be recognized by those skilled in the art of
 organic synthesis that the acid derivatives of the *N,N*-
 25 disubstituted α -amino acid esters (IV) and (VI) are the
 required precursors for the preparation of the thrombin
 inhibitors disclosed in this invention. It is recommended
 that compounds (IV) and (VI) be prepared as either the
 benzyl, methyl or *t*-butyl esters because of the ease with
 30 which esters of these types may be converted to their

corresponding acids. In the case of a benzyl ester (e.g., (IV) or (VI), where $M = -CH_2C_6H_5$), hydrogenolysis of an alcohol solution of the compound may be effected under an atmosphere of hydrogen gas in the presence of platinum or palladium on carbon catalyst according to the reported by Hartney and Simonoff, *Org. React. VII*, 263 (1953); with a methyl ester (IV) or (VI), where $M = -CH_3$, treatment of an ethanol solution of the compound with an aqueous base, such as one equivalent of sodium hydroxide solution, will give the desired acid. The t-butyl ester (IV) or (VI), where $M = -C(CH_3)_3$, is readily cleaved by acid under anhydrous conditions; for example trifluoroacetic acid in dichloromethane solution removes the t-butyl ester of derivatives of (IV) at ambient temperature as reported by Bryan et. al., *J. Am. Chem. Soc.* 99, 2353 (1977). A number of alternative esters and procedures are detailed in Greene and Wuts (1991).

Scheme 3 illustrates the coupling of the acid derivatives of (IV) or (VI) with boropeptide synthons (VII) or (VIII) to give intermediates (IX) or (X).

Scheme 3




25

The preparation of synthons (VII) and (VIII) has been described by Kettner and Shenvi (EP 293 881 A2). It will be recognized by those skilled in the art of organic synthesis that the methodology described by Kettner and
5 Shenvi can be applied to make homologous boro-peptide synthons related to (VII) and (VIII). These homologues may be used in the appropriate processes described herein to prepare the corresponding thrombin inhibitors. The coupling of the carboxylic acid derivative of (IV) or (VI)
10 to boro-peptide synthon (VII) or (VIII) has been described previously by Kettner et al. in *J. Biol. Chem.* 265 ,18289 (1990) and, in general, the standard amino acid coupling protocols detailed by Bodanszky and Bodanszky (1984) are effective for making the compounds of this invention.
15 Preferred methods are the mixed anhydride procedure of Anderson et al. (1967) and the hydroxybenzotriazole/dialkylcarbodiimide method of Koenig and Geiger (1970). In the mixed anhydride procedure, the anhydride is generated by dissolving a carboxylic acid
20 related to (IV) or (VI) in a non polar anhydrous solvent, such as tetrahydrofuran or dichloromethane, and adding one equivalent of a trialkylamine base. The solution is stirred at -78° and up to 0°C, then one equivalent of an alkylchloroformate is added. After formation of the mixed
25 anhydride is complete, a solution of boro-peptide synthon (VII) or (VIII) and a trialkylamine base is added. The mixture is stirred for one hour with cooling followed by several hours at ambient temperature. By the hydroxybenzotriazole/dialkylcarbodiimide method, (VII) or
30 (VIII) and the acids of (IV) or (VI) are dissolved in an aprotic solvent, such as *N,N*-dimethylformamide, dichloromethane or tetrahydrofuran, at -78° or higher. To this solution one equivalent each of dialkylcarbodiimide, hydroxybenzotriazole and a trialkylamine base are added.

If necessary, the solution is allowed to stir and thaw to ambient temperature over several hours.

A process for the preparation of the boropeptide thrombin inhibitors of this invention from intermediates (IX) and (X) is disclosed in Scheme 4. Compound (IX) serves as a starting point for isothiuronium thrombin inhibitors (XI) and (XII). The boronic ester (XI) is prepared by stirring a solution of (IX) and thiourea in an inert polar solvent, such as an alcohol or *N,N*-dimethylformamide, at temperatures ranging from ambient to the reflux temperature of the selected solvent. It is understood that a boronic acid ester like compound (XI) is an effective thrombin inhibitor, however, it may be transformed to the corresponding free boronic acid (XII) without a loss of biological activity. Compound (XII) is derived from the boron ester (XI) by transesterification under equilibrium conditions.

Scheme 4



Thus stirring ester (XI) with an excess of an alkyl- or
 5 aryl boric acid in a biphasic mixture of neutral or acidic
 water and an immiscible solvent, such as ethyl ether or
 toluene, gives (XII) after several hours at ambient
 temperature. The conditions generally preferred use 5 to
 10 equivalents of phenylboric acid in ethyl ether/water at
 10 neutral pH. Thrombin inhibitors (XIII) to (XVI) are
 obtained by reduction of an azide intermediate prepared
 from (IX) or (X). The azide intermediate is prepared by
 heating either (IX) or (X) with an inorganic azide, such as
 sodium or potassium azide, in an anhydrous polar aprotic
 15 solvent, such as acetone, dimethylformamide or methyl

sulfoxide at temperatures ranging from ambient to 130°C. Alternatively, phase transfer conditions may be employed to prepare the azide intermediate from (IX) or (X). For example, a tetraalkylammonium azide in a non-polar aprotic solvent, such as tetrahydrofuran or toluene, or a crown ether and inorganic azide in biphasic mixtures of water and an immiscible solvent, such as benzene, toluene or xylene, can be stirred at room temperature or heated up to the reflux point of the selected solvent. The primary amines (XIII) and (XIV) are most conveniently obtained from the catalytic hydrogenation of the azide in an inert solvent, such as an alcohol, ethyl acetate or tetrahydrofuran with a transition metal catalyst such as platinum or palladium on carbon under an atmosphere of hydrogen gas. A variety of alternative methods are also useful and can be found in the monograph by Hudlicky (1984, pp. 76). The acid salt of the resulting amines (XIII) and (XIV) may be formed by the addition of one equivalent of the desired acid to the hydrogenation mixture. Phenylboric acid mediated hydrolysis of esters (XIII) and (XIV) gives the free boronic acid thrombin inhibitors (XV) and (XVI), compounds of formula (I) of the invention.


Compounds containing a primary guanidine or N-alkyl guanidine functionality may be prepared by the alternative process outlined in Scheme 4. As illustrated with primary amine (XIII), the transformation to (XVII) is effected with a guanidinylation agent, such as an S-alkyl thiourea, aminoiminomethane sulfonic acid reported by Miller and Bischoff *Synthesis* 9, 777 (1986), cyanamide reported by Kettner et al. (1990) or their N-alkyl derivatives. This mixture is stirred at room temperature or higher with a base, such as potassium carbonate, triethylamine or N,N-dimethylaminopyridine in an inert solvent like water, alcohol, N,N-dimethylformamide or acetone. The guanidine boronic acid esters (XVII) can be deesterified to give the

corresponding boronic acid (XVIII) by the phenylboric acid procedure described above.

According to Scheme 5, the bromide (X) is converted to the corresponding alkynitrile (XIX) upon exposure to the cyanide anion under a variety of conditions.

5

Scheme 5




- Effective methods include the use of potassium or sodium cyanides in polar aprotic solvents, such as *N,N*-dimethylformamide, methylsulfoxide, acetone or ethylmethyl ketone, at temperatures ranging from ambient up to the reflux point of the selected solvent. More useful, however, are conditions employing phase transfer agents such as tetrabutylammonium cyanide in a nonpolar aprotic solvent such as tetrahydrofuran or toluene, or a biphasic mixture of a crown ether and an inorganic cyanide in water with an immiscible solvent like benzene, toluene or xylene. These mixtures can be stirred at ambient temperature or heated up

to the reflux temperature of the selected solvent. An amidine like (XX) is prepared by first treating nitrile (XIX) with a saturated solution of a mineral acid such as hydrogen chloride in an alcohol solvent at room temperature or lower. The intermediate O-alkylimidate can be exposed to ammonia, or a primary or secondary amine under anhydrous conditions with or without an inert solvent. As illustrated in Scheme 5, compound (XX) is produced by treating the O-alkylimidate formed from (XIX) with neat anhydrous ammonia at reflux. The free boronic acid (XXI) is obtained by transesterification of (XX) with phenylboric acid in a mixture of water and diethyl ether.


The formamidine substituted boronic acid (XXIII) is prepared from alkylamine (XV) as shown in Scheme 6. Compounds of (XV) can be stirred with an O-alkyl or O-aryl formimidate from 0°C or up to the reflux temperature of an inert anhydrous solvent such as tetrahydrofuran or *N,N*-dimethylformamide to give formamidine (XXII). Free boronic acid (XXIII) is produced from (XXII) by the phenylboric acid transesterification protocol.

Scheme 6



- 5 As shown in Scheme 7, the N-cyanoguanidine substituted boronic acid (XXVI), can be prepared by the reaction of (XV) with an N-cyanoisourylation agent such as *S,S*-dimethyl N-cyanoiminodithiocarbonate or *O,O*-diphenyl N-cyano-diimino-
- 10 (XV) are combined with a selected iminocarbonate in an inert, anhydrous solvent like tetrahydrofuran or *N,N*-dimethylformamide. The mixture is stirred at 0°C or up to the reflux temperature of the chosen solvent until there is obtained an N-cyano-*S*-isourea or N-cyano-*O*-isourea of the
- 15 Formula (XXIV) similar to that reported by Barpill et al., *J. Heterocyclic Chem.* 25, 1698 (1988). This intermediate is treated with an amine such as


Scheme 7



- 5 ammonia, or more generally, an alkylamine or an arylamine with or without an inert solvent like water, tetrahydrofuran or an alcohol at temperatures ranging from 0°C to reflux to give the aminolysis product (XXV). Treatment of (XXV) as described above with phenylboric acid
- 10 can provide (XXVI).

- The *N*-hydroxyguanidino inhibitors, as shown in Scheme 8, are prepared by treating amine (XV) with cyanogen bromide or cyanogen chloride followed by hydroxylamine in an inert solvent to yield (XXVII) according to Nakahara et.
- 15 al., *Tetrahedron* 33, 1591 (1977); and Belzecki et al., *J. Chem. Soc. Chem. Commun.* p. 806 (1970). Transesterification of (XXVII) by the phenylboric acid method can provide (XXVIII).

Scheme 8.




- 5 A general preparation for the new aromatic boronic acids is illustrated in Scheme 9. Functionalized benzylic anions containing either a halo- or cyano- substituent are obtained with a variety of metalation agents, such as
- 10 activated zinc metal/ $\text{CuCN} \cdot 2\text{LiCl}$ based on the report of Berk et al. *Organometallics* 9, 3053 (1990); or use of lithium metal according to Michel et al., *J. Organometallic Chem.* 204, 1 (1981); or lithium naphthalenide in the presence of zinc chloride based on the report of Zhu et al., *J. Org. Chem.* 56, 1445 (1991) in an inert solvent like
- 15 tetrahydrofuran or 1,2-dimethoxyethane at temperatures of -78°C or higher. Dichloromethyl boronic acid pinanediol, prepared by the method described by Tsai et al. in *Organometallics* 2, 1543 (1983), is allowed to react with the transmetalated anion in the selected solvent to give
- 20 (XXIX). The α -aminoboronic acid, (XXX), can be obtained by treating (XXIX) with the sodium or lithium salt of hexamethyldisilazane in a polar aprotic solvent like

acetone, *N,N*-dimethylformamide or methyl sulfoxide with heating at temperature up to the reflux point of the selected solvent, if necessary. The trimethylsilyl protecting groups are removed by treatment with

5

Scheme 9.




- 10 anhydrous acid such as gaseous hydrogen chloride or trifluoroacetic acid in an inert solvent like tetrahydrofuran or dichloromethane at -78°C or higher. Compound (XXX) was coupled to the *N,N*-disubstituted α -amino acids (IV) or (VI), using the techniques described in
- 15 Scheme 3, to give the boronic acid ester (XXXIa). Transesterification of (XXXIa) by the phenylboric acid protocol (*vide infra*) gives inhibitor (XXXIb). In Scheme

9, the aromatic nitrile (XXXIa) is converted to the amidine (XXXIIa) by methods described for the synthesis of aliphatic amidine (XX) in Scheme 5. Removal of the pinanediol protecting group of (XXXIIa) gives the free
 5 boronic acid derivative (XXXIIb).

As detailed in Scheme 10, compound (XXXIa) is a versatile intermediate that can be hydrogenated to yield the aminomethyl derivative (XXXIIIa) under a variety of conditions (Hudlicky, (1984), pp 173).

10

Scheme 10.




15 Catalysts recommended for this transformation include transition metals like rhodium, Raney nickel, nickel

boride, nickel, platinum or palladium; these reductions occur readily under atmospheres of hydrogen or ammonia at pressures ranging from 1 to 300 atmospheres, at room temperature or higher, and in inert solvents such as water, an alcohol, ethyl acetate or tetrahydrofuran. Furthermore, from (XXXIIIIa), the formamidino- (XXXIVa), cyanoguanidino- (XXXVa), hydroxyguanidino- (XXXVIa) and guanidino- analogs (XXXVIIa) can be prepared by the same procedures described for the aliphatic series in Schemes 4, 6 through 8. The boronic acid esters (XXXIIIIa)-(XXXVIIa) can all be transesterified to the corresponding free boronic acid inhibitors (XXXIIIIb)-(XXXVIIb) using the phenyl boronic acid method previously described.

Aromatic boronic acid inhibitors (XLIa,b), with the guanidine functionality substituted directly on the aromatic nucleus, can be prepared from precursor (XXXVIII) according to Scheme 11. Nitration of the aromatic ring of (XXXVIII) according to the method of Olah and Kuhn, J. Amer. Chem. Soc. 84, 3684 (1962) can occur readily with agents such as acetyl nitrate, nitrosonium tetrafluoroborate ($\text{NO}_2^+\text{BF}_4^-$) and nitrosonium hexafluorophosphate ($\text{NO}_2^+\text{PF}_6^-$) in inert solvents like tetrahydrofuran or dichloromethane at -78°C or higher. The products of formula (XXXIX) can be reduced to the aniline derivative (LX) by catalytic hydrogenation. The catalysts recommended for this procedure include iron, zinc, platinum oxide, rhodium - platinum oxide, palladium, Raney nickel, copper chromite, and rhenium sulfide. While reduction occurs readily under an atmosphere of hydrogen gas at pressures range from 1 to 350 atmosphere in an inert solvent like water, an alcohol or ethyl acetate, other reagents which may affect this reaction are transfer agents such as hydrazine, formic acid or triethyl formate (Hudlicky, (1984), pp 73).


Scheme 11.



- 5 The aniline (LX) can be converted to the phenylguanidine (LXIa) by the procedure described for (XVII) in Scheme 4. The transformation of (LXIa) to the free boronic acid (LXIb) is effected as in Scheme 4.
- The several types of inhibitors disclosed in this
- 10 invention can be broadly classified by their electrophilic functional group A, as defined in Formula -(I). The

- compounds described below, unlike the boron containing peptides, utilize a highly electrophilic carbon atom at Δ to interact with the active site serine of thrombin. The precursor for the electrophilic carbon inhibitors is the
- 5 appropriately protected amino acid (LXII) of Scheme 12.

Scheme 12



$Q = \text{-(CH}_2\text{)}_v\text{- or -(CH}_2\text{)}_{q-1}\text{C}_6\text{H}_4\text{(CH}_2\text{)}_{p-1}\text{-}$

$v = 0-10$

M = alkyl or benzyl



PG = protecting group

- 10 The preparation of (LXII) can be found in the general chemical literature, one such reference being the review by Morrison and Mosher (1976). According to Scheme 12 various terminal functional groups are available from (LXII) : the

formamidino- (XLIII), cyanoguanidino- (XLIV), hydroxyguanidino- (XLV) and guanidino- analogs (XLVI). These compounds are prepared by the same procedures described for the boropeptide series in Schemes 4, 6-8.

- 5 The preparation of amidine derivative (XLVIII) and phenylguanidines of formula (L) from amino acids (XLVII) and (XLIX) is shown in Scheme 13. The conditions used to prepare amidines of formula (XLVIII) is discussed for (XX) of Scheme 5 while the method for formamidinylation of
- 10 (XLIX) to give (L) is the same as that described to prepare (XVII) of Scheme 4.

Scheme 13.



$v = 0-10$

M = alkyl or benzyl


PG = suitable amine protecting group

15

As shown in Scheme 14, appropriately protected derivatives of formulae (XLII)-(L), wherein M is an alkyl

or benzyl group can be coupled with *N,N*-disubstituted acid (IV) or (VI) (wherein M is hydrogen). The methodology to accomplish these transformations is the same as that used to prepare boropeptides (IX) and (X) of Scheme 3. The X group in compounds of formulae (XLII) through (L) and (LI) in Scheme 14, as well as in compounds illustrated in the Schemes to follow, is a protected version of the terminal functional group X, as defined by Formula (I), unless deprotection is indicated to obtain the final compound of the sequence.

Scheme 14.



15


It is understood that the protecting group(s) used should be compatible with the conditions of the process discussed; a good source for information on protecting group chemistry is Greene and Wuts (1991).

20

The preparation of the thrombin inhibitors trihalomethyl ketone (LIII) and α -ketoester (LIV) are shown in Scheme 15. The coupled ester (LI), wherein M is alkyl or benzyl can be converted to the acid (M is hydrogen) by the methodology appropriate for the particular ester functionality as described in Greene and Wuts (1984). The aldehyde (LII) can be prepared by selective reduction of the acid (LI, M is hydrogen) to the primary alcohol followed by oxidation.

25

Scheme 15.



- 5 To obtain the primary alcohol, the acid can be transformed to the mixed anhydride by condensation of the trialkylammonium salt of the acid with an alkyl- or arylchloroformate in an inert non-polar solvent such as tetrahydrofuran, 1,2-dimethoxyethane or toluene at -78°C to
- 10 room temperature. The solution of the resulting mixed anhydride is filtered and reduced to the peptidyl alcohol with an excess of a borohydride reducing agent in a compatible solvent like water or an alcohol at -78°C to room temperature according to the method of Rodriguez et.
- 15 al., *Tetrahedron Lett.* 32, 923 (1991). The peptidyl alcohol can be oxidized to aldehyde (LII) without over oxidation by a variety of procedures, as detailed by Hudlicky in *Oxidations in Organic Chemistry*, American Chemical Society, p. 114 (1991); the preferred methods
- 20 include Swern oxidation described by Omura and Swern, *Tetrahedron* 34, 1651 (1978); and the Pfitzner-Moffat oxidation described by Fearon et al. in *J. Med. Chem.* 30, 1617 (1987). A two step protocol reported by Edwards,

the trifluoromethyl ketones (LIII) (J is fluorine) from aldehyde (LII). In this procedure a metallated trifluoromethyl anion is generated from an excess of trifluoromethyliodide or -bromide and an active metal such as zinc, magnesium, lithium or cadmium in inert, anhydrous solvents like tetrahydrofuran or N,N-dimethylformamide at temperatures of -100°C up to the reflux point of the solvent. Alternatively, the metalated trifluoromethyl anion may be generated by the transmetalation of trifluoromethyliodide or -bromide with an organometallic compound such as a Grignard reagent or alkyllithium compound in an inert solvent like tetrahydrofuran, hexane or ether at temperatures ranging from -78°C up to the reflux point of the selected solvent. Aldehyde (LII) can be added to the solution of the metalated trifluoromethyl anion to form the trifluoroethanol derivative at temperatures of -100°C or higher. To obtain the trifluoromethyl ketone (LIII) where J is fluoro, the alcohol is oxidized by the Pfitzner-Moffat or Swern procedure. Removal of the protecting group(s) on terminal group X by the appropriate method will provide the thrombin inhibitors of formulae (LIII).


Trihalomethyl analogs of (LIII), where J is fluoro can also be prepared from aldehyde (LII) by a different method. The trihalomethyl ketones are prepared by treating aldehyde (LII) with either the trimethylsilyl trihaloacetate or the potassium or sodium trihaloacetate in a polar solvent such as an alcohol, N,N-dimethylformamide or methylsulfoxide with or without a base such as a trialkyl amine, potassium carbonate or sodium hydroxide at temperatures of -78°C or higher according to the method of Beaulieu, *Tetrahedron Lett.* 32, 1031 (1991); Shell Int. Res., European Patent Application EP 16504). The resulting *a,a,a*-trihaloethanol is oxidized and group X can be deprotected as above to give the thrombin inhibitors or formulae (LIII).

The α -ketoester thrombin inhibitors, exemplified by (LV), are prepared according to a route disclosed by Iwanowicz et. al. in *Bioorgan. Med. Chem. Lett.* 12, 1607 (1992). The tris(ethylthio)methyl anion is added to the
5 peptidyl aldehyde (LII) in a solvent such as tetrahydrofuran, 1,2-dimethoxyethane or toluene at -100°C or higher to give the alcohol (LIV). The α -hydroxyl ester is generated from (LIV) by treatment with a mixture of mercuric salts, such as mercuric chloride and mercuric
10 oxide, in an alcohol or water. Swern or Pfitzner-Moffat oxidation of the α -hydroxyl ester followed by the deprotection of substituent X protecting group provides thrombin inhibitors of formula (LV).

Another method for the preparation of compound (LV)
15 substitutes a 1-lithio-1-alkoxyethene or 1-magnesio-1-alkoxyethene for the tris(ethylthio)methyl anion of Scheme 15 in an addition reaction with peptidyl aldehyde (LII). There can be obtained an adduct analogous to the tris(ethylthio)hydroxyethyl compound (LIV) when excess 1-
20 magnesio- or 1-lithio-1-alkoxyethene anion is stirred at temperatures ranging from -100°C to ambient temperature with (LII) in anhydrous solvents such as diethyl ether or tetrahydrofuran. This alkoxyolefin product may then be transformed to (LV) by oxidative cleavage with reagents
25 such as ozone or periodate in an inert solvent such as a halohydrocarbon, lower alkyl ketone, an alcohol or water at temperatures ranging from -100°C to ambient temperature, followed by oxidation of the intervening α -hydroxyester and deprotection as described above.

30 The preparation of the α,α -dihalomethylketone thrombin inhibitors of this invention is outlined in Scheme 16.

Scheme 16.



- 5 The α,β -dihalomethylketone (LVII), where J is fluoro can be prepared from the aldehyde (LII) by selective reaction of the aldehyde with the anion of the corresponding dihalomethane. The metalated dihalomethane anion is generated from one equivalent each of a strong hindered
- 10 base, such as lithium tetramethylpiperidide or *tert*butyllithium, and the selected dihalomethane in an anhydrous, inert solvent like tetrahydrofuran or 1,2-dimethoxyethane at -100°C or higher according to the method of Taguchi et. al. *Bull. Chem. Soc. Jpn.*, 50, 1588 (1977).
- 15 The metalated dihalomethane anion can be added to the aldehyde (LII) at -100°C or higher. Alternatively, the dihalomethane anion is generated from a dihalomethyl(trimethyl)silane and an anhydrous fluoride ion source such as tris(diethylamino)sulfonium difluoromethyl
- 20 silicate in an inert solvent like benzene, acetonitrile or tetrahydrofuran at -78°C or higher, then (LII) can be added to give dihaloethanol (LVI) according to the method of

Fujita and Hiyama, *J. Am. Chem. Soc.* 107, 4085 (1985).

The resulting dihaloethanol can be oxidized to ketone (LVII) by the Swern or Pfitzner-Moffat procedure. Removal of the protecting group(s) on substituent X of (LVII) gives the α,α -dihalomethylketone thrombin inhibitors.


α -Halomethylketone thrombin inhibitors can be prepared by the process illustrated in Scheme 17.

The acid chloride (LVIII) can be prepared from acid (LI), wherein M is hydrogen or its trialkylammonium, sodium or potassium salt with a chlorinating agent such as thionyl chloride, oxalyl chloride or dichloromethylmethyl ether in a solvent like tetrahydrofuran or dichloromethane with or without a catalytic amount of *N,N*-dimethylformamide at -78°C or higher. Alternatively, the mixed anhydride of

(LI) may be prepared as described for (LI) in Scheme 15.

Compound (LVIII) or the mixed anhydride of (LI) can be treated with an ether solution of diazomethane and either anhydrous hydrogen fluoride or hydrogen chloride gas according to that described by McPhee and Klingsbury, *Org. Synth. Coll. III*, 119 (1955); or hydrogen bromide according to the method Miescher and Kaji, *Helv. Chim. Acta.* 24, 1471 (1941).

Scheme 17.




- 5 Selection of the hydrogen fluoride gas will give the α -fluoromethylketone analog, (LIX) wherein J is fluoro; and hydrogen chloride gas gives the α -chloromethylketone analog (LIX) wherein J is chloro. Deprotection of X gives the corresponding thrombin inhibitors of (LIX).
- 10 The general preparative route for the α, β -diketoester, -amide and -ketone thrombin inhibitors of this invention is exemplified in Scheme 18. Compound (LVIII) or the mixed anhydride of (LI) can be reacted with a Wittig reagent such as methyl (triphenyl-phosphoranylidene)acetate in a solvent
- 15 like tetrahydrofuran or acetonitrile at temperatures ranging from 0°C to the reflux point of the solvent to give (LX). Oxidative cleavage of the phosphoranylidene (LX) with an oxidizing agent like ozone or OXONE™ in an inert solvent such as tetrahydrofuran, dichloromethane or water
- 20 at temperatures of -78°C or higher gives the vicinal

tricarbonyl compound (LXI), analogous to that described by Wasserman and Vu, *Tetrahedron Lett.* 31, 5205 (1990). Cleavage of the protecting group can provide thrombin inhibitors of formula (LXI).


5

Scheme 18.



- 10 The preparative routes for the synthesis of the α -mono- and α,α -dihalo- β -ketoester -amide and ketone thrombin inhibitors of this invention are summarized in Scheme 19. The exemplified β -ketoester (LXII) is available from the acid derivative (LI). The acid (LI) can be treated with
- 15 carbonyl diimidazole in an inert solvent such as tetrahydrofuran or dichloromethane at 0°C or higher to form the acyl imidazole. This acyl imidazole, or the mixed anhydride of (LI), can be further reacted with
- 20 lithioethylacetate in solvents such as 1,2-dimethoxyethane or tetrahydrofuran/hexane at temperatures ranging from -100°C to ambient temperature, according to the method of Dow, *J. Org. Chem.* 55, 386 (1990) to give β -ketoester (LXII).

Scheme 19.



- 5 Compound (LXII) serves as a substrate for both mono- and dihalogenation. The α -monochloro analog of (LXIII), where J is each chlorine and hydrogen, can be prepared by controlled halogenation reactions with reagents like N-chlorosuccinimide or thionyl chloride in an inert
- 10 halogenated solvent and at temperatures ranging from -20°C to the reflux point of the selected solvent according to the methods of Uhle, *J. Am. Chem. Soc.* 83, 1460 (1961); and DeKimpe et. al., *Synthesis* 2, 188 (1987). The α,α -dihalo analog (LXIV) where J is chloro is available from
- 15 halogenation with molecular chlorine in a halogenated solvent at temperatures of -20°C or higher according to the method of Bigelow and Hanslick, *Org. Syn. Coll. II*, 244 (1943). Reagents such as N-

fluorobis[(trifluoromethyl)sulfonyl]imide are useful for the preparation of mono- and difluoro analogs (LXIII) and (LXIV) by reacting the appropriate stoichiometry of this reagent with (LXII) in a halogenated solvent at

5 temperatures of -78°C or higher according to the method of Resnati and DesMarteau, *J. Org. Chem.* 56, 4925 (1991). Deprotection of substituent X of the halogenation products (LXIII) and (LXIV) can provide the corresponding thrombin inhibitors.


10 Compounds of formula (LXII) also serves as a substrate for the preparation of tricarbonyl derivatives such as (LXI) (Scheme 18). Condensation of (LXII) with an aldehyde, such as benzaldehyde, gives an *b*-ene-*a,g*-dione. This ene-dione can be oxidatively cleaved with reagents

15 like ozone or periodate to give tricarbonyl analog (LXI).

The preparation of the mono- and dihalomethylketone thrombin inhibitors is outlined in Scheme 20. The intermediates formed in the preparation of the α -mono- and α,α -dihalo-*b*-ketoester thrombin inhibitors of Scheme 19 can

20 be used in these preparations.

Scheme 20.



25


The decarboxylation of these halogenation products, (LXIII) and (LXIV), can be effected by saponification of the ester with mild aqueous base such as potassium carbonate or sodium hydroxide in water miscible solvents like an

alcohol, tetrahydrofuran or *N,N*-dimethylformamide, followed by adjusting the pH to a range of 4 to 6. This mixture can be either stirred at ambient temperatures or heated at various temperatures up to the reflux point of the solvent
5 chosen until the formation of (LVII) or (LIX) is complete and is similar to that reported in Matsuda et. al., *Tetrahedron Lett.* 30, 4259 (1989). Removal of protecting group(s) can provide thrombin inhibitors corresponding to (LVII) or (LIX).

10


Compounds of the present invention wherein the electrophilic group A is an α -hydroxy ester are prepared according to Scheme 21. The appropriate amino acid (LXVI) is reduced to the corresponding alcohol (LXVII) via NaBH₄
15 treatment of the mixed anhydride. (LXVII) is then oxidized to the aldehyde (LXVIII) utilizing a Swern oxidation. (LXVIII) is converted to the thiocarbinal (XIX) via a lithiated orthoethylthioformate followed by conversion to the α -hydroxy methyl ester (LXX) upon treatment with
20 mercuric salts. (LXX) is readily converted to the peptides of the invention via coupling with (IV) (M=H) to form (LXXI) under the conditions described in Scheme 3.

Scheme 21.




The preparation of compounds of the present invention
 5 wherein A is an α -keto ester, α -keto acid or α -keto ester
 hemiacetal is shown in Scheme 22. (LXXI) is converted to
 the α -keto ester LXXIII via a Swern Oxidation. (LXXIII) is
 further elaborated to hemiketal (LXXIV) by treating with
 10 methanol or to (LXXV) by treatment with hydroxide.

Scheme 22.




- 5 The compounds of the present invention wherein A is an alkyl carbinol (LXXVII) or an alkyl ketone (LXXVIII) are prepared according to Scheme 23. (LXXVIII) is treated with an alkyl-CeCl₂ to form the alkyl carbinol (LXXVII) which is then subjected to the Swern oxidation to yield the alkyl
- 10 ketone (LXXVIII). (LXXVIII) is then further elaborated to the peptide compounds of the present invention (LXXX) by following the conditions outlined in Scheme 3.



- Compounds of the present invention wherein R^3 is an optionally substituted thiophenylbenzoyl group (LXXXIII) are prepared according to Scheme 24. The desired thiophenol (LXXXII) is coupled to the bromobenzoic acid via a copper promoted coupling reaction to form (LXXXIII). (LXXXIII) is then coupled to (IV) ($\text{M}=\text{H}$) under the conditions outlined in Scheme 3 to form (LXXXIV) which is then coupled to (LXXXVI) under the conditions outlined in Scheme 3 to form (LXXXV). It is understood that (LXXXV) need not be in final form and that any or all of the functional groups present may be converted to their desired final form using methods known to the skilled artisan.


Scheme 24.



Compounds of the present invention wherein R^3 is an
 5 optionally substituted benzylbenzoyl group are prepared
 according to Scheme 25. An optionally substituted
 bromophenyl compound (LXXXVII) is converted to its phenyl
 lithium derivative and reacted with a bromobenzaldehyde to
 form the optionally substituted diphenylmethyl carbinol
 10 (LXXXVIII). (LXXXVIII) is further reduced to the
 substituted diphenylmethane (LXXXIX) with Et_3SiH . (LXXXIX)
 is converted to XC. XC is then further elaborated to
 XCI and XCII by following the appropriate outline in
 previous schemes.

15

Scheme 25




Inhibitors which contain a substituted phenethyl group as R^{11} are easily prepared according to Scheme 26. The appropriate phenylacetate (XCIV) is readily dialkylated with an excess of a small, unbranched alkyl halide ($\text{R}^{18}\text{-X}$) and a suitable base such as potassium tert-butoxide to form an α,α -bisalkylated ester (XCIVa). Reduction of XCIVa to the

primary alcohol may accomplished with many hydride reducing agents, a preferred agent being lithium aluminum hydride. Oxidation of the alcohol under Swern conditions or with pyridinium chlorochromate affords the aldehyde (XCV).

5 (XCV) is best coupled to the appropriate glycine derivative by reductive amination, a preferred procedure being reduction with sodium cyanoborohydride. The resulting amine (XCVI) is then coupled with R^3 by any of several standard amide bond forming reactions familiar to those
10 skilled in the art. A preferred method involves treating the amine with the appropriate acid chloride in the presence of a tertiary amine base, such as N-methylmorpholine or triethylamine. Saponification of the ester affords the carboxylic acid (XCVII).


15 The acid (XCVII) is then coupled to (LXXXVI) and elaborated to the inhibitors of the present invention by following the procedures outlined in Schemes 3, 4, and 5.

Scheme 26.



Inhibitors which contain a 1,w-alkanediyl substituted
 5 phenethyl group (XCVb) as R¹¹ are easily prepared according
 to Scheme 27. This procedure is similar to that of Scheme
 26, except that a 1,w-bifunctional alkylating agent (X-R¹⁸-
 X) instead of a monofunctional alkylating agent (R¹⁸-X).
 In this manner, inhibitors of the present invention with
 10 the general formula (XCVIIIb) may be prepared.

Scheme 27.




Inhibitors in which R³ is an acylalkyl terminated by a
5 carboxylic acid or ester (CI) are prepared by the general
route described in Scheme 28. Reaction of a suitably
substituted cyclic anhydride (C) with an alkoxide such as
sodium benzyl oxide affords a mono-protected diacid (CI).

(CI) is then coupled to an appropriate N-alkylglycine derivative ((IV), (M=H) by any of a number of methods known to the skilled artisan. The choice of ester groups should allow for selective deprotection of the glycine carboxylate. Preferred ester groups are methyl or ethyl on the glycine carboxylate and benzyl on the acylalkyl chain,

so that saponification gives the acid (CII). (CII) is then converted to the final products (CIII) following methods described in previous schemes.

5

Scheme 28.



Experimental Section

Intermediate 1

10

N-Methyl-*N*-[(3-phenyl)propionyl]glycine

Part A: To hydrocinnamic acid (10.0 g, 66.7 mmol) and 4-methylmorpholine (6.74 g, 66.7 mmol) in tetrahydrofuran (THF, 200 mL) at 0°C was added *n*-butylchloroformate. The reaction was maintained at 0°C for 15 minutes, and the hydrochloride salt of sarcosine ethyl ester (10.23 g, 66.7 mmol) followed by triethylamine (Et_3N , 16.84 g, 166.8 mmol) was added. The reaction was allowed to thaw to ambient temperature and stirred for 18 hours. After this time, the solvent was removed and the residue partitioned between aqueous hydrochloric acid (HCl, 1 N, 200 mL) and ethyl acetate (EtOAc, 200 mL). The aqueous acid phase was extracted with additional EtOAc (200 mL), the combined

organic extracts were washed with HCl (1 N, 100 mL), saturated sodium bicarbonate (NaHCO₃, 100 mL) and brine (100 mL). The organic phase was dried over sodium sulfate and evaporated to give ethyl *N*-methyl-*N*-[(3-phenyl)propionyl]glycine (11.81 g, 71% yield). This material was used in the next step without further purification.

Part B: To a solution of ethyl *N*-methyl-*N*-[(3-phenyl)propionyl]glycine (11.81 g, 47.4 mmol) in ethanol (300 mL) was added aqueous sodium hydroxide (NaOH, 1 N, 94.8 mL, 94.8 mmol). The reaction was stirred at ambient temperature for 18 hour, after which the solvent was removed by distillation in vacuo. The residue was dissolved in HCl (1 N, 100 mL) and the solution extracted with methylene chloride (CH₂Cl₂, 2 x 100 mL). The extracts were dried over sodium sulfate (Na₂SO₄), evaporated and the resulting solid (9.42 g) was recrystallized from EtOAc to give the title compound (7.14 g, 68% yield) as a solid (mp: 123 - 126 °C).

Example 21.1.3

Pinanediol *N*-{*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl}-1-amido-5-aminopentaneboronate, benzenesulfonic acid salt

Part A: A mixture of Intermediate 1 (0.31 g, 1.5 mmol), pinanediol 1-amino-5-bromopentaneboronate (0.57 g, 1.85 mmol), 1-hydroxybenzotriazole (0.20 g, 1.5 mmol), 4-methylmorpholine (0.17 mL, 1.5 mmol), and 1,3-dicyclohexylcarbodiimide (DCC, 0.33 g, 1.5 mmol) were stirred in dry CH₂Cl₂ at 0°C for 1 hour. The reaction was thawed to ambient temperature and stirred an additional 18 hour. After this time, the reaction mixture was diluted with CH₂Cl₂ (25 mL) and filtered. The filtrate was washed with aqueous citric acid (10 %) and saturated NaHCO₃ (25 mL each), dried (Na₂SO₄) and evaporated. The intermediate

pinanediol *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-bromopentaneboronate (0.75 g, 92% yield) was carried on to the next step without further purification.

- 5 Part B: The intermediate from Part A (0.75 g, 1.4 mmol) was heated with sodium azide (NaN₃, 0.15 g, 2.3 mmol) in *N,N*-dimethylformamide (DMF, 10 mL) at 100°C for 2 hours. The reaction mixture was partitioned between water (H₂O) and EtOAc (25 mL each), and the EtOAc layer was washed with
10 additional H₂O (6 x 15 mL). The organic layer was dried (Na₂SO₄) and evaporated to give pinanediol *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-azidopentaneboronate (0.67 g) in 95% yield.
- 15 Part C: The azide from Part B (0.48 g, 0.9 mmol) was dissolved in methanol (MeOH, 15 mL) with benzenesulfonic acid (0.15 g, 0.9 mmol) and Pearlman's catalyst (palladium hydroxide on carbon, 0.05 g). This mixture was shaken under
20 an atmosphere of 50 psi of hydrogen for 18 hours at ambient temperature. The reaction mixture was purged with nitrogen and the catalyst was removed by filtration through a pad of diatomaceous earth. The clear filtrate was evaporated and pinanediol *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-aminopentaneboronate was obtained as its
25 benzenesulfonate salt (0.51 g) in 88% yield. High Res Mass Spec: found (M+H)⁺ 484.334758; calculated (M+H)⁺ = 484.334663.

Intermediate 2

- 30 *N*-[(2-Phenyl)ethyl]-*N*-[(3-phenyl)propionyl]glycine

Part A: A mixture of benzyl glycinate, *p*-toluenesulfonic acid salt (2.68 g, 7.94 mmol), (2-phenyl)bromoethane (0.98 g, 5.29 mmol), and solid NaHCO₃ (1.56 g, 18.5 mmol) in
35 acetonitrile (25 mL) were heated at reflux for 18 hour.

The reaction was concentrated and diluted with EtOAc (25 mL). The organic solution was washed with H₂O (25 mL) and brine (25 mL), dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by elution through a pad of silica gel with a gradient mixture of hexane:EtOAc. The intermediate benzyl N-[(2-phenyl)ethyl]-glycinate (0.82 g) was obtained in 38% yield. Low Res MS: (M+H)⁺ = 270.

Part B: A mixture of intermediate from Part A (0.82 g, 3.04 mmol) and 4-methylmorpholine (0.62 g, 6.08 mmol) in THF (15 mL) at 0°C was added hydrocinnamoyl chloride (0.51 g, 3.04 mmol). The reaction was thawed to ambient temperature and stirred for 1 hour. The reaction mixture was diluted with EtOAc (50 mL), washed with HCl (10%, 25 mL) and NaHCO₃ (saturated, 25 mL), dried (MgSO₄) and evaporated. The intermediate benzyl N-[(2-phenyl)ethyl]-N-[(3-phenyl)-propionyl]glycinate (1.2 g) prepared was used in the next procedure without further purification. LRMS: (M+NH₃)⁺ = 419.0, (M+H)⁺ = 402.1.

Part B A methanol solution (20 mL) of benzyl N-[(2-phenyl)ethyl]-N-[(3-phenyl)propionyl]glycinate (1.3 g, 3.24 mmol) and palladium on carbon (10%, 180 mg) was stirred under 1 atmosphere of hydrogen gas for 18 hours. The reaction was purged with nitrogen and filtered through a pad of diatomaceous earth and evaporated to give N-[(2-phenyl)ethyl]-N-[(3-phenyl)propionyl]glycine (1.0 g) in quantitative yield. LRMS : (M+NH₃)⁺ = 326.

Example 23.1.3

Pinanediol N-{N-[(2-phenyl)ethyl]-N-[(3-phenyl)propionyl]glycyl}-1-amido-5-aminopentaneboronate, hydrochloride salt

Part A: To a solution of *N*-[(2-phenyl)ethyl]-*N*-[(3-phenyl)propionyl]glycine (1.0 g, 3.24 mmol) and 4-methylmorpholine (0.66 g, 6.48 mmol) in THF (15 mL) at 0°C was added isobutylchloroformate (0.44 g, 3.24 mmol). The
5 reaction was stirred for 15 min at 0°C, pinanediol 1-amino-5-bromopentaneboronate (1.23 g, 3.24 mmol) was added followed by additional 4-methylmorpholine (0.33 g, 3.24 mmol) and the reaction was stirred at ambient temperature for 18 hours. The reaction was diluted with EtOAc (50 mL),
10 washed sequentially with HCl (10%) and NaHCO₃ (saturated) and brine (25 mL each), then dried over magnesium sulfate (MgSO₄) and evaporated. The residue was purified by flash chromatography (silica gel) using 3:1 EtOAc:hexane to give pinanediol *N*-[*N*-[(2-phenyl)ethyl]-*N*-[(3-phenyl)propionyl]glycyl]-1-amido-5-bromopentaneboronate
15 (0.8 g) in 43% yield. LRMS: (M+H)⁺ = 637/638, (M-HBr)⁺ = 557.

Part B: The intermediate pinanediol *N*-[*N*-[(2-phenyl)ethyl]-*N*-[(3-phenyl)propionyl]glycyl]-1-amido-5-bromopentaneboronate (0.8 g, 1.4 mmol) and NaN₃ (0.11 g, 1.7 mmol) in DMF (10 mL) was stirred at 100°C for 2 h. The cooled reaction mixture was diluted with EtOAc (50 mL), then it was washed with H₂O (6 x 20 mL) and dried (MgSO₄).
25 The EtOAc solution was evaporated to give pinanediol *N*-[*N*-[(2-phenyl)ethyl]-*N*-[(3-phenyl)propionyl]glycyl]-1-amido-5-azidopentaneboronate (0.7 g) in 86% yield. LRMS : (M+H)⁺ = 600.

Part C: A mixture of the product from Part B (0.7 g, 1.2 mmol) and Pearlman's catalyst (0.1 g) in HCl (1.2 N, 1 mL, 1.2 mmol) and MeOH (20 mL) was stirred under an atmosphere of hydrogen (1 atm) for 2 hours. The reaction mixture was purged with nitrogen, filtered through a pad of
35 diatomaceous earth and evaporated. The residue was dried

by azeotropic distillation with benzene and triturated with hexane to give the title compound (0.45 g) as a yellow powder in 67% yield. LRMS: $(M+H)^+ = 574.4$.

5 Example 8.1.3

N-{*N*-[(2-Phenyl)ethyl]-*N*-[(3-phenyl)propionyl]glycyl}-1-amido-5-aminopentaneboronic acid, hydrogen chloride salt

A mixture of Example 23.1.3 (0.45 g, 0.8 mmol) in diethyl ether (Et₂O): H₂O (15 mL:15 mL) was stirred with phenylboric acid (0.45 g, 3.7 mmol) at ambient temperature for 18 hours. The phases were separated, the Et₂O layer was discarded, and the H₂O layer was washed with Et₂O (15 mL) and 1:1 hexane:EtOAc (15 mL). The H₂O solution was concentrated by distillation under reduced pressure and dried by azeotropic distillation with toluene. The dried residue was dissolved in a minimal amount of CH₂Cl₂ and the title compound was precipitated from solution by the addition of hexane. LRMS: (M+H of glycerol ester)⁺ = 496.

Intermediate 3

N-methyl-*N*-[(3,4-dichlorophenyl)acetyl]glycine

25 The title compound was prepared from commercially available sarcosine ethyl ester and 3,4-dichlorophenylacetic acid according to the procedure of Intermediate 1.

Example 50

30 Pinanediol *N*-{*N*-methyl-*N*-[(3,4-dichlorophenyl)
acetyl]glycyl}-1-amido-4-formamidinobutaneboronate,
hydrochloride salt

Part A: By substituting pinanediol 1-amino-4-
35 bromobutaneboronate for pinanediol 1-amino-5-

bromopentaneboronate and coupling with Intermediate 3 according to the procedure in Example 21.1.3, Parts A-C, the amino intermediate was prepared.

- 5 Part B: To an ethanol solution (20 mL) of the product from Part A (600 mg, 1.2 mmol) was added ethylformimidate hydrogen chloride (400 mg, 3.62 mmol) and 4-dimethylamino pyridine (DMAP, 442 mg, 3.62 mmol). This mixture was heated at reflux for 5 hours, and the reaction mixture was
10 evaporated. The residue was chromatographed (Sephedex LH 20, MeOH elutant) to give the title compound as a yellow solid. LRMS: (M+H)⁺ = 551.

15 Example 51

Pinanediol *N*-(*N*-methyl-*N*-[(3,4-dichlorophenyl)acetyl]glycyl)-1-amido-4-guanidinobutaneboronate, hydrochloride salt

- 20 Part A: The intermediate from Example 50, Part A hydrochloride salt (1.0 g, 2 mmol), formamidine sulfonic acid (0.496 g, 4 mmol) and DMAP (0.488 g, 4 mmol) in ethanol (50 mL) were heated at reflux for 3 hours. The reaction was cooled to ambient temperature, filtered
25 through a pad of Celite, rinsed with chloroform (CHCl₃) and evaporated. The residue was dissolved in CHCl₃ and washed with HCl (0.1 N) and brine, dried and evaporated. The title compound was obtained as a white solid. HRMS calcd for C₂₆H₃₉BN₅O₄Cl₂: 582.247216⁺; found: 566.247905.

30

Intermediate 4

Pinanediol 1-amino-2-(3-cyanophenyl)ethylboronate, hydrochloride salt

35

Part A: The intermediate, $\text{Cl-CH}[\text{CH}_2-(m\text{-cyanophenyl})]\text{BO}_2\text{-C}_{10}\text{H}_{16}$, was prepared from *m*-cyanobenzyl bromide and dichloromethyl boronate pinanediol. Zinc dust (1.0 g) in THF (1 mL) was cooled to 0-5°C and a solution of *m*-cyanobenzyl bromide (1.37 g, 7.0 mmol) in THF (7 mL) was added dropwise (5 sec/drop). The reaction mixture was allowed to stir at 5°C for 2 hours. A mixture consisting of lithium bromide (LiBr, 1.22 g, 14 mmol), copper(I) cyanide (CuCN, 0.63 g, 7.0 mmol) and THF (6 mL) was placed in a 50 mL flask and cooled to -40°C; the benzylic organozinc reagent was added by cannulation. The mixture was allowed to warm to -20°C and stir for 5 minutes. Following cooling to -78°C, neat dichloromethyl boronic acid pinanediol (1.47 g, 5.6 mmol) was added dropwise and the resulting mixture was stirred at -78°C for 2 h, and additionally at room temperature for 2 days. Aqueous ammonium chloride (NH_4Cl , saturated, 20 mL) was added to the mixture and the aqueous solution was extracted with Et_2O (3 x 20 mL). The combined organic layers was dried over anhydrous MgSO_4 and evaporated in vacuo to give crude compound (1.8 g). Purification was carried out using silica gel chromatography where the column was stepwise eluted with hexane (100 mL) and then 15% ether in hexane (200 mL) to give the desired product (0.53 g) in 27% yield. LRMS($\text{NH}_3\text{-CI}$) *m/e* for $\text{M}+\text{NH}_4^+$ calcd. for $\text{C}_{19}\text{H}_{23}\text{NO}_2\text{BCl}$: 361.2; found: 361.1.

Part B: To a solution of hexamethyldisilazane (0.21 mL, 0.98 mmol) in THF (2 mL) at -78°C was added *n*-butyllithium (1.45 M, 0.67 mL, 0.98 mmol). The solution was allowed to slowly warm to room temperature to ensure the anion generation was complete and recooled to -78°C, upon which a solution of product from Part A (0.33 g, 0.98 mmol) in THF (2 mL) was added. The mixture was allowed to warm to room temperature and to stir overnight. The volatiles were

- evaporated and hexane (8 mL) was added to give a suspension. Anhydrous hydrogen chloride in dioxane (4.1 N, 1.5 mL, 6.0 mmol) was added at -78°C and the mixture was slowly warmed to room temperature and stirred for 2 hour.
- 5 Additional hexane (6 mL) was added and crude product was isolated as a precipitate. This product was dissolved in CHCl_3 and insoluble material was removed by filtration. The filtrate was evaporated at a reduced pressure to give an oil (~0.2 g). Final purification was achieved by
- 10 chromatography on a column of Sephadex™ LH 20 column using MeOH as a solvent. H-boroPhe(m-CN)- $\text{C}_{10}\text{H}_{16}\cdot\text{HCl}$ was obtained as an oil (0.12 g) in 34% yield. HRMS($\text{NH}_3\text{-CI}$) m/e ($\text{M}+\text{H}$)⁺ calcd. for $\text{C}_{19}\text{H}_{26}\text{BN}_2\text{O}_2$: 325.2087; found: 325.2094.

15

Example 52

Pinanediol N-{N-methyl-N-[(3,4-dichlorophenyl)acetyl]glycyl}-l-amido-2-(3-cyanophenyl)ethylboronate

20

- Part A: To Intermediate 3 (0.77 g, 2.8 mmol) and 4-methylmorpholine (0.28 g, 2.8 mmol) in THF (50 mL) at -20°C was added isobutylchloroformate (0.38 g, 2.8 mmol). After 20 minutes at -20°C, the cold solution was added to a -20°C
- 25 solution of Intermediate 4 (1.0 g, 2.8 mmol) and Et_3N (0.28 g, 2.8 mmol) in CHCl_3 (50 mL). This mixture was maintained at -20°C for 5 hours and stirred at ambient temperature for 18 hours. The reaction was filtered and concentrated in vacuo. The residue was dissolved in EtOAc, washed with HCl (0.1N), saturated NaHCO_3 and brine. After the solution was
- 30 dried and evaporated, the resulting yellow solid was applied to a column of Florisil and the desired product eluted with a gradient of CHCl_3 : MeOH (0% MeOH to 7% MeOH). The title compound was obtained as a white solid. HRMS:

calcd. (M+H)⁺ for C₃₀H₃₅BN₃O₄Cl₂: 582.209768; found:
582.209631.

5

Example 53

Pinanediol *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-(*N*-methylguanidino)butylboronate, hydrochloride salt

Part A: Pinanediol *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-aminobutylboronate, hydrochloride salt was prepared by the method outlined for Example 21.1.3, wherein pinanediol 1-amino-4-bromobutylboronate hydrochloride was used instead of pinanediol 1-amino-5-bromopentane-boronate hydrochloride.

15

Part B: To a solution of the product from Part A (0.45 g, 0.89 mmol) in ethanol (10 mL) was added DMAP (0.22 g, 1.78 mmol). After 15 minutes at room temperature, *N*-methylaminoiminomethanesulfonic acid (0.25 g, 1.78 mmol) was added and the resulting suspension stirred at reflux for 5 hours. The reaction was cooled to room temperature, filtered, the precipitate washed with CHCl₃ and the combined filtrate concentrated under vacuum. The resulting oil was dissolved in CHCl₃ (40 mL) and the organic solution washed with ice cold HCl (0.1 M, 1x10 mL), ice cold H₂O (1x10 mL), brine and dried (MgSO₄). The filtered solution was concentrated *in vacuo* to give of the desired *N*-methyl guanidino compound (0.35 g) in 70% yield. The material was purified through a florisil column using 10% MeOH/CHCl₃ as eluant to give the purified product (0.22 g); LRMS: (M+H)⁺: 526.

25
30

35

Example 54

Ac-(D)Phe-Sar-boroLys-OH

Part A: Boc-(D)Phe-OH (6.9 g, 26 mmol) was dissolved in
5 THF (50 mL) and 4-methylmorpholine (2.86 mL, 26 mmol) was
added. The solution was cooled to -20°C and
isobutylchloroformate (3.38 mL, 26 mmol) was added.
After stirring 5 minutes at -20°C, the mixture was added to
a cold solution of H-Sar-Bzl-toluenesulfonic acid dissolved
10 in CHCl₃ (50 mL), followed by Et₃N (3.6 mL, 26 mmol).
The mixture was allowed to stir for 1 hour at -20°C and 2 h
at room temperature. The solids were removed by filtration
and the solvent was removed by evaporation. The residue
was dissolved in EtOAc and was washed with HCl (0.20 N),
15 NaHCO₃ (5%), and brine. The solution was dried over
anhydrous Na₂SO₄, filtered, and evaporated to yield Boc-
(D)Phe-Sar-O-Bzl as thick oil (10.4 g).

Part B: The product from Part A (10.4 g) was dissolved in
20 MeOH (100 mL) and the sample was hydrogenated for 2 hour on
a Parr apparatus in the presence of palladium on carbon
(10%, 0.5 g). The catalysis was removed by filtration and
solvent was evaporated to yield Boc-(D)Phe-Sar-OH as a foam
(7.8 g).

25 Part C: The mixed anhydride of product from Part B (4.42
g, 13.1 mmol) was prepared as previously described and
coupled to NH₂-CH[(CH₂)₄Br]BO₂C₁₀H₁₆•HCl (5.0 g, 13.1
mmol) using the procedure described in Part A. The crude
30 product (7.7 g) was purified by chromatography of a 4.2 g
portion on a 2.5 x 100 cm column of Sephadex LH-20 using
MeOH as a solvent to give Boc-(D)Phe-Sar-NH-CH[(CH₂)₄-
Br]BO₂C₁₀H₁₆.

Part D: The product from Part C (3.5 g, 5.8 mmol) was dissolved in anhydrous HCl in dioxane (4.1 N, 50 mL) and was stirred for 1 hour at room temperature. Solvent and excess HCl were removed by evaporation. The residue was
5 triturated with hexane to yield H-(D)Phe-Sar-NH-CH[(CH₂)₄-Br]BO₂C₁₀H₁₆•HCl (2.9 g).

Part E: The product from Part D (2.9 g, 4.8 mmol) was dissolved in 30 mL of a 50% (v/v) solution of dioxane:
10 water and acetic anhydride (0.92 mL, 9.7 mmol) was added. NaHCO₃ (0.81 g, 9.7 mmol) was added and the solution was allowed to stir 45 minutes at room temperature. Acetic acid (3 mL) was added and solution was concentrated approximately 50% by evaporation. It was diluted to 100 mL
15 with EtOAc and was washed with NaHCO₃ (5%), HCl (0.2 N), and brine. The organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated to yield Ac-(D)Phe-Sar-NH-CH[(CH₂)₄-Br]BO₂C₁₀H₁₆ as a foam (2.7 g). HRMS calcd for C₂₉H₄₃N₃O₅BBR (M+H): 604.2557; found: 604.2558.

20

Part F: The product from Part E (2.5 g, 4.1 mmol) and NaN₃ (0.54 g, 8.3 mmol) were dissolved in DMF (5 mL) and heated at 100°C for 1 hour. The reaction was allowed to cool and was diluted with EtOAc (100 mL). The organic
25 phase was washed with H₂O and saturated brine, dried over Na₂SO₄, filtered, and evaporated to yield Ac-(D)Phe-Sar-NH-CH[(CH₂)₄-N₃]BO₂C₁₀H₁₆ as a white foam (2.2 g).

Part G: The product from Part F (2.0 g, 3.5 mmol) was
30 dissolved in MeOH (100 mL) and was hydrogenated on a Parr apparatus in the presence of HCl in dioxane (4.1 N, 1.3 mL, 5.3 mmol) and palladium on carbon (10%, 0.5 g). The catalysis was removed by filtration and solvent was removed by evaporation. The product, Ac-(D)Phe-Pro-boroLys-
35 C₁₀H₁₆•HCl (Ac-(D)Phe-Sar-NH-CH[(CH₂)₄-NH₂]BO₂C₁₀H₁₆•HCl),

was purified by chromatography on 2.5 X 100 cm column of LH-20 in MeOH to yield 1.8 g.

Part H: The product from Part G (1.5 g, 2.5 mmoles) and
5 phenyl boronic acid (1.5 g, 12 mmoles) was dissolved in H₂O
and Et₂O (15 ml each). The mixture was stoppered and
allowed to stir for 3 hour at room temperature. The phases
were separated and the aqueous phase was washed extensively
10 with Et₂O. The aqueous phase was evaporated, dried in
vacuo., and triturated with Et₂O to yield the title
compound (0.98 g). An analytical sample was prepared as
the pinacol ester by treating 4 mg of the boronic acid with
2 equivalents of pinacol in 1.4 ml of MeOH for 5 minutes
and evaporating solvent. HRMS calcd for the pinacol ester
15 C₂₅H₄₁N₄O₅B (M+H): 489.3248. found: 489.3242.

Example 55

20 Pinanediol *N*-(*N*-2-propyl-*N*-[(3-phenyl)propionyl]glycyl)-1-
amido-5-aminopentaneboronate, hydrochloride salt

Part A: A mixture of glycine methyl ester hydrochloride
(3.83 g, 30.5 mmol), acetone (1.77 g, 30.5 mmol) and NaOH
(1.22 g, 30.5 mmol) in MeOH (200 mL) was stirred under an
25 atmosphere of hydrogen (1 atm) in the presence of palladium
on carbon (10%, 0.4 g) for 24 hours. The reaction was
flushed with nitrogen and filtered through a Celite pad,
acidified with HCl (1N), dried (MgSO₄) and evaporated.
Trituration of the residue with Et₂O gave *N*-2-propylglycine
30 methyl ester hydrochloride (1.0 g) as an off-white solid;
LRMS (M+H)⁺ = 132.1.

Part B: To the hydrochloride salt prepared above (1.0 g,
5.97 mmol) and hydrocinnamic acid (0.9 g, 5.97 mmol) in DMF
35 (20 mL) was added *O*-benzotriazole-*N,N,N',N'*-

tetramethyluronium hexafluorophosphate (2.26 g, 5.97 mmol) followed by *N,N*-diisopropylethylamine (1.69 g, 13.1 mmol). The reaction was stirred at ambient temperature for 48 hours. The reaction mixture was diluted with 1:1 EtOAc:hexane and washed with H₂O (2 x), HCl (10%), saturated NaHCO₃ and brine. The solution was dried (MgSO₄), evaporated, and combined with an additional material obtained by the same acylation procedure. The combined batches were purified by flash chromatography on silica gel with 2:1 hexane:EtOAc as the eluent. There was obtained *N*-2-propyl-*N*-[(3-phenyl)propionyl]glycine methyl ester (2.8 g); LRMS (M+H)⁺ = 264.0.

Part C: A mixture of the ester from Part B (2.8 g, 10.52 mmol) and LiOH monohydrate in THF:H₂O (20 mL:10 mL) was stirred at ambient temperature for 18 hours. The reaction was diluted with H₂O and washed with 1:1 hexane:EtOAc and the organic washings were discarded. The aqueous layer was acidified with HCl (10%) and extracted with EtOAc. The EtOAc extract was washed with brine, dried (MgSO₄) and evaporated to give *N*-2-propyl-*N*-[(3-phenyl)propionyl]glycine (2.0 g); LRMS (M+H)⁺ = 250.1.

Part D: *N*-2-propyl-*N*-[(3-phenyl)propionyl]glycine was reacted with pinanediol 1-amino-5-bromopentaneboronate according to the procedure of Example 23.1.3 to prepare pinanediol *N*-{*N*-2-isopropyl-*N*-[(3-phenyl)propionyl]glycyl}-1-amido-5-bromopentaneboronate; LRMS (M+H)⁺ = 575/577.

Part E-F: This material was reacted with NaN₃ according to the procedure in Example 23.1.3 to give pinanediol *N*-{*N*-2-isopropyl-*N*-[(3-phenyl)propionyl]glycyl}-1-amido-5-azidopentaneboronate; LRMS (M+H)⁺ = 538.3. The azide was hydrogenated under the conditions in Example 23.1.3 to give the title compound, pinanediol *N*-{*N*-2-propyl-*N*-[(3-

phenyl)propionyl]-glycyl)-1-amido-5-aminopentaneboronate hydrochloride; LRMS (M+H)⁺ = 512.

5

Example 56

N-(*N*-2-propyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-aminopentaneboronic acid, hydrochloride salt

Part A: *N*-(*N*-2-propyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-aminopentane-boronic acid, hydrochloride salt, was prepared from pinanediol *N*-(*N*-2-propyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt by the procedure of Example 8.1.3; LRMS (M+H-H₂O)⁺ = 360.1, (M+H-2H₂O)⁺ = 342.0.

15

Example 57

Pinanediol *N*-(*N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt

20

Part A: A mixture of 2-(methylphenyl)benzoic acid (3.09 g, 14.55 mmol), sarcosine ethyl ester hydrochloride salt (2.23 g, 14.55 mmol), DCC (3.0 g, 14.55 mmol), HOBT (1.97 g, 14.55 mmol) and Et₃N (1.47 g, 14.55 mmol) in THF (50 mL) were stirred at ambient temperature for 48 hours. The reaction was evaporated and the residue dissolved in EtOAc. The EtOAc solution was washed with HCl (10%), saturated NaHCO₃ and brine, and dried (MgSO₄). The EtOAc solution was filtered through a plug of silica gel followed by a second filtration through a plug of neutral alumina. Evaporation of the solution gave *N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycine ethyl ester (4.5 g); LRMS (M+H)⁺ = 312.2.

30

Part B: *N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycine ethyl ester (4.5 g, 14.45 mmol) and KOH (2.43 g, 43.4 mmol) in MeOH/H₂O (200 mL/50 mL) were heated at reflux for 45 minutes. The solvent was removed and the residue dissolved in H₂O. The aqueous solution was washed with Et₂O and acidified with HCl (10%). The acidified aqueous layer was extracted with EtOAc, the EtOAc extract was washed with brine (2 x), dried over (MgSO₄) and evaporated. There was obtained *N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycine (2.0 g); LRMS (M+H)⁺ = 284.1, (M+NH₄)⁺ = 301.1

Part C-E: Pinanediol *N*-(*N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycyl)-1-amido-5-bromopentaneboronate was prepared by reaction of *N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycine with pinanediol 1-amino-5-bromopentaneboronate according to the procedure of Example 23.1.3; LRMS (M+H)⁺ = 611.2. Pinanediol *N*-(*N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycyl)-1-amido-5-bromopentaneboronate was reacted with NaN₃ by under the conditions detailed above to give pinanediol *N*-(*N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycyl)-1-amido-5-azidopentaneboronate; LRMS (M+H)⁺ = 572.4. Hydrogenation of the azide was effected by the conditions previously described to give the title compound, pinanediol *N*-(*N*-methyl-*N*-[2-(methylphenyl)benzoyl]glycyl)-1-amido-5-amino-pentaneboronate, hydrochloride acid salt; LRMS (M+H)⁺ = 546.3.

Example 35.5.3

Part A: Trimethylsilyl cyanide (5.80 mL, 44.0 mmol) was added dropwise to a solution of benzaldehyde (3.10 g, 29.0 mmol) and zinc iodide (280 mg, 8.80 mmol) at 0 °C. The reaction mixture was warmed to room temperature over 18 h

then treated with saturated aqueous NaHCO_3 (ca. 100 mL). The layers were separated and the aqueous was extracted with EtOAc (2 x 75 mL). The combined organics were washed with saturated aqueous NaCl (1 x 50 mL), dried (Na_2SO_4), and concentrated under reduced pressure to give 3.78 g of 2-[(trimethylsilyl)oxy]-phenylacetonitrile as an oil, which was carried on without purification.

Lithium aluminum hydride (2.10 g, 55.0 mmol) was added in portions over 15 min to a solution of [2 - (trimethylsilyl)oxy]-phenylacetonitrile (3.75 g, 18.3 mmol) in anhydrous THF (75 mL) at 0 °C. The reaction was quenched by the sequential addition of H_2O (2.10 mL), 10% aqueous NaOH (2.10 mL), and H_2O (6.30 mL) then dried (Na_2SO_4) and filtered through a pad of Celite using EtOAc (ca. 75 mL). The filtrate was concentrated under reduced pressure to provide an oil which was purified by flash chromatography, elution with 9:1 CH_2Cl_2 -MeOH containing 2% Et_3N , to give 2-hydroxy-1-phenethylamine (2.40 g) as an oil in 95% yield. (^1H NMR, 300 MHz) δ 7.32 (comp, 5H), 4.66 (dd, 1H, J = 7.8, 4.0 Hz), 3.03 (dd, 1H, J = 12.5, 4.0 Hz), 2.83 (dd, 1H, J = 12.5, 9.1 Hz), 2.46 (br s, 3H). LRMS 155 ($\text{M}+\text{NH}_4$), 138 ($\text{M}+\text{H}$).

Part B: Phosgene (6.0 mL of a 1.93 M solution in toluene (PhCH_3), 12.0 mmol) was added to a solution of 2-hydroxy-1-phenethylamine (1.18 g, 8.60 mmol) in PhCH_3 (100 mL) at 0 °C followed by the dropwise addition of Et_3N (1.80 mL, 13.0 mmol). The reaction mixture was warmed to room temperature over 48 h and poured into EtOAc (ca. 200 mL). The layers were separated and the aqueous was extracted with EtOAc (1 x 50 mL). The combined organics were washed with saturated aqueous NaCl (1 x 100 mL), dried (Na_2SO_4) and concentrated under reduced pressure to give 5-phenyl-2-oxazolidinone (1.05 g) as a solid in 75% yield. (^1H NMR, 300 MHz) δ 7.39 (comp, 5H), 5.69 (br s, 1H), 5.63 (dd, 1H, J = 8.4, 8.1

Hz), 3.99 (dd, 1H, J = 8.4, 8.1 Hz), 3.55 (dd, 1H, J = 8.4, 8.1 Hz). LRMS 181 (M+NH₄), 164 (M+H).

Part C: A solution of 5-phenyl-2-oxazolidinone (500 mg, 3.1 mmol) in anhydrous THF was added dropwise to a suspension of NaH (91 mg, 3.7 mmol) in anhydrous THF at 0 °C. The reaction mixture was warmed to room temperature over 30 min then heated at reflux for 15 min. Methyl bromoacetate (0.32 mL, 3.4 mmol) was added and the mixture was heated at reflux for 2h. The reaction mixture was cooled to room temperature and quenched with H₂O (ca. 20 mL). The aqueous was extracted with EtOAc (2 x 75 mL). The combined organics were washed with saturated aqueous NaCl (1 x 50 mL), dried (MgSO₄), and concentrated under reduced pressure to give an oil which was purified by flash chromatography, elution with 3:1 EtOAc-hexanes, to provide 2-[3-(5-phenyl-2-oxazolidino)]-acetic acid, methyl ester (545 mg) as an oil in 76% yield. (¹H NMR, 300 MHz) δ 7.42 (comp, 5H), 5.56 (dd, 1H, J = 8.4, 8.1 Hz), 4.10 (d, 2H, J = 3.0 Hz), 4.06 (dd, 1H, J = 8.4, 8.1 Hz), 3.78 (s, 3H), 3.64 (dd, 1H, J = 8.4, 8.1 Hz). LRMS 253 (M+NH₄, base), 236 (M+H).

Part D: A solution of 2-[3-(5-phenyl-2-oxazolidino)]acetic acid, methyl ester (540 mg, 2.30 mmol) in MeOH (10 mL) and H₂O (10 mL) was treated with NaOH (138 mg, 3.40 mmol) and heated at reflux for 15 min. The reaction mixture was cooled to room temperature, acidified to pH 2 with 2M aqueous HCl, and extracted with EtOAc (3 x 50 mL). The combined organics were washed with saturated aqueous NaCl (1 x 25 mL), dried (MgSO₄), and concentrated to give 2-[3-(5-Phenyl-2-oxazolidino)]acetic Acid (505 mg) as an oil in 99% yield. (¹H NMR, 300 MHz) δ 7.41 (comp, 5H), 5.57 (dd, 1H, J = 8.0, 8.0 Hz), 4.15 (s, 2H), 4.05

(dd, 1H, J = 8.0, 8.0 Hz), 3.65 (dd, 1H, J = 8.0, 8.0 Hz).
LRMS 239 (M+NH₄, base), 222 (M+H).

- Part E: Triethylamine (0.23 mL, 1.60 mmol) was added to a mixture of (2R)-4-bromo-1-aminobutane-1-boronic acid, (+)-pinanediol ester hydrochloride (540 mg, 1.47 mmol), HOBT (200 mg, 1.47 mmol), DCC (300 mg, 1.47 mmol), and 2-[3-(5-phenyl-2-oxazolidino)]acetic acid (325 mg, 1.47 mmol) in anhydrous THF (12 mL) and anhydrous DMF (3 mL) at 0 °C.
- 10 The reaction mixture was warmed to room temperature over 18 h, diluted with Et₂O (ca. 30 mL), and filtered through Celite with additional Et₂O (ca. 50 mL). The filtrate was washed with H₂O (3 x 25 mL), saturated aqueous NaCl (1 x 25 mL), dried (Na₂SO₄), and concentrated under reduced
- 15 pressure to give (2R)-2-[[3-(5-phenyl-2-oxazolidino)]-acetamido]-4-bromo-1-aminobutane-1-boronic acid, (+)-pinanediol ester (770 mg) as a foam in 98% yield. LRMS 535, 533 (M+H) 453 (base).
- 20 Part F: A solution of (2R)-2-[[3-(5-phenyl-2-oxazolidino)]-acetamido]-4-bromo-1-aminobutane-1-boronic acid, (+)-pinanediol ester (770 mg, 1.45 mmol) and thiourea (220 mg, 2.90 mmol) in EtOH (15 mL) was heated at reflux for 36 hours then cooled to room temperature and diluted
- 25 with Et₂O (ca. 100 mL) which was decanted. The residue was purified by size exclusion chromatography on Sephadex LH - 20, elution with MeOH, to give a foam. The foam was dissolved in 5 mL of anhydrous THF and treated with Et₂O (ca. 30 mL) to give a solid that was washed with Et₂O (ca.
- 30 10 mL) and dried to afford the title compound (180 mg) as a white powder in 21% yield, mp 93 - 96 °C. LRMS 529 (M+1, base); HRMS Calcd for C₂₆H₃₈BN₄O₅S: 529.2656. Found: 529.2644.

35

Example 35.6.2

5 A solution of (2R)-2-[[3-(5-phenethyl-2-oxazolidino)]-
acetamido]-4-bromo-1-aminobutane-1-boronic acid, (+)-
pinanediol ester (710 mg, 1.27 mmol) was prepared by an
analogous method to that reported for Example 35.5.3,
10 however substituting hydrocinnamaldehyde for benzaldehyde.
Further reaction with thiourea (190 mg, 2.50 mmol) in EtOH
(13 mL) was heated at reflux for 36 h then cooled to room
temperature and diluted with Et₂O (ca. 200 mL) which was
decanted. The residue was purified by size exclusion
15 chromatography on Sephadex LH - 20, elution with MeOH, to
give a foam. The foam was dissolved in 5 mL of anhydrous
THF and treated with Et₂O (ca. 40 mL) to give a solid that
was washed with Et₂O (ca. 10 mL) and dried to afford the
title compound (150 mg) as a white powder in 19% yield, mp
20 93 - 96 °C. LRMS 557 (M+H, base); HRMS Calcd for
C₂₈H₄₂BN₄O₅S: 557.2969. Found: 557.2965.

Example 59

25 Part A: A mixture of 1,8-naphthalic anhydride (1.0 g, 5.1
mmol), glycine (0.42g, 5.6 mmol) and camphorsulfonic acid
(ca. 100 mg) was suspended in absolute EtOH (60 mL) and
DMF (20 mL). The reaction mixture was heated at reflux for
72 h, then the solvent removed by distillation in vacuo.
30 The residue was diluted with H₂O (10 mL), acidified with
HCl (1N) to pH = 3 and the resulting solid was isolated by
filtration and air dried. There was obtained N,N-(1,8-
naphthyldiimido)-glycine (1.22 g) in 95% yield. LRMS :
(M+H)⁺ = 256 ; mp 278-279 °C.

An alternative to the above preparation of *N,N*-(1,8-naphthyldiimido)glycine would be to react the sodium salt of 1,8-naphthalic phthalimide with ethyl bromoacetate in dimethylformamide at 60°C. The resulting ester can then be
5 hydrolyzed with 1*N* sodium hydroxide in ethanol solution to give the title compound.

Part B: *N,N*-(1,8-Napthyldiimido)glycine (0.56 g, 2.1 mmol) and *N*-methylmorpholine (0.53 mL, 4.82 mmol) were
10 dissolved in THF (10 mL) and DMF (1 mL) then cooled to -20 °C. Isobutylchloroformate (0.31 mL, 2.32 mmol) was added to the cold solution and the reaction was stirred at -20 °C for 20 min. After this time a THF suspension (5 mL) of pinanediol 1-amino-4-bromobutane-boronate hydrochloride
15 salt (0.80 g, 2.19 mmol) was added to the mixture and the reaction was allowed to warm to room temperature over 3 h. The reaction was partitioned between H₂O (10 mL) and EtOAc (15 mL). The organic layer was washed with H₂O (3 x 15 mL), then with saturated NaHCO₃ (15 mL), and brine (15 mL).
20 After the solution was dried (MgSO₄) and evaporated under reduced pressure, there was obtained pinanediol *N*-[*N,N*-(1,8-naphthyl-diimido)glycyl]-1-amido-4-bromobutaneboronate (1.2 g) in 98% yield. LRMS: (M+H)⁺ = 568.

25 Part C: To a solution of pinanediol *N*-[*N,N*-(1,8-napthyldiimido)glycyl]-1-amido-4-bromobutaneboronate (1.0 g, 1.76 mmol) in MeOH (30 mL) was added thiourea (0.27 g, 3.53 mmol). The reaction mixture was heated at reflux for 4h, then was allowed to cool to ambient temperature and the
30 solvent was removed by distillation. The resulting viscous liquid was dissolved in a minimal amount of MeOH and passed through a short column (35 g, LH-20 Sephadex) by elution with MeOH. Product containing fractions were combined and concentrated *in vacuo*, then the resulting foam
35 was dissolved in a minimal amount of MeOH and triturated

with Et₂O. After solvent was decanted, the residue was rinsed with additional Et₂O and placed under vacuum. There was obtained pinanediol *N*-[*N,N*-(1,8-naphthyldiimido)glycyl]-1-amido-4-*S*-thiourylbutane-boronate hydrogen bromide (1.0 g) as an amorphous foam in 100% yield. LRMS: (M+H)⁺ = 563.

Part D: To a solution of pinanediol *N*-[*N,N*-(1,8-naphthyldiimido)glycyl]-1-amido-4-bromobutaneboronate (1.21g, 2.13 mmol) in DMF (10 mL) was added NaN₃ (0.28 g, 4.27 mmol). The reaction mixture was heated at 65 °C for 8 h, then it was allowed to cool to room temperature and partitioned between H₂O (15 mL) and EtOAc (20 mL). The layers were separated and the organic phase was washed with H₂O (3x20 mL) and brine (20 mL). This solution was dried (MgSO₄) and concentrated *in vacuo* to give pinanediol *N*-[*N,N*-(1,8-naphthyldiimido)glycyl]-1-amido-4-azidobutaneboronate (0.92 g) in 82% yield. LRMS: (M+H)⁺ = 530.

Part D: A suspension of the azide prepared above (1.19g, 2.25 mmol) and 10% Pd/C (100 mg) in MeOH (15 mL) was placed under an atmosphere of H₂ (1 atm). The reaction mixture was stirred at room temperature for 5 h, then purged with a stream of N₂. The catalyst was removed by filtration through a pad of diatomaceous earth and the filtrate was concentrated under reduced pressure to give pinanediol *N*-[*N,N*-(1,8-naphthyldiimido)glycyl]-1-amido-4-amino-butaneboronate (1.1 g) in 85% yield. LRMS: (M+H)⁺ = 504.

Part E: To a solution of pinanediol *N*-[*N,N*-(1,8-naphthyldiimido)glycyl]-1-amido-4-aminobutaneboronate (0.51 g, 1.01 mmol) in pyridine (10 mL) was added aminoiminomethanesulfonic acid (0.13 g, 1.01 mmol). The reaction mixture was heated at reflux for 4 h, then was concentrated *in vacuo* to give pinanediol *N*-[*N,N*-(1,8-

napthyldiimido)glycyl]-1-amido-4-guanidinobutane-boronate sulfonic acid salt (0.21 g) in 35% yield.

Part F: Pinanediol *N*-[*N,N*-(1,8-napthyldiimido)glycyl]-1-amido-4-guanidinobutane-boronate sulfonic acid salt (0.21 g, 0.35 mmol) was dissolved in MeOH (2 mL) and Et₂O (10 mL). A single portion of phenylboric acid (0.21g, 1.76 mmol) was added to the solution followed by H₂O (10 mL) and this mixture was stirred for 15 h. The phases were separated and the aqueous layer was washed with Et₂O (6 x 10 mL). The aqueous layer was concentrated *in vacuo* and the resulting residue was placed under vacuum to give *N*-[*N,N*-(1,8-napthyldiimido)-glycyl]-1-amido-4-guanidinobutane-boronic acid as the sulfonic acid salt (0.16 g) in quantitative yield.

The following compounds were prepared according to the methods outlined in the Synthesis and Experimental sections. Appropriate physical data to characterize the compounds are provided:

Example 52.1.2

Hydrocinnamoyl-[*N*-(3-methylphenethyl)-Gly]-boroLys-OH hydrochloride salt.

25

Part A. Preparation of 3-methylphenethyl bromide.

To a solution of 3-methylphenethyl alcohol (5.0 g, 36.7 mmol) in methylene chloride at 0° C was added triphenylphosphine (10.6 g, 40.4 mmol) and carbon tetrabromide (13.4 g, 40.4 mmol). The mixture was allowed to stir with warming to 25° C for 16 h. The solvent was removed *in vacuo* and the residue was taken up in ether and filtered through a pad of silica gel. The solvent was removed *in vacuo* to afford 7.0 g (95%) of the title bromide.

Part B. Preparation of N-(3-methylphenethyl)-Gly-OMe.

To a solution of 3-methylphenethyl bromide (7.0 g, 35.0 mmol) in acetonitrile was added glycine methyl ester hydrochloride (6.6 g, 52.5 mmol) and sodium bicarbonate (10.3 g, 122.5 mmol). The resulting mixture was allowed to stir at 80° C for 16 h. The reaction mixture was allowed to cool to 25° C and then was diluted with ethyl acetate. The mixture was washed with water and brine, dried (MgSO₄), and concentrated to afford the title compound. MS (CI): m/z 208 (M+H)⁺. Part C. Preparation of hydrocinnamoyl-[N-(3-methylphenethyl)-Gly]-OMe.

To a solution of N-(3-methylphenethyl)-Gly-OMe (3.15 g, 15.2 mmol) in THF at 0° C was added N-methylmorpholine (3.34 mL, 30.4 mmol) and hydrocinnamoyl chloride (2.26 mL, 15.2 mmol). The mixture was allowed to stir with warming to 25° C for 6 h. The solvent was removed in vacuo and the residue was taken up in ethyl acetate and washed with 10% aq HCl, sat'd aq NaHCO₃ and brine. The organic layer was dried (MgSO₄) and concentrated to afford 4.4 g (86%) of the title compound. MS (CI): m/z 340 (M+H)⁺.

Part D. Preparation of Hydrocinnamoyl-[N-(3-methylphenethyl)-Gly]-OH.

To a solution of hydrocinnamoyl-[N-(3-methylphenethyl)-Gly]-OMe (4.4 g, 13.0 mmol) in 50 mL of 2:1 THF/H₂O was added lithium hydroxide monohydrate (0.65 g, 15.6 mmol). The reaction mixture was allowed to stir at 25° C for 4 h and then the THF was removed in vacuo. The basic solution was extracted with 1:1 hexanes/ethyl acetate and the organic layer was discarded. The aqueous layer was

acidified with concentrated HCl and then was extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried (MgSO₄) and concentrated to afford the title compound as a white solid. MS (CI): m/z 326 (M+H)+.

5

Part E. Preparation of Hydrocinnamoyl-[N-(3-methylphenethyl)-Gly]-boroLys-OH hydrochloride salt.

10

The carboxylic acid hydrocinnamoyl-[N-(3-methylphenethyl)-Gly]-OH was elaborated to the title compound according to the procedures described in Example ????. MS (ES): m/z 454.4 (M+H)+.

15

Example 53.1.1

Hydrocinnamoyl-[N-(2,2-dimethyl)-phenethyl-Gly]-boroLys-OH hydrochloride salt

20 Part A. Preparation of Methyl 2,2-(dimethyl)-2-phenylacetate.

To a cooled (-78° C) solution of methyl phenylacetate (1.0 g, 6.7 mmol) in THF was added methyl iodide (0.91 mL, 14.7 mmol) followed by potassium *tert*-butoxide (14.7 mL of a 1.0 M solution in THF, 14.7 mmol). The reaction mixture was allowed to stir while slowly warming to 25° C. After 1 h the reaction was quenched by addition of saturated aq NH₄Cl, diluted with ethyl acetate and washed with brine. The organics were dried (MgSO₄) and concentrated to afford 1.1 g (92%) of the title compound.

25

30

Part B. Preparation of 2,2-(Dimethyl)-2-phenylethyl alcohol.

To a cooled (0° C) solution of 1M lithium aluminum

hydride in ether (31.1 mL, 31.1 mmol) was added methyl 2,2-(dimethyl)-2-phenylacetate (5.54 g, 31.1 mmol) as a solution in ether. The reaction mixture was allowed to warm to 25° C and was stirred for 3 h. The mixture was
5 cooled to 0° C and was quenched by slow sequential addition of 1.2 mL of water, 1.2 mL of 15% aq NaOH and 3.6 mL of water. The resulting slurry was stirred vigorously with warming to 25° C for 1 h, and then was dried (MgSO₄),
10 filtered and concentrated to afford 3.8 g (81%) of the title compound.

Part C. Preparation of 2,2-(Dimethyl)-2-phenylacetaldehyde.

To a solution of 2,2-(dimethyl)-2-phenylethyl alcohol
15 (3.8 g, 25.1 mmol) in methylene chloride was added pyridinium chlorochromate (16.2 g, 75.3 mmol) and the resulting mixture was stirred vigorously at 25° C for 4h. The mixture was filtered through a pad of layered silica gel (bottom)/Celite/Florasil (top) and concentrated to the
20 give the title aldehyde.

Part D. Preparation of N-(2,2-dimethyl)-phenethyl-Gly-OEt.

To a solution of glycine ethyl ester hydrochloride (1.7 g, 12.3 mmol) in methanol was added sodium
25 cyanoborohydride (0.77 g, 12.3 mmol) and 2,2-(dimethyl)-2-phenylacetaldehyde (2.0 g, 13.5 mmol). Glacial acetic acid was added if necessary to maintain the pH at 5-6. The mixture was allowed to stir at 25° C for 16 h. The reaction was quenched by addition of excess satd. aq. K₂CO₃
30 and then was diluted with ethyl acetate. The layers were separated and the organic layer was washed with brine (2x), dried (MgSO₄) and concentrated to afford 2.5 g (86%) of the title compound. MS (CI): m/z 236 (M+H)+.

Part E. Preparation of Hydrocinnamoyl-N-(2,2-dimethyl)-phenethyl-Gly-OEt.

To a cooled (0° C) solution of N-(2,2-dimethyl)-phenethyl-Gly-OEt (2.4 g, 10.1 mmol) in THF was added N-methylmorpholine (2.22 mL, 20.2 mmol) followed by hydrocinnamoyl chloride (1.50 mL, 10.1 mmol). The resulting solution was allowed to warm to 25° C and was stirred for 3h. The THF was removed in vacuo and the residue was taken up in ethyl acetate and washed with 10% aq HCl, satd. aq. NaHCO₃ and brine. The organics were dried (MgSO₄) and concentrated. The residue was purified by silica gel flash chromatography (solvent gradient 7:1 hexanes/ethyl acetate to 3:1 hexanes/ethyl acetate) to afford 2.0 g (54%) of the title compound. MS (CI): m/z 368 (M+H)+.

Part F. Preparation of Hydrocinnamoyl-N-(2,2-dimethyl)-phenethyl-Gly-OH.

To a solution of hydrocinnamoyl-N-(2,2-dimethyl)-phenethyl-Gly-OEt (1.5 g, 4.1 mmol) in 25 mL of 1:1 methanol/water was added potassium hydroxide (0.34 g, 6.1 mmol). The reaction mixture was allowed to stir at reflux for 1 h and then was allowed to cool to 25° C and the methanol was removed in vacuo. The basic aqueous solution was extracted with 1:1 hexanes/ethyl acetate and the organic layer was discarded. The aqueous layer was acidified with concentrated HCl and then was extracted with ethyl acetate. The ethyl acetate layer was washed with brine, dried (MgSO₄) and concentrated to afford the title compound as a white solid. MS (CI): m/z 340 (M+H)+.

Part G. Preparation of Hydrocinnamoyl-[N-(2,2-dimethyl)-phenethyl-Gly]-boroLys-OH hydrochloride salt.

The carboxylic acid hydrocinnamoyl-N-(2,2-dimethyl)-phenethyl-Gly-OH was elaborated to the title compound

according to the procedures described in Example ??? . MS
(ES): m/z 468.4 (M+H)+.

Example 1.1.3

- 5 *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-(guanidino)butylboronate, hydrochloride salt; LRMS (M+H, ethylene glycol ester)+ = 404.

Example 6.1.1

- 10 *N*-(*N*-methyl-*N*-benzoylglycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd : (M+H, ethylene glycol ester)+ = 348.209462, obs.: (M+H, ethylene glycol ester)+ = 348.208418.

Example 6.1.2

- 15 *N*-(*N*-methyl-*N*-(phenylacetyl)glycyl)-1-amido-5-aminopentaneboronic acid, hydrochloride salt; LRMS (M+H, ethylene glycol ester)+ = 362.

Example 6.1.3

- 20 *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-aminopentaneboronate; HRMS (M+H)+ calcd: 376.240762, found : 376.240727.

Example 9.1.2

- 25 *N*-(*N*-phenyl-*N*-(phenylacetyl)glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd: (M+H, ethylene glycol ester)+ = 424.240762, obs.: (M+H, ethylene glycol ester)+ = 424.242097.

30

Example 9.1.3

- 35 *N*-(*N*-phenyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd : (M+H, ethylene glycol ester)+ = 438.256412, obs.: (M+H, ethylene glycol ester)+ = 438.256557.

Example 15.1.3

Pinanediol *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-
1-amido-4-(guanidino)butylboronate, hydrochloride salt;
5 LRMS (M+H)⁺ = 512.3.

Example 21.1.1

Pinanediol *N*-(*N*-methyl-*N*-benzoylglycyl)-1-amido-5-
aminopentaneboronate, hydrochloride salt; HRMS calcd :
10 (M+H)⁺ = 456.303362, obs.: (M+H)⁺ = 456.302964.

Example 21.1.2

Pinanediol *N*-(*N*-methyl-*N*-(phenylacetyl)glycyl)-1-
amido-5-aminopentaneboronate, hydrochloride salt; LRMS
15 (M+H)⁺ = 470.

Example 21.9.1

Pinanediol *N*-(*N*-methyl-*N*-[2-(phenyl)benzoyl]glycyl)-1-
amido-5-amino-pentaneboronate, hydrochloride acid salt;
20 LRMS (M+H)⁺ = 532.3.

Example 24.1.2

Pinanediol *N*-(*N*-phenyl-*N*-(phenylacetyl)glycyl)-1-
amido-5-aminopentaneboronate, hydrochloride salt; HRMS
25 calcd: (M+H)⁺ = 532.334663, obs.: (M+H)⁺ = 532.334090.

Example 24.1.3

Pinanediol *N*-(*N*-phenyl-*N*-[(3-phenyl)propionyl]glycyl)-
1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS
30 calcd: (M+H)⁺ = 546.350313, obs: (M+H)⁺ = 546.352069.

Example 24.59.1

Pinanediol *N*-(*N*-phenyl-*N*-(*N*'-methyl-*N*'-
methylphenyl)aminocarbonyl]glycyl)-1-amido-4-

isothiuroniumbutylboronate ; HRMS (M+H)⁺ calcd:
606.338533, found: 606.329421.

Example 26.1.3

- 5 Pinanediol *N*-{*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl}-
1-amido-4-isothiuroniumbutylboronate; HRMS (M+H)⁺ calcd:
529.301983, found: 529.302078.

Example 26.9.1

- 10 Pinanediol *N*-{*N*-methyl-*N*-[(2-phenyl)benzoyl]glycyl}-1-
amido-4-isothiuroniumbutylboronate; HRMS (M+H)⁺ calcd:
577.301983, found: 577.302704.

Example 26.9.3

- 15 Pinanediol *N*-{*N*-methyl-*N*-[(3-(2-
phenyl)phenyl)propionyl]glycyl}-1-amido-4-
isothiuroniumbutylboronate ; HRMS (M+H)⁺ calcd: 605.3333,
found: 605.3325.

Example 26.12.1

- 20 Pinanediol *N*-{*N*-methyl-*N*-[(3-(2-
phenyl)phenyl)propionyl]glycyl}-1-amido-4-
isothiuroniumbutylboronate ; HRMS (M+H)⁺ calcd: 606.3285,
found: 606.3294.

25

Example 27.1.3

- 30 Pinanediol *N*-{*N*-[(4-hydroxyphenyl)methyl]-*N*-[(3-
phenyl)propionyl]-glycyl}-1-amido-4-
isothiuroniumbutylboronate; HRMS (M+H)⁺ calcd: 621.328198,
found: 621.329437.

Example 28.1.3

Pinanediol *N*-{*N*-[(2-phenyl)ethyl]-*N*-[(3-
phenyl)propionyl]glycyl}-1-amido-4-

isothiouroniumbutylboronate; HRMS (M+H)⁺ calcd: 619.348934, found: 619.348587.

Example 29.1.3

- 5 Pinanediol *N*-(*N*-phenyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-isothiouroniumbutylboronate; HRMS (M+H)⁺ calcd: 591.317633, found: 591.316620.

Example 30.1.3

- 10 Pinanediol *N*-(*N*-[(naphth-2-yl)methyl]-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-isothiouroniumbutylboronate; HRMS (M+H)⁺ calcd: 655.348934, found: 655.347870.

Example 36.6.1

- 15 Pinanediol *N*-(2-[(2-oxo-4-methylphenyl)-4,5-(*H*)oxazol-3-yl]acetyl)-1-amido-4-isothiouroniumbutylboronate; mp. 120-130 °C; Anal calcd. for C₂₇H₃₉BN₄O₅S HBr %C: 52.02; %H: 6.47; %N: 8.99; %B: 1.73; found: %C: 52.01; %H: 6.43; %N: 8.84; %B: 1.75.

Example 49.1.1

- 25 Hydrocinnamoyl-[*N*-(Phenethyl)-Gly]-boroOrn-C₁₀H₁₆ HCl; MS (ESI) (M+H)⁺ 560.4.

Example 49.1.2

Hydrocinnamoyl-[*N*-(Phenethyl)-Gly]-boroOrn(CH=NH)-C₁₀H₁₆ HCl; MS (NH₃-CI) (M+H)⁺ 587.7.

Example 49.1.3

- 30 Hydrocinnamoyl-[*N*-(Phenethyl)-Gly]-boroOrn(CH=NH)-OH HCl; MS (ESI) (M+H)⁺ 453.1.

Example 49.2.1

Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroArg(CH₃)-C₁₀H₁₆ HCl;
MS (ESI) (M+H)⁺ 616.4.

Example 50.1.1

5 Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroOrn-C₁₀H₁₆ HCl; MS
(ESI) (M+H)⁺ 499.2

Example 50.1.2

10 Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroOrn(CH=NH)-C₁₀H₁₆ HCl;
MS (ESI) (M+H)⁺ 526.1

Example 50.1.3

15 Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroLys-C₁₀H₁₆ HCl; MS
(NH₃-Cl) (M+H)⁺ 513.5.

Example 51.1.1

Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-
boroLys-C₁₀H₁₆ HCl; MS (ESI) (M+H)⁺ 642.5

20 Example 51.1.2

Hydrocinnamoyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-
C₁₀H₁₆ HCl; MS (ESI) (M+H)⁺ 588.4

Example 52.1.1

25 Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-
boroLys-OH HCl; MS (ESI) (M+H)⁺ 534 for ethylene glycol
ester.

EXAMPLE 61.1.1

30 Hydrocinnamoyl-Sar-Lys[C(O)CO₂H]

Part A: Preparation of Na-t-Boc-Ne-Cbz-lysine[N(OMe)Me]

A flask was charged 150 ml of anhydrous CH₂Cl₂
followed by the addition of Na-t-boc-NE-Cbz-lysine (15.00
35 grams, 39.43 mmol), N-methylmorpholine (13.0 ml, 118.29

mmol) and was cooled to -78°C followed by the addition of isobutylchloroformate (5.11 ml, 39.43 mmol). The mixture was stirred for 1 hr at which time the N,O-Dimethylhydroxylamine hydrochloride was added, stirred for 5 1 hr. and allowed to warm to room temperature. The solvent was removed in vacuo, the residue diluted with EtOAc and washed with 10% aq HCl, sat'd aq NaHCO₃ and brine. After drying (MgSO₄), the solution was filtered through a pad of silica gel and the solvent removed in vacuo to give the 10 product (16.32 g). MS: ESI, m/z 424.2 (M+H)+.

Part B: Preparation of Part A: Na-t-boc-Ne-Cbz-lysinal

A flask was charged with 200 ml of anhydrous THF followed by the addition of Na-t-boc, NE-Cbz 15 lysine[N(OMe)Me] (4.00 gr, 9.44 mmol), cooled to 0°C and followed by the addition of Lithium aluminum hydride (450 mg, 11.80 mmol). The solution was stirred for 30 min. and was slowly quenched with a sat'd KHSO₃ solution (2.25 gr, 16.53 mmol). The volatiles were removed in vacuo and the 20 residue dissolved in EtOAc and washed with 10% aq HCl, sat'd aq NaHCO₃ and brine. After drying (MgSO₄), the solution was filtered through a pad of silica gel and the solvent removed in vacuo to give the product (3.29 grams) MS: ESI, m/z 365.2 (M+H)+.

25

Part C: Preparation of Na-t-boc, Ne-Cbz lysine[C(OH)CO₂CH₃]

A flask was charged with 150 ml of anhydrous THF followed by the addition of orthoethylthioformate (6.82 gr, 30 34.77 mmol), cooled to -78°C and lithiated with n-butyllithium (2.5 M, 14.0 ml, 34.7 mmol). After stirring for 20 min., Na-t-boc-NE-Cbz-lysinal was added as a THF solution via cannula and continued to stir at -78°C for and additional 4 hrs; the solution was quenched using sat'd 35 NH₄Cl and the volatiles removed in vacuo. The residue was

dissolved in EtOAc and washed twice with brine, dried over MgSO₄, filtered and dried in vacuo. The residue was dissolved in 95% MeOH followed by the addition of HgO (12.57 gr, 58.06 mmol) and HgCl₂ (40.8 gr, 150.2 mmol) and stirred at rt. for 3 hrs. The solution was filtered through a pad of celite and the volatiles removed in vacuo followed by the addition of chloroform, the solution filtered and the volatiles removed in vacuo. The residue was dissolved in EtOAc and washed with 10% aq HCl, sat'd aq NaHCO₃ and brine. After drying (MgSO₄), the solution was filtered through a pad of silica gel and the solvent removed in vacuo. The residue was purified by flash chromatography to give the product (1.49 grams) MS: CI m/z 425.2 (M+H)+

15

Part D: Preparation of NE-Cbz-lysine[C(OH)CO₂CH₃] TFA salt Na-t-boc-Ne-Cbz-lysine[C(OH)CO₂CH₃] (1.49 gr, 3.51 mmol) was dissolved in 50 ml of neat TFA and the reaction monitored by TLC. The volatiles were removed in vacuo and the residue dissolved in a minimum amount of CH₂Cl₂ followed by the addition of Et₂O, cooled to -78°C and the product ppt. out with hexane (1.36 gr). MS: CI m/z 325.0 (M+H)+.

25

Part E: Preparation of Hydrocinnamoyl-Sar-ethyl ester Hydrocinnamic acid was added to 100 ml of anhydrous CH₂Cl₂ followed by the addition of N-methylmorpholine (44.0 ml, 400.0 mmol), and cooled to -78°C. To the resulting solution was added isobutylchloroformate (17.3 ml, 133.17 mmol) and stirred for 1 hr. The sarcosine ethyl ester hydrochloride (20.00 gr, 133.17 mmol) was added and the solution stirred for an additional hr at -78°C and allowed to warm to rt. The volatiles were removed in vacuo and the residue was dissolved in EtOAc and washed with 10% aq HCl, sat'd aq NaHCO₃ and brine. After drying (MgSO₄), the

35

solution was filtered through a pad of silica gel and the solvent removed in vacuo (31.56 gr) MS: CI m/z 250.0 (M+H)+.

5 Part F: Preparation of Hydrocinnamoyl-Sar-OH

Hydrocinnamoyl-Sar-ethyl ester (31.57 gr, 126.63 mmol) and KOH (21.32 gr, 380 mmol) were combined in a 50/50 methanol-water solution and stirred at rt, the reaction was monitored by TLC. The methanol was removed in vacuo and
10 the organics were extracted using EtOAc. The aq extract was acidified with a 10% HCl solution and the organics extracted with EtOAc and washed with brine. After drying (MgSO₄), the solution was filtered and the solvent removed in vacuo to a white solid. MS: CI m/z 222.0 (M+H)+.

15

Part G: Preparation of Hydrocinnamoyl-Sar-NE-Cbz-lysine[C(OH)CO₂CH₃]

Hydrocinnamoyl-Sar-OH (690 mg, 3.10 mmol), NE-Cbz lysine[C(OH)CO₂CH₃] TFA salt (1.36 gr, 3.10 mmol), N-Methyl
20 morpholine (1.0 ml, 9.3 mmol), HOBT (420 mg, 3.10 mmol) and 1-(3-Dimethyl amino propyl)-3 ethyl carbodiimide (600 mg, 3.10 mmol) were dissolved in 50 ml of anhydrous DMF and stirred overnight at rt. The resulting solution was diluted with 300 ml of EtOAc and washed repeatedly with
25 brine. The organic were dried over MgSO₄, filtered through a pad of silica gel, and the volatiles dried in vacuo to an oil (1.08 gr). MS: CI m/z 528.4 (M+H)+.

30 Part H: Preparation of Hydrocinnamoyl-Sar-NE-Cbz-lysine[C(O)CO₂CH₃]

Anhydrous CH₂Cl₂ (100 ml) was charged with oxalylchloride (20 ml 2.25 mmol) and cooled to -40°C; this was followed by the addition of anhydrous DMSO (.35 ml, 4.91 mmol) and stirred for 20 min. Hydrocinnamoyl-Sar-NE-
35 Cbz-lysine[C(OH)CO₂CH₃] (1.08 gr, 2.04 mmol) was added as a

CH₂Cl₂ solution and stirred for an additional 20 minutes. Triethylamine (1.42 ml, 10.23 mmol) was added to the resulting solution and stirred for an additional 20 min. The volatiles were removed in vacuo and the resulting
5 residue subject to flash chromatography yielding the product as an oil. (73 gr) MS: CI m/z 526.4 (M+H)+.

Part I: Preparation of Hydrocinnamoyl-Sar-NE-Cbz-lysine[C(O)CO₂H]

10 Hydrocinnamoyl-Sar-NE-Cbz lysine[C(O)CO₂CH₃] (.73 gr, 1.39 mmol) and LiOH (150 mg, 3.48 mmol) were combined in a 50/50 mixture of methanol/water, stirred at rt and the reaction monitored by TLC. The volatiles were removed in vacuo, the residue dissolved in EtOAc and acidified with
15 10% HCl. The organics were dried (MgSO₄) and the volatiles removed in vacuo to yield .57 gr of product MS: CI m/z 468.2 (M+H-CO₂)++.

Part J: Hydrocinnamoyl-Sar-Lys[C(O)CO₂H]

20 Hydrocinnamoyl-Sar-Ne-Cbz-lysine[C(O)CO₂H] (570 mg, 1.11 mmol) was dissolved in 100 ml of methanol followed by the addition of 20% Pd/C catalyst (60 mg) and stirred under 1 atm. of H₂ at rt for 3 hrs. The solution was filtered through a pad of celite and the volatiles removed in vacuo
25 to give the product MS: CI m/z 380.3 (M+H)+

Example 53.1.2

Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 466.3
30

Example 53.2.1

Hydrocinnamoyl-[N-(N-(Methyl)-Phenyl)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 441.3

35

Example 53.2.2

Hydrocinnamoyl-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-OH HCl;
MS (ESI) (M+H)⁺ 455.4

Example 53.4.3

5 Hydrocinnamoyl-[N-(Cyclohexyl)-Gly]-boroLys-OH HCl; MS
(ESI) (M+H)⁺ 418.3

Example 54.1.1

10 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroLys-
C10H16 HCl; MS (ESI) (M+H)⁺ 616.3

Example 54.1.2

15 Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroLys-
C10H16 HCl; MS (NH₃CI) (M+H)⁺ 600.5

Example 54.1.3

Hydrocinnamoyl-[N-(2,2-(Diethyl)-Phenethyl)-Gly]-boroLys-
C10H16 HCl; MS (ESI) (M+H)⁺ 630

20 Example 54.2.1

Hydrocinnamoyl-[N-(N-(Methyl)-Phenyl)-Gly]-boroLys-C10H16
HCl; MS (NH₃CI) (M+H)⁺ 575.4

Example 54.2.2

25 Hydrocinnamoyl-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-C10H16
HCl; MS (NH₃CI) (M+H)⁺ 589.4

Example 54.2.3

30 Hydrocinnamoyl-[N-(Succinyl)-Gly]-boroLys-C10H16; MS (ESI)
(M+H)⁺ 542.5

Example 54.3.1

35 Hydrocinnamoyl-[N-(Methyl Succinyl)-Gly]-boroLys-C10H16
HCl; MS (ESI) (M+H)⁺ 556.5

Example 54.3.2

Hydrocinnamoyl-[N-(2-(Cyclopentyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl; MS (ESI) (M+H)⁺ 628.3

5

Example 54.3.3

Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl; MS (ESI) (M+H)⁺ 630.4

Example 54.4.1

10 Hydrocinnamoyl-[N-{2-(3,5-dimethylphenyl)-ethyl}-Gly]-boroLys-C10H16 HCl; MS (ESI) (M+H)⁺ 602.4

Example 54.4.2

15 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl; MS (NH₃Cl) (M+H)⁺ 510.3

Example 54.4.3

20 Hydrocinnamoyl-[N-(Cyclohexyl)-Gly]-boroLys-C10H16 HCl; MS (NH₃Cl) (M+H)⁺ 552.4

Example 55.1.1

Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroArg-OH HCl; MS (ESI) (M+H)⁺ 496.4

25

Example 56.1.1

Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroArg-C10H16 HCl; MS (ESI) (M+H)⁺ 630.4

Example 56.1.2

30 Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroArg-C10H16 HCl; MS (ESI) (M+H)⁺ 628.3

Example 56.3.3

35 Hydrocinnamoyl-[N-[2,2-(Dimethyl)-2-(3,5-dimethylphenyl)-ethyl]-Gly]-boroArg-C10H16 HCl; MS (ESI) (M+H)⁺ 658.4

Example 56.4.1

Hydrocinnamoyl-[N-(2-(3,5-dimethylphenyl)-ethyl)-Gly]-
boroArg-ClO₄H₁₆ HCl; MS (ESI) (M+H)⁺ 630.4

5

Example 57.1.1

Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
boroOrn(CH=NH)-OH HCl; MS (ESI) (M+H)⁺ 481.2

10

Example 57.1.2

Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-
boroOrn(CH=NH)-OH HCl; MS (ESI) (M+H)⁺ 479

Example 57.4.2

15 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn(CH=NH)-OH HCl;
MS (ESI) (M+H)⁺ 389.3

Example 58

20 N-(N-methyl-N-[2-(methylphenyl)benzoyl]glycyl)-1-amido-5-
aminopentaneboronic acid, hydrochloride salt

Using the procedure of Example 8.1.3, however using
pinanediol N-(N-methyl-N-[2-(methylphenyl)benzoyl]glycyl)-
1-amido-5-aminopentaneboronate, hydrochloride salt, the
25 title compound was prepared; LRMS (M -H₂O)⁺ = 394.1, (M
-2H₂O)⁺ = 376.1.

Example 58.1.1

30 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
boroOrn(CH=NH)-ClO₄H₁₆ HCl; MS (ESI) (M+H)⁺ 615.4

Example 58.3.3

35 Hydrocinnamoyl-[N-[2,2-(Dimethyl)-2-(3,5-dimethylphenyl)-
ethyl]-Gly]-boroOrn(CH=NH)-ClO₄H₁₆ HCl; MS (ESI) (M+H)⁺
643.4

Example 58.4.1

Hydrocinnamoyl-[N-(2-(3,5-dimethylphenyl)-ethyl)-Gly]-
boroOrn(CH=NH)-C10H16 HCl; MS (ESI) (M+H)⁺ 615.4

5

Example 58.4.2

Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn(CH=NH)-C10H16
HCl; MS (NH₃CI) (M+H)⁺ 524.3

10

Example 59.1.1

Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroLys-
OH HCl; MS (ESI) (M+H)⁺ 482.2

Example 59.4.2

15 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys-OH HCl; MS
(ESI) (M+H)⁺ 376.2

Example 60

20 Pinanediol N-{N-[(naphth-1-yl)methyl]-N-[(3-
phenyl)propionyl]glycyl}-1-amido-4-
isothiouroniumbutylboronate; HRMS (M+H)⁺ calcd: 655.348934,
found: 655.349243.

Example 60.1.1

25 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroOrn-
C10H16 HCl; MS (NH₃DCI) (M+H)⁺ 602.5

Example 60.3.3

30 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroOrn-
C10H16 HCl; MS (ESI) (M+H)⁺ 616.4

Example 60.4.1

35 Hydrocinnamoyl-[N-(2-(3,5-dimethylphenyl)-ethyl)-Gly]-
boroOrn-C10H16 HCl; MS (ESI) (M+H)⁺ 588.3

Example 60.4.2

Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn-C10H16 HCl;
MS (NH₃CI) (M+H)⁺ 496.3

5

Example 61

Pinanediol N-{N-methyl-N-[(3-phenyl-2-(phenyl)methyl)propionyl]-glycyl}-1-amido-5-aminopentylboronate; HRMS (M+H)⁺ calcd: 560.365963, found: 560.364426.

10

Example 61.1.1

Hydrocinnamoyl-Sar-Lys[C(=O)-C(=O)-OH]; MS: ESI m/z 380.3 (M+H)⁺

15

EXAMPLE 62.3.3

2-(2-cyanothiophenyl)-benzoyl-Sar-BoroArg C₁₀H₁₆·HCl

Part A: Preparation of 2-(2-cyanothiophenyl)benzoyl-Sar-ethyl ester

20

2-(2-cyanothiophenyl)benzoic acid (5.00 gr, 19.58 mmol), sarcosine ethyl ester hydrochloride (3.00 gr, 19.58 mmol), triethylamine (8.2 ml, 58.75 mmol), HOBT (2.64 gr, 19.58 mmol) and 1,3-diisopropylcarbodiimide (3.0 ml, 19.58 mmol) were combined in 100 ml of anhydrous CH₂Cl₂ and

25

stirred at rt overnight. The volatiles were removed in vacuo, the organics dried over MgSO₄, filtered and concentrated. The product was purified by flash chromatography (4.93 gr) MS: CI m/z 355.1 (M+H)⁺.

30

Part B: Preparation of 2-(2-cyanothiophenyl)benzoyl-Sar-OH

2-(2-cyanothiophenyl)benzoyl-Sar-ethyl ester (4.93 gr, 14.03 mmol) and KOH (790 mg, 14.03 mmol) were combined in 75 ml of a 50/50 methanol-water solution and stirred at rt, the reaction was monitored by TLC. The methanol was

35

removed in vacuo and the organics were diluted with EtOAc

and extracted with H₂O. The aq extract was acidified with a 10% HCl solution and the organics extracted with EtOAc, washed with brine. After drying (MgSO₄), the solution was filtered and the solvent removed in vacuo to a white solid.

5 MS: CI m/z 327.0 (M+H)+

Part C: Preparation of 2-(2-cyanothiophenyl)benzoyl-Sar-NH-CH[(CH₂)₃Br]BO₂-C₁₀H₁₆

2-(2-cyanothiophenyl)benzoyl-Sar-OH (4.23 gr, 12.96 mmol) and NMM (4.3 ml, 38.9 mmol) were dissolved in 150 ml of anhydrous CH₂Cl₂ and stirred at -78°C. This was followed by the addition of isobutylchloroformate (1.70 ml, 12.96 mmol) and stirred for 1 hr, at which time NH₂CH[(CH₂)₃Br]BO₂-C₁₀H₁₆·HCl (4.75 gr, 12.96 mmol) was added and stirred for an additional hr. and allowed to warm to rt. The volatiles were removed in vacuo, the residue was dissolved in EtOAc and the organics were washed with sat'd NaHCO₃, 10% HCl and brine. The residue was dried (MgSO₄) and filtered through a pad of florisil and concentrated in vacuo to give the product (6.01 gr) MS: CI m/z 558.2 (M-HBr)+

Part D: Preparation of 2-(2-cyanothiophenyl)benzoyl-Sar-NH-CH[(CH₂)₃N₃]BO₂-C₁₀H₁₆

25 2-(2-cyanothiophenyl)benzoyl-Sar-NH-CH[(CH₂)₃Br]BO₂-C₁₀H₁₆ (6.01 gr, 9.21 mmol) and NaN₃ (1.80 gr, 27.64 mmol) were combined in 75 ml of DMF and stirred for 3 hrs. at 110°C. The solution was diluted with EtOAc and washed repeatedly with brine. The organics were dried over MgSO₄ and filtered through a pad of florisil and concentrated in vacuo to give the product (5.38 gr). MS: ESI m/z 601.4 (M+H)+

Part E: Preparation of 2-(2-cyanothiophenyl)benzoyl-Sar-boroOrn-C₁₀H₁₆·HCl

To a solution of 2-(2-cyanothiophenyl)benzyloyl-Sar-NH-CH[(CH₂)₃N₃]BO₂-C₁₀H₁₆ (5.38 gr, 8.96 mmol) in MeOH (75 ml) was added 20% Pd/C catalyst (600 mg). The mixture was stirred under 1 atm of H₂ for 2 hrs and then filtered through a pad of celite and concentrated to give the product MS: CI m/z 575.2 (M+H)+.

Part F: Preparation of 2-(2-cyanothiophenyl)benzyloyl-Sar-boroArg-C₁₀H₁₆·HCl

2-(2-cyanothiophenyl)benzyloyl-Sar-boroOrn-C₁₀H₁₆·HCl (1.77 gr, 2.90 mmol), DMAP (710 mg, 5.79 mmol) and H₂NC(NH)SO₃H (720 mg, 5.79 mmol) were combined in 50 ml of absolute EtOH and refluxed overnight. The volatiles were removed and the residue dissolved in CH₃Cl and washed with 10% HCl and brine. The organics were dried (NaSO₄) and concentrated to give the product MS: CI m/z 617.3 (M+H)+.

Example 61.2.1

Hydrocinnamoyl-Sar-Lys-C(=O)-OCH₃ HCl; MS: CI m/z 364.2 (M+H)+

Example 61.2.3

Hydrocinnamoyl-Sar-Lys-C(=O)-CH₃ HCl; MS: CI m/z 348.2 (M+H)+

Example 61.4.1

Hydrocinnamoyl-Sar-Lys[CH(OH)(OCH₃)-C(=O)-OCH₃] HCl; MS: CI m/z 392.3 (M+H)+

Example 62

Pinanediol N-(N-methyl-N-[(3,4-dichlorophenyl)acetyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt; LRMS (M+H)+ = 538.

Example 62.1.3

DM-6666-C

(2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroIrg-C10H16 HBr;
MS: DCI m/z 648. (M+H)⁺

Example 62.2.2

5 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-borohomoIrg-C10H16
HBr: MS: ESI m/z 634.4 (M+H)⁺

Example 62.3.2

(2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-borohomoArg-C10H16
10 HCl; MS: DCI m/z 631. (M+H)⁺

EXAMPLE 64.2.3

2-(3-chlorobenzyl)-benzoyl-Sar-Borolys C₁₀H₁₆·HCl

15 Part A: Preparation of 2-bromo-3'-chloro diphenyl methanol
Anhydrous THF (400 ml) was charged with 3-(chloro)
bromo benzene (19.63 ml, 167.13 mmol), cooled to -78°C,
lithiated with n-BuLi (2.5 M, 66.85 ml, 167.13 mmol) and
stirred for 20 minutes. 2-bromobenzaldehyde (19.51 ml,
20 167.13 mmol) was added and stirred for an additional 30
minutes and allowed to warm to rt. The solution was
quenched with sat'd NH₄Cl and the volatiles removed in
vacuo. The residue was dissolved in EtOAc and washed with
brine; the organics were dried over MgSO₄, filtered through
25 a pad of silica and the volatiles dried in vacuo. The
product was purified by flash chromatography (38.8 gr) MS:
CI m/z 281.0 (M+H-H₂O)⁺

Part B: Preparation of 2-bromo-3'-chloro diphenyl methane
30 2-bromo-3'-chloro diphenyl methanol (38.8 gr, 130.35
mmol) and triethylsilane (31.23 ml, 195.53 mmol) were
combined in 200 ml of TFA and stirred overnight at rt. The
volatiles were removed in vacuo and the residue purified by
flash chromatography (33.32 grams) MS: CI m/z 283.0
35 (M+H)⁺.

Part C: Preparation of 3-chlorobenzylbenzoic acid

2-bromo-3'-chloro diphenyl methane was dissolved in 250 ml of anhydrous THF, cooled to -78°C and lithiated with n-BuLi (2.5 M, 47.5 ml, 118.34 mmol). After stirring for 30 minutes, CO₂ was slowly bubbled in for 15 minutes and the solution warmed to rt. The volatiles were removed in vacuo and the residue dissolved in H₂O and the organics removed with EtOAc, the aq. layer was acidified with 10% HCl, the organics extracted with EtOAc, washed with brine, dried (MgSO₄) and the volatiles removed in vacuo to a white solid MS: CI m/z 264.0 (M+H)+.

Part D: Preparation of 2-(3-chlorobenzyl)benzoyl-Sar ethyl ester

3-chlorobenzylbenzoic acid (10.28 gr, 41.67 mmol), sarcosine ethyl ester hydrochloride (6.40 gr, 41.67 mmol), 1-(3-Dimethyl amino propyl)-3 ethyl carbodiimide (8.0 gr, 41.67 mmol), NMM (13.75 ml, 125.0 mmol) and DMAP (1.27 gr, 10.42 mmol) were combined in anhydrous CH₂Cl₂ and stirred at rt overnight. The volatiles were removed in vacuo, the residue dissolved in EtOAc, washed with 10% aq HCl, sat'd aq NaHCO₃ and brine. After drying (MgSO₄), the solution was filtered through a pad of silica gel and the solvent removed in vacuo to give the product (3.19 grams) MS: CI, m/z 346.0 (M+H)+.

Part E: Preparation of 2-(3-chlorobenzyl)benzoyl-Sar-OH

3-chlorobenzylbenzoyl-Sar ethyl ester (3.19 gr, 9.22 mmol) and KOH (2.0 gr, 36.90 mmol) were combined in 75 ml of a 50/50 methanol-water solution and stirred at rt, the reaction was monitored by TLC. The MeOH was removed in vacuo and the organics were diluted with EtOAc and extracted with H₂O. The aq extract was acidified with a 10% HCl solution and the organics extracted with EtOAc and

washed with brine. After drying (MgSO_4), the solution was filtered and the solvent removed in vacuo to a white solid.
MS: CI m/z 318.0 (M+H)+

5 Part F: Preparation of 2-(3-chlorobenzyl)benzyloyl-Sar-NH-
CH[(CH₂)₄Br]BO₂-C₁₀H₁₆

3-chlorobenzylbenzyloyl-Sar-OH (2.66 gr, 8.37 mmol) and
NMM (2.76 ml, 25.11 mmol) were dissolved in anhydrous
CH₂Cl₂ and stirred at -78°C. This was followed by the
10 addition of isobutylchloroformate (1.1 ml, 8.37 ml) and
stirred for 1 hr, at which time NH₂CH[(CH₂)₄Br]BO₂-C₁₀H₁₆·
HCl (3.19 gr, 8.37 mmol) was added and stirred for an
additional hr. and allowed to warm to rt. The volatiles
were removed in vacuo, the residue was dissolved in EtOAc
15 and the organics were washed with sat'd NaHCO₃, 10% HCl and
brine. The residue was dried (MgSO_4), filtered through a
pad of florisil and concentrated in vacuo to give the
product (.4.45 gr) MS: CI m/z 645.5 (M+H)+

20 Part G: Preparation of 2-(3-chlorobenzyl)benzyloyl-Sar-NH-
CH[(CH₂)₄N₃]BO₂-C₁₀H₁₆

3-chlorobenzylbenzyloyl-Sar-NH-CH[(CH₂)₄Br]BO₂-C₁₀H₁₆
(4.45 gr, 6.91 mmol) and NaN₃ (1.34 gr, 20.73 mmol) were
combined in 50 ml of DMF and stirred for 3 hrs. at 110°C.
25 The solution was diluted with EtOAc and washed repeatedly
with brine. The organics were dried over MgSO_4 and
filtered through a pad of florisil and concentrated in
vacuo to give the product (3.33 gr) MS: DCI m/z 623.0
(M+NH₄)+

30

Part H: Preparation of 2-(3-chlorobenzyl)benzyloyl-Sar-
borolys-C₁₀H₁₆·HCl

To a solution of 3-chlorobenzylbenzyloyl-Sar-NH-
CH[(CH₂)₄N₃]BO₂-C₁₀H₁₆ (3.33 gr, 5.49 mmol) in MeOH (75 ml)
35 was added 20% Pd/C catalyst (300 mg). The mixture was

stirred under 1 atm of H₂ for 2 hrs and then filtered through a pad of celite and concentrated to give the product MS: CI m/z 580.5 (M+H)⁺.

5 Example 62.4.1

(2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroOrn(CH=NH)-C₁₀H₁₆
HCl; MS: ESI m/z 602.3 (M+H)⁺

Example 62.4.2

10 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroLys(CH=NH)-C₁₀H₁₆
HCl; MS: ESI m/z 616.2 (M+H)⁺

Example 62.4.3

 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroLys-C₁₀H₁₆ HCl;
15 MS: CI m/z 589.3 (M+H)⁺

Example 63

 Pinanediol *N*-(*N*-methylphenyl)-*N*-{(3-
phenyl)propionyl}glycyl)-1-amido-5-aminopentaneboronate,
20 hydrochloride salt; HRMS calcd: (M+H)⁺ = 560.365963, obs:
(M+H)⁺ = 560.366107.

Example 63.1.3

2-(Thiophenyl)-Benzoyl-Sar-boroIrg-C₁₀H₁₆ HBr; MS: CI m/z
25 567.2 (M-H₂NCN)⁺

Example 63.3.1

2-(Thiophenyl)-Benzoyl-Sar-boroOrn-C₁₀H₁₆ HCl; MS: CI m/z
30 550.3 (M+H)⁺

Example 63.4.1

2-(Thiophenyl)-Benzoyl-Sar-boroOrn(CH=NH)-C₁₀H₁₆ HCl; MS:
CI m/z 577.3 (M+H)⁺

35 Example 63.4.2

2-Thiophenyl-Benzoyl-Sar-boroLys(CH=NH)-C₁₀H₁₆; MS: CI
m/z 564.2 (M-HCN)⁺

Example 63.5.1

- 5 Pinanediol N-(N-methyl-N-[2-(Thiophenyl)-Benzoyl]Sar)-1-
amido-5-thiocyanatobutane boronate; MS: CI m/z 592.2
(M+H)⁺

Example 64

- 10 N-(N-methylphenyl-N-[(3-phenyl)propionyl]glycyl)-1-
amido-5-aminopentaneboronate, hydrochloride salt; HRMS
calcd (M+H, ethylene glycol ester)⁺ = 452.272062, obs.:
(M+H, ethylene glycol ester)⁺ = 452.270496.

- 15 Example 64.1.1

2-Benzyl-(N-Benzyl)-Sar-boroLys-C₁₀H₁₆ HCl; MS: CI m/z
532.5 (M+H)⁺

Example 64.1.2

- 20 Acetyl-Gly[N-(2-(Benzyl)-Benzyl)]-boroLys-C₁₀H₁₆ HCl; MS:
CI m/z 560.4 (M+H)⁺

Example 64.1.3

- 25 Pinanediol N-(N-methyl-N-[2-(pyrrol-1-ylmethyl)-
Benzyl]glycyl)-1-amido-5-aminopentaneboronate,
hydrochloride salt; MS: CI m/z 535.3 (M+H)⁺

Example 64.2.2

- 30 [3-(Trifluoromethyl)-Benzyl]-Benzoyl-Sar-boroLys-C₁₀H₁₆
HCl; MS: CI m/z 614.3 (M+H)⁺

Example 65

- 35 Piananediol N-(N-methyl-N-[(4-phenyl)butanoyl]glycyl)-
1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS
calcd: (M+H)⁺ = 498.350313, obs.: (M+H)⁺ = 498.350585.

Example 65.1.3

N-{N-methyl-N-[2-(pyrrol-1-ylmethyl)-Benzyl]glycyl}-1-amido-5-aminopentaneboronic acid, hydrochloride salt; MS:
5 ESI m/z 601.3 (M+H)⁺

Example 66

N-{N-methyl-N-[(4-phenyl)butanoyl]glycyl}-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd: (M+H, ethylene glycol ester)⁺ = 390.256412, obs.: (M+H, ethylene glycol ester)⁺ = 390.257428.
10

Example 66.1.1

Glutaryl-[N-(Phenethyl)-Gly]-boroLys-OH HCl; MS (ESI)
15 (M+H)⁺ 422.3

Example 66.1.2

Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-OH; MS
(ESI) (M+H)⁺ 450.5
20

Example 66.1.3

Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-OH HCl; MS (CDI) (M+H)⁺ 490
25

Example 66.3.2

Methanesulfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 458.3

Example 67

Pinanediol N-{N-methyl-N-[N-methanesulphonyl-D-phenylalanyl]glycyl}-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd: (M+H)⁺ = 577.323113, obs.: (M+H)⁺ = 577.322891.
30

35 Example 67.1.2

Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-C10H16;
MS (ESI) (M+H)⁺ 584.6

Example 67.1.3

- 5 Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl; MS (ESI) (M+H)⁺ 598.6

Example 67.3.2

- 10 Methanesulfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-C10H16 HCl; MS (ESI) (M+H)⁺ 592.3

Example 68

- 15 N-(N-methyl-N-[N-methanesulphonyl-D-phenylalanyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd: (M+H, ethylene glycol ester)⁺ = 469.229212, obs.: (M+H, ethylene glycol ester)⁺ = 469.228962.

Example 68.2.1

- 20 Boc-Glu-[N-(Phenethyl)-Gly]-boroLys-OH

Example 68.3.1

- 25 Succinyl-[N-(Phenethyl)-Gly]-boroLys-OH; MS (ESI) (M+H)⁺ 408.3

Example 68.3.3

- Methyl Succinyl-[N-(Phenethyl)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 422.3

30 Example 68.4.1

- Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 336.3

Example 68.4.2

Methanesulfonyl-Sar-[N-(Phenethyl)-Gly]-boroLys-OH HCl; MS
(ESI) (M+H)⁺ 457.0

Example 69

- 5 Pinanediol N-{N-methyl-N-[3-(4-methylphenyl)propionyl]glycyl}-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd: (M+H)⁺ = 498.350313, obs.: (M+H)⁺ = 498.349676.

10 Example 69.1.1

Glutaryl-[N-(Phenethyl)-Gly]-boroLys-C10H16; MS (ESI)
(M+H)⁺ 556.4

Example 69.2.1

- 15 Boc-Glu-[N-(Phenethyl)-Gly]-boroLys-C10H16; MS (ESI)
(M+H)⁺ 671.6

Example 69.2.2

- Boc-Asp-[N-(Phenethyl)-Gly]-boroLys-C10H16; MS (ESI)
20 (M+H)⁺ 657.6

Example 69.2.3

- Boc-Glu(OCH3)-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl; MS
(ESI) (M+H)⁺ 685.6
25

Example 69.3.2

Methanesulfonyl-Gly-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl;
MS (NH₃Cl) (M+H)⁺ 577

30 Example 69.4.1

Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl; MS
(ESI) (M+H)⁺ 570.5

Example 69.4.2

Methanesulfonyl-Sar-[N-(Phenethyl)-Gly]-boroLys-ClOH16 HCl;
MS (NH₃Cl) (M+H)⁺ 591.4

Example 70

- 5 N-(N-methyl-N-[3-(4-methylphenyl)propionyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt; HRMS calcd: (M+H, ethylene glycol ester)⁺ = 390.256412, obs.: (M+H, ethylene glycol ester)⁺ = 390.256960.

Example 71

- 10 Pinanediol N-(N-methyl-N-[2-(methyl(4-methoxyphenyl))benzoyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride acid salt; LRMS (M+H)⁺ = 576.3.

Example 72

- 15 Pinanediol N-(N-methyl-N-[2-(methyl(4-methylphenyl))benzoyl]glycyl)-1-amido-5-aminopentaneboronate, hydrochloride acid salt; LRMS (M+H)⁺ = 560.5.

Example 72.1.3

- 25 Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 379.0

Example 73

- 30 Pinanediol N-(N-((O-tert-butyl)methylenecarboxylate)-N-[(3-phenyl)propionyl]-glycyl)-1-amido-5-aminopentaneboronate, hydrochloride salt; LRMS (M+H)⁺ = 584.

Example 73.1.2

- 35 Succinyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-ClOH16 HCl; MS (ESI) (M+H)⁺ 556

Example 74

Pinanediol *N*-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-(formamidino)butylboronate, hydrochloride salt; LRMS (M+H)⁺ = 497.

5

Example 75

N-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-(*N*-methylguanidino)butylboronate, hydrochloride salt; LRMS (M+H, ethylene glycol ester)⁺ = 418.3.

10

Example 75.3.1

(2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroArg-OH HCl; MS (ESI) (M+H)⁺ 483.1

15

Example 76

N-(*N*-methyl-*N*-[(3-phenyl)propionyl]glycyl)-1-amido-4-(formamidino)butylboronate, hydrochloride salt; LRMS (M+H, ethylene glycol ester)⁺ = 389.2.

20

Example 76.1.1

Hydrocinnamoyl-[*N*-(Cyclopropyl)-Gly]-boroLys(CH=NH)-OH HCl; MS (ESI) (M+H)⁺ 403.0

Example 77.1.1

25 Hydrocinnamoyl-[*N*-(Cyclopropyl)-Gly]-boroLys(CH=NH)-C10H16 HCl; MS (NH₃CI) (M+H)⁺ 537.3

Example 78.1.2

30 Phenoxyacetyl-[*N*-(Cyclopropyl)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 378.3

Example 78.1.3

Thiophenacetyl-[*N*-(Cyclopropyl)-Gly]-boroLys-OH HCl; MS (ESI) (M+H)⁺ 394.2

35

Example 79.1.2

Phenoxyacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl; MS
(NH₃Cl) (M+H)⁺ 512.3


5

Example 79.1.3


Thiophenacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl;
MS (NH₃Cl) (M+H)⁺ 528.3

10


Tables 1-79




Formula I



Formula II



Formula III












Formula IV

5 Table 1

Formula I: A = -B(OH)₂; X = guanidinyll; R³ = table below; R¹¹ = CH₃

	.1	.2	.3
1.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
1.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
1.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
1.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
1.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
1.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
1.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
1.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
1.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
1.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
1.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
1.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
1.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
1.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
1.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
1.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
1.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
1.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
1.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
1.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
1.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
1.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
1.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
1.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
1.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
1.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
1.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
1.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
1.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
1.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
1.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
1.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
1.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)

1.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
1.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
1.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
1.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
1.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
1.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
1.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
1.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
1.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
1.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
1.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
1.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
1.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
1.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
1.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
1.50	-C(O)(C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
1.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
1.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
1.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxo)indolin-3-yl
1.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
1.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
1.56			
1.57			
1.58			
1.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph








1.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
1.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
1.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
1.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
1.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
1.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
1.66			

Table 2

5 Formula I: A = -B(OH)₂; X = guanidinyI; R³ = table below; R¹¹ = -CH₂(p-PhOH).

	.1	.2	.3
2.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
2.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
2.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
2.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
2.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
2.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
2.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
2.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
2.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
2.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
2.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
2.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
2.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
2.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
2.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
2.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
2.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
2.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
2.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
2.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
2.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
2.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
2.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
2.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
2.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
2.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
2.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
2.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
2.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
2.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)

2.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
2.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
2.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
2.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
2.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
2.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
2.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
2.39	-C(O)thiazo-2-yl	-C(O)CH ₂ (thiazo-2-yl)	-C(O)CH ₂ CH ₂ (thiazo-2-yl)
2.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
2.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
2.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
2.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
2.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
2.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
2.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
2.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
2.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
2.49	-C(O)W-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
2.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
2.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
2.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
2.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
2.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
2.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
2.56			
2.57			



2.58			
2.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
2.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
2.61	-C(O)C(CH ₃) ₂ OPh	-C(O)ClI(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
2.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
2.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
2.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
2.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
2.66			

Table 3

Formula I: A = -B(OH)₂; X = guanidinyI; R³ = table below; R¹¹ = -CH₂CH₂Ph.

5

	.1	.2	.3
3.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
3.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
3.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
3.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
3.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
3.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
3.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
3.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
3.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
3.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
3.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
3.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
3.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
3.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
3.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
3.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
3.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
3.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
3.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
3.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
3.22	-C(O)o-PhClI ₂ SPh	-C(O)CH ₂ (o-PhClI ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhClI ₂ SPh)

3.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
3.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
3.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
3.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
3.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
3.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
3.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
3.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
3.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
3.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
3.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
3.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
3.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
3.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
3.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
3.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
3.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
3.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
3.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
3.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
3.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
3.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
3.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
3.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
3.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
3.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
3.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
3.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
3.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
3.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
3.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
3.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
3.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
3.56			

3.57			
3.58			
3.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
3.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
3.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
3.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
3.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
3.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
3.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
3.66			

Table 4

Formula I: A = -B(OH)₂; X = guanidinyI; R³ = table below; R¹¹ = -Ph.

5

	1	2	3
4.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
4.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
4.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
4.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
4.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
4.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
4.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
4.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
4.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
4.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
4.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
4.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
4.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
4.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
4.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
4.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
4.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
4.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)

4.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
4.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
4.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
4.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
4.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
4.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
4.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
4.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
4.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
4.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
4.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
4.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
4.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
4.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
4.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
4.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
4.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
4.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
4.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
4.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
4.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
4.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
4.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
4.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
4.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
4.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
4.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
4.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
4.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
4.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
4.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
4.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
4.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
4.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxo)indolin-3-yl
4.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
4.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)




















4.56			
4.57			
4.58			
4.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
4.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
4.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
4.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
4.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
4.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
4.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
4.66			

Table 5

Formula I: A = -B(OH)₂; X = guanidinyI; R³ = table below; R¹¹ = -CH₂(naphth-2-yl).

	.1	.2	.3
5.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
5.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
5.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
5.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
5.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
5.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
5.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
5.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
5.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
5.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
5.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
5.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
5.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
5.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
5.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
5.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
5.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
5.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
5.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
5.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
5.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
5.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
5.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
5.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
5.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
5.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
5.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
5.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
5.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
5.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
5.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
5.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
5.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
5.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
5.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
5.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
5.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
5.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)

5.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
5.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
5.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
5.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
5.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
5.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
5.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
5.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
5.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
5.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
5.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
5.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
5.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
5.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
5.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
5.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
5.56			
5.57			
5.58			
5.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
5.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
5.61	-C(O)C(CH ₃) ₂ OPh	-C(O)C(CH ₃) ₂ OPh	-C(O)CH ₂ OCH ₂ Ph








5.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
5.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
5.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
5.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
5.66			

Table 6

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = table below; R¹¹ = CH₃

5

	1	2	3
6.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
6.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
6.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
6.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
6.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
6.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
6.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
6.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
6.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
6.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
6.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
6.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
6.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
6.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
6.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
6.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
6.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
6.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
6.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
6.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
6.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
6.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
6.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
6.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
6.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
6.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
6.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
6.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
6.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)

6.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
6.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
6.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
6.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
6.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
6.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
6.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
6.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
6.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
6.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
6.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
6.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
6.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
6.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
6.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
6.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
6.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
6.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
6.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
6.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
6.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
6.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
6.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
6.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
6.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
6.56			
6.57			





6.58			
6.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
6.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
6.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
6.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
6.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
6.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
6.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
6.66			

Table 7

Formula I : A = -B(OH)₂ ; X = -CH₂NH₂ ; R³ = table below ; R¹¹ = -CH₂(p-PhOH).

5

	1	2	3
7.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
7.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
7.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
7.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
7.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
7.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
7.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
7.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
7.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
7.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
7.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
7.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
7.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
7.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
7.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
7.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
7.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
7.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
7.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
7.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
7.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)

175

7.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
7.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
7.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
7.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
7.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
7.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
7.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
7.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
7.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
7.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
7.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
7.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
7.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
7.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
7.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
7.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
7.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
7.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
7.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
7.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
7.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
7.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
7.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
7.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
7.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
7.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
7.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
7.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
7.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
7.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
7.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
7.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
7.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)

7.56			
7.57			
7.58			
7.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
7.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
7.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
7.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
7.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
7.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
7.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
7.66			

Table 8

Formula I: A = -B(OH)₂; X = Cl₂NH₂; R³ = table below; R¹¹ = -CH₂CH₂Ph.

	.1	.2	.3
8.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
8.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
8.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
8.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
8.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
8.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
8.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
8.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
8.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
8.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
8.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
8.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
8.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)

8.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
8.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
8.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
8.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
8.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
8.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
8.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
8.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
8.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
8.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
8.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
8.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
8.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
8.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
8.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
8.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
8.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
8.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
8.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
8.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
8.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
8.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
8.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
8.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
8.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
8.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
8.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
8.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
8.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
8.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
8.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
8.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
8.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
8.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
8.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl











8.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
8.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
8.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
8.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
8.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
8.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
8.56			
8.57			
8.58			
8.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
8.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
8.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
8.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
8.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
8.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
8.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
8.66			










Table 2

Formula I: A = -B(OH)₂; X = CH₂NI₂; R³ = table below; R¹¹ = -Ph.

5

	1	2	3
9.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph

9.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
9.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
9.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
9.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
9.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
9.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
9.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
9.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
9.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
9.11	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
9.12	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
9.13	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
9.14	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
9.15	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
9.16	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
9.17	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
9.18	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
9.19	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
9.20	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
9.21	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
9.22	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
9.23	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
9.24	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
9.25	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
9.26	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
9.27	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
9.28	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
9.29	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
9.30	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
9.31	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
9.32	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
9.33	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
9.34	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
9.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
9.36	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
9.37	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
9.38	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
9.39	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
9.40	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
9.41	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
9.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)

9.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
9.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
9.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
9.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
9.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
9.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
9.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
9.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
9.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
9.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
9.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
9.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
9.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
9.56			
9.57			
9.58			
9.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
9.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
9.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
9.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
9.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
9.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
9.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)











9.66			
------	---	--	--

Table 10

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = table below; R¹¹ = -CH₂(naphth-2-yl).

	.1	.2	.3
10.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
10.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
10.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
10.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
10.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
10.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
10.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
10.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
10.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
10.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
10.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
10.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
10.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
10.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
10.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
10.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
10.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
10.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
10.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
10.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
10.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
10.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
10.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
10.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
10.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
10.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
10.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
10.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
10.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
10.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
10.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
10.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
10.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
10.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
10.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
10.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
10.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
10.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
10.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)

10.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
10.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
10.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
10.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
10.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
10.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
10.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
10.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
10.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
10.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
10.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
10.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
10.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
10.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
10.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
10.56			
10.57			
10.58			
10.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
10.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
10.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
10.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
10.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
10.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)








10.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
10.66			

Table 11

Formula I: A = -B(OH)₂; X = -SC(=NH)NH₂; R³ = table below; R¹¹ = CH₃

5

	1	2	3
11.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
11.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
11.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
11.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
11.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
11.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
11.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
11.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
11.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
11.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
11.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
11.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
11.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
11.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
11.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
11.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
11.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
11.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
11.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
11.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
11.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
11.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
11.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
11.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
11.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
11.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
11.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
11.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
11.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
11.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
11.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
11.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)

11.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
11.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
11.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
11.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
11.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
11.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
11.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
11.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
11.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
11.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
11.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
11.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
11.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
11.47	-C(O) <i>o</i> -Ph(P(O)Ph ₃)	-C(O) <i>m</i> -Ph(P(O)Ph ₃)	-C(O) <i>p</i> -Ph(P(O)Ph ₃)
11.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
11.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
11.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
11.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
11.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
11.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
11.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
11.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
11.56			
11.57			





11.58			
11.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
11.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
11.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
11.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
11.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
11.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
11.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
11.66			

Table 12

Formula I : A = -B(OH)₂ ; X = -SC(=NH)NH₂ ; R³ = table below ; R¹¹ = -CH₂(p-PhOH).

5

	.1	.2	
12.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
12.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
12.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
12.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
12.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
12.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
12.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
12.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
12.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
12.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
12.11	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
12.12	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
12.13	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
12.14	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
12.15	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
12.16	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
12.17	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
12.18	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
12.19	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
12.20	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
12.21	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
12.22	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)

12.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
12.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
12.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
12.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
12.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
12.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
12.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
12.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
12.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
12.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
12.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
12.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
12.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
12.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
12.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
12.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
12.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
12.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
12.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
12.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
12.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
12.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
12.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
12.46	-C(O)benzothiazio-2-yl	-C(O)CH ₂ (benzothiazio-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazio-2-yl)
12.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
12.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
12.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
12.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
12.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
12.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
12.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
12.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
12.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)

12.56			
12.57			
12.58			
12.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
12.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
12.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
12.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
12.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
12.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
12.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
12.66			

Table 13

Formula I : A = -B(OH)₂ ; X = -SC(=NI)NI₂ ; R³ = table below ; R¹¹ = -CH₂CH₂Ph.

5

	1	2	3
13.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
13.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NIHPh	-C(O)CH ₂ SPh
13.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
13.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
13.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
13.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
13.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
13.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
13.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
13.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
13.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
13.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)

13.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
13.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
13.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
13.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
13.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
13.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
13.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
13.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
13.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
13.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
13.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
13.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
13.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
13.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
13.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
13.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
13.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
13.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
13.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
13.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
13.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
13.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
13.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
13.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
13.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
13.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
13.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
13.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
13.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
13.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
13.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
13.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
13.46	-C(O)benzothiaz-2-yl	-C(O)CH ₂ (benzothiaz-2-yl)	-C(O)CH ₂ CH ₂ (benzothiaz-2-yl)
13.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
13.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
13.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
13.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
13.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
13.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)




















13.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
13.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
13.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
13.56			
13.57			
13.58			
13.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
13.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (uniphen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
13.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
13.62	-C(O)CH ₂ O(α-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
13.63	-C(O)CH ₂ O(α-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
13.64	-C(O)CH ₂ O(α-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
13.65	-C(O)CH ₂ O(α-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
13.66			

Table 14

Formula I: A = -B(OH)₂; X = -SC(=NH)NH₂; R³ = table below; R¹¹ = -Ph.

	.1	.2	.3
14.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
14.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
14.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
14.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
14.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
14.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
14.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
14.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
14.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
14.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
14.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
14.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
14.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
14.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
14.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
14.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
14.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
14.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
14.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
14.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
14.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
14.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
14.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
14.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
14.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
14.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
14.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
14.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
14.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
14.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
14.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
14.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
14.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
14.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
14.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
14.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
14.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
14.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
14.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)

14.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
14.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
14.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
14.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
14.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
14.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
14.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
14.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
14.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
14.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
14.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
14.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
14.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
14.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
14.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
14.56			
14.57			
14.58			
14.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
14.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
14.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
14.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
14.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
14.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
14.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)

14.66			
-------	---	--	--










Table 15

Formula I : A = -B(OH)₂ ; X = -SC(=NH)NH₂ ; R³ = table below ; R¹¹ = -CH₂(naphth-2-yl).

5

	1	2	3
15.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
15.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
15.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
15.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
15.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
15.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
15.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naph-1-yl)
15.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naph-2-yl)
15.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
15.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
15.11	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
15.12	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
15.13	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
15.14	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
15.15	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
15.16	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
15.17	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
15.18	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
15.19	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
15.20	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
15.21	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
15.22	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
15.23	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
15.24	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
15.25	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
15.26	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
15.27	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
15.28	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
15.29	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
15.30	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
15.31	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
15.32	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
15.33	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
15.34	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
15.35			

194

15.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
15.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
15.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
15.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
15.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
15.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
15.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
15.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
15.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
15.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
15.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
15.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
15.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
15.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
15.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
15.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
15.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2.2-(Ph ₂)
15.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
15.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
15.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
15.56			
15.57			
15.58			
15.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
15.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)








15.61	-C(O)C(CH ₃) ₂ OPh	-C(O)Cl(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
15.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)ClCH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
15.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
15.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
15.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
15.66			

Table 16

Formula I : A = -B(pinanediol) ; X = guanidinyl ; R³ = table below ; R¹¹ = CH₃

5

	.1	.2	.3
16.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
16.2	-C(O)CH ₂ OPh	-C(O)ClCH ₂ NHPh	-C(O)CH ₂ SPh
16.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
16.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
16.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
16.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
16.7	-C(O)naphth-1-yl	-C(O)ClCH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
16.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
16.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
16.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
16.12	-C(O)p-biphenyl	-C(O)ClCH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
16.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
16.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
16.15	-C(O)p-PhOPh	-C(O)ClCH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
16.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
16.17	-C(O)m-PhNHPh	-C(O)ClCH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
16.18	-C(O)p-PhNHPh	-C(O)ClCH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
16.19	-C(O)o-PhSPh	-C(O)ClCH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
16.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
16.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
16.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
16.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
16.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
16.25	-C(O)adamantyl	-C(O)ClCH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
16.26	-C(O)cyclopentyl	-C(O)ClCH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
16.27	-C(O)cyclohexyl	-C(O)ClCH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
16.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)ClCH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
16.29	-C(O)ClCH ₂ O(cyclohexyl)	-C(O)ClCH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
16.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)

16.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
16.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
16.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
16.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
16.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
16.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
16.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
16.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
16.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
16.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
16.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
16.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
16.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
16.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
16.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
16.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
16.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
16.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
16.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
16.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
16.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
16.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
16.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
16.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
16.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
16.56			
16.57			





16.58			
16.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
16.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
16.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
16.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
16.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
16.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
16.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
16.66			

Table 17

Formula I: A = -B(pinenediol); X = guanidinyI; R³ = table below; R¹¹ = -CH₂(p-PhOH).

5

	1	2	3
17.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
17.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
17.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
17.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
17.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
17.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
17.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
17.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
17.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
17.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
17.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
17.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
17.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
17.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
17.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
17.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
17.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
17.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
17.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
17.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
17.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)

17.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
17.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
17.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
17.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
17.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
17.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
17.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
17.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
17.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
17.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
17.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
17.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
17.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
17.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
17.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
17.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
17.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
17.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
17.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
17.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
17.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
17.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
17.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
17.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
17.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
17.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
17.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
17.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
17.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
17.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
17.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
17.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
17.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)




















17.56			
17.57			
17.58			
17.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
17.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
17.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
17.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
17.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
17.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
17.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
17.66			

Table 18

Formula I: A = -B(pinanediol); X = guanidinyI; R³ = table below; R¹¹ = -CH₂CH₂Ph.

	.1	.2	.3
18.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
18.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
18.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
18.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
18.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
18.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
18.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
18.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
18.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
18.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
18.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
18.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
18.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
18.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
18.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
18.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
18.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
18.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
18.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
18.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
18.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
18.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
18.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
18.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
18.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
18.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
18.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
18.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
18.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
18.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
18.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
18.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
18.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
18.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
18.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
18.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
18.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
18.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
18.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)

201

18.41	-C(O)benzofuran-3-yl	-C(O)Cl ₁₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
18.42	-C(O)benzothiophen-2-yl	-C(O)Cl ₁₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
18.43	-C(O)thiophen-2-yl	-C(O)Cl ₁₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
18.44	-C(O)benzimidazo-2-yl	-C(O)Cl ₁₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
18.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
18.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
18.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
18.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
18.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
18.50	-C(O)C(CH ₃) ₂ NHISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
18.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
18.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
18.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
18.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)Cl ₁₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
18.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)Cl ₁₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
18.56			
18.57			
18.58			
18.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)Cl ₁₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
18.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
18.61	-C(O)C(CH ₃) ₂ OPh	-C(O)Cl ₁₂ (C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
18.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)Cl ₁₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
18.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)Cl ₁₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
18.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
18.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)Cl ₁₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)











18.66			
-------	---	--	--

Table 12

Formula 1: A = -B(pinenediol); X = guanidinyI; R³ = table below; R¹¹ = -Ph.

	.1	.2	.3
19.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
19.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
19.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
19.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
19.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
19.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
19.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
19.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
19.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
19.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
19.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
19.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
19.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
19.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
19.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
19.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
19.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
19.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
19.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
19.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
19.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
19.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
19.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
19.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
19.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
19.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
19.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
19.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
19.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
19.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
19.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
19.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
19.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
19.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
19.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
19.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
19.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
19.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
19.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)

204

19.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
19.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
19.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
19.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
19.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
19.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
19.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
19.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
19.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
19.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
19.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
19.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
19.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
19.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
19.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
19.56			
19.57			
19.58			
19.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
19.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
19.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
19.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
19.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
19.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)








19.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
19.66			

Table 20

Formula I: A = -B(pinanediol); X = guanidiny; R³ = table below; R¹¹ = -CH₂(naphth-2-yl).

5

	.1	.2	.3
20.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
20.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
20.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
20.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
20.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
20.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
20.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
20.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
20.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
20.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
20.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
20.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
20.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
20.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
20.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
20.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
20.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
20.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
20.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
20.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
20.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
20.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
20.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
20.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
20.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
20.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
20.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
20.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
20.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
20.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
20.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
20.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
20.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)

20.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
20.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
20.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
20.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
20.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
20.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
20.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
20.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
20.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
20.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
20.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
20.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
20.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
20.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
20.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
20.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
20.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
20.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph) ₂
20.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
20.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
20.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
20.56			
20.57			





20.58			
20.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
20.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
20.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
20.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
20.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
20.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
20.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
20.66			

Table 21

5 Formula I : A = -B(pinenediol) ; X = -CH₂NH₂ ; R³ = table below ; R¹¹ = CH₃

	.1	.2	.3
21.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
21.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
21.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
21.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
21.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
21.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
21.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
21.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
21.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
21.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
21.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
21.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
21.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
21.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
21.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
21.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
21.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
21.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
21.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
21.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)

21.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
21.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
21.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
21.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
21.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
21.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
21.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
21.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
21.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
21.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
21.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
21.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
21.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
21.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
21.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
21.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
21.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
21.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
21.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
21.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
21.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
21.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
21.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
21.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
21.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
21.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
21.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
21.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
21.50	-C(O)C(CH ₃) ₂ NHISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
21.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
21.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
21.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxo)indolin-3-yl
21.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)




















21.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
21.56			
21.57			
21.58			
21.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
21.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
21.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
21.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
21.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
21.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
21.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
21.66			

Table 22

Formula I: A = -B(pinanediol); X = -CH₂NH₂; R³ = table below; R¹¹ = -CH₂(p-PhOH).

	.1	.2	.3
22.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
22.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
22.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
22.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
22.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
22.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
22.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
22.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
22.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
22.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
22.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
22.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
22.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
22.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
22.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
22.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
22.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
22.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
22.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
22.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
22.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
22.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
22.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
22.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
22.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
22.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
22.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
22.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
22.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
22.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
22.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
22.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
22.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
22.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
22.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
22.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
22.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
22.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)

22.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
22.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
22.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
22.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
22.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
22.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
22.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
22.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
22.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
22.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
22.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
22.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
22.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
22.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
22.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
22.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
22.56			
22.57			
22.58			
22.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
22.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
22.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
22.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)











22.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
22.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
22.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
22.66			

Table 23

Formula I: A = -B(pinanediol); X = CH₂NH₂; R³ = table below; R¹¹ = -CH₂CH₂Ph.

	.1	.2	.3
23.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
23.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
23.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
23.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
23.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
23.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
23.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
23.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
23.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
23.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
23.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
23.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
23.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
23.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
23.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
23.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
23.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
23.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
23.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
23.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
23.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
23.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
23.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
23.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
23.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
23.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
23.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
23.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
23.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
23.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
23.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
23.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
23.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
23.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
23.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
23.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
23.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
23.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
23.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
23.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)










23.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
23.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
23.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
23.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
23.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
23.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
23.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
23.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
23.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
23.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
23.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
23.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
23.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
23.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
23.56			
23.57			
23.58			
23.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
23.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
23.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
23.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
23.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
23.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
23.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)

23.66			
-------	---	--	--

Table 24

5 Formula I : A = -B(pinanediol) ; X = CH₂NH₂; R³ = table below ; R¹¹ = -Ph.

	.1	.2	.3
24.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
24.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
24.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
24.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
24.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
24.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
24.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
24.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
24.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
24.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
24.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
24.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
24.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
24.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
24.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
24.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
24.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
24.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
24.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
24.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
24.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
24.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
24.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
24.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
24.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
24.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
24.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
24.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
24.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
24.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
24.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
24.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
24.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
24.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
24.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)

24.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
24.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
24.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
24.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
24.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
24.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
24.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
24.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
24.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
24.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
24.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
24.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
24.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
24.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
24.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
24.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
24.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
24.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
24.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
24.56			
24.57			
24.58			
24.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
24.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)








24.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
24.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
24.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
24.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
24.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
24.66			

Table 25

Formula I: A = -B(pinnediol); X = -CH₂NH₂; R³ = table below; R¹¹ = -CH₂(naphth-2-yl).

5

	.1	.2	.3
25.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
25.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
25.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
25.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
25.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
25.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
25.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
25.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
25.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
25.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
25.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
25.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
25.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
25.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
25.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
25.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
25.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
25.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
25.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
25.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
25.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
25.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
25.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
25.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
25.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
25.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
25.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
25.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
25.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
25.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)

25.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
25.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
25.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
25.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
25.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
25.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
25.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
25.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
25.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
25.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
25.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
25.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
25.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
25.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
25.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
25.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
25.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
25.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
25.50	-C(O)C(CH ₃) ₂ NH ₂ SO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
25.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
25.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph) ₂
25.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxo)indolin-3-yl
25.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
25.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
25.56			
25.57			














25.58			
25.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
25.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
25.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
25.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
25.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
25.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
25.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
25.66			

Table 26

Formula I: A = -B(pinanediol); X = -SC(=NII)NI12; R³ = table below; R¹¹ = CH₃

	1	2	3
26.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
26.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
26.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
26.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
26.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
26.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
26.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
26.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
26.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
26.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
26.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
26.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
26.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
26.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
26.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
26.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
26.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
26.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
26.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
26.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
26.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
26.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
26.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
26.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
26.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
26.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
26.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI1(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
26.29	-C(O)CH ₂ X(cyclohexyl)	-C(O)CH ₂ NI1(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
26.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
26.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
26.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
26.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
26.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
26.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
26.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
26.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
26.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
26.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
26.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
26.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)

26.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
26.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
26.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
26.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
26.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
26.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
26.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
26.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
26.50	-C(O)C(CH ₃) ₂ NHISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
26.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
26.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
26.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxo)indolin-3-yl
26.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
26.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
26.56			
26.57			
26.58			
26.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
26.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
26.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
26.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
26.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
26.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
26.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)










26.66			
-------	---	--	--

Table 27

Formula I: A = -B(pinanediol); X = -SC(=NH)NH₂; R³ = table below; R¹¹ = -CH₂(p-PhOH).

5

	.1	.2	.3
27.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
27.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
27.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
27.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
27.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
27.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
27.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
27.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
27.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
27.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
27.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
27.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
27.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
27.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
27.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
27.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
27.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
27.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
27.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
27.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
27.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
27.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
27.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
27.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
27.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
27.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
27.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
27.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
27.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
27.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
27.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
27.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
27.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
27.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
27.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
27.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)

27.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
27.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
27.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
27.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
27.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
27.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
27.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
27.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
27.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
27.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
27.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
27.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
27.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
27.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
27.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
27.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
27.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
27.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
27.56			
27.57			
27.58			
27.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
27.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
27.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph











27.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
27.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
27.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
27.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
27.66			

Table 28

Formula I: A = -B(pinenediol); X = -SC(=NH)NH₂; R³ = table below; R¹¹ = -CH₂CH₂Ph.

	1	2	3
28.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
28.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
28.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
28.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
28.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
28.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
28.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
28.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
28.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
28.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
28.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
28.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
28.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
28.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
28.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
28.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
28.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
28.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
28.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
28.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
28.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
28.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
28.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
28.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
28.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
28.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
28.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
28.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
28.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
28.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
28.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
28.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
28.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
28.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
28.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
28.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
28.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
28.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)

28.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
28.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
28.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
28.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
28.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
28.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
28.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
28.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
28.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
28.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
28.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
28.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
28.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
28.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
28.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
28.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
28.56			
28.57			
28.58			
28.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
28.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
28.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph








28.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
28.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
28.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
28.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
28.66			

Table 29

Formula I : A = -B(pinacediol) ; X = -SC(=N)NH₂ ; R³ = table below ; R¹¹ = -Ph.

5

	1	2	3
29.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
29.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
29.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
29.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
29.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
29.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
29.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
29.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
29.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
29.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
29.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
29.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
29.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
29.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
29.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
29.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
29.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
29.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
29.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
29.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
29.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
29.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
29.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
29.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
29.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
29.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
29.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
29.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
29.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)

29.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
29.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
29.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
29.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
29.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
29.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
29.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
29.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
29.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
29.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
29.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
29.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
29.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
29.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
29.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
29.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
29.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
29.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
29.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
29.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
29.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
29.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph) ₂
29.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
29.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
29.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
29.56			
29.57			

29.58			
29.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
29.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
29.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
29.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
29.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
29.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
29.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
29.66			

Table 30

Formula I : A = -B(pinanediol) ; X = -SC(=NII)NII₂ ; R³ = table below ; R¹¹ = -CH₂(naphth-2-yl).

5

	1	2	3
30.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
30.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
30.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
30.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
30.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
30.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
30.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
30.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
30.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
30.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
30.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
30.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
30.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
30.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
30.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
30.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
30.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
30.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
30.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
30.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
30.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)

30.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
30.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
30.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
30.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
30.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
30.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
30.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
30.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
30.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
30.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
30.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
30.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
30.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
30.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
30.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
30.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
30.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
30.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
30.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
30.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
30.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
30.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
30.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
30.46	-C(O)benzothiaz-2-yl	-C(O)CH ₂ (benzothiaz-2-yl)	-C(O)CH ₂ CH ₂ (benzothiaz-2-yl)
30.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
30.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
30.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
30.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
30.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
30.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2.2-(Ph ₂)
30.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
30.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
30.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)














30.56			
30.57			
30.58			
30.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
30.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
30.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
30.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
30.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
30.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
30.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
30.66			

Table 31

Formula II : A = -B(OH)₂ ; X = guanidinyI ; Y = table below.

5

	.1	.2	.3
31.1	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
31.2	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
31.3			






















31.4			
31.5			
31.6			

Table 32Formula II : A = -B(OH)₂ ; X = -CH₂NH₂ ; Y = table below.

	.1	.2	.3
32.1	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
32.2	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
32.3			
32.4			
32.5			
32.6			

5

Table 33Formula II : A = -B(OH)₂ ; X = -SC(=NH)NH₂ ; Y = table below.

	.1	.2	.3
33.1	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
33.2	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
33.3			








33.4			
33.5			
33.6			

Table 34

Formula II: A = -B(pinenediol); X = guanidiny!; Y = table below.

5











	1	2	3
34.1	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
34.2	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
34.3			
34.4			
34.5			
34.6			

Table 35Formula II : A = -B(pinanediol) ; X = -CH₂NH₂ ; Y = table below.

5














	.1	.2	.3
35.1	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
35.2	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
35.3			
35.4			
35.5			
35.6			

Table 36Formula II : A = -B(pinanediol) ; X = -SC(=NH)NH₂ ; Y = table below.

10

	.1	.2	.3
36.1	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
36.2	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
36.3			

















36.4			
36.5			
36.6			

Table 37

Formula III : A = -B(OH)₂ ; X = -CN ; R³ = table below : R¹¹ = CH₃

	.1	.2	.3
37.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
37.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NIIPh	-C(O)CH ₂ SPh
37.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
37.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
37.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
37.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
37.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
37.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
37.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
37.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
37.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
37.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
37.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
37.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
37.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
37.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
37.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
37.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
37.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
37.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
37.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
37.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
37.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
37.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
37.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
37.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
37.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
37.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
37.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
37.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
37.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
37.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
37.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
37.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
37.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
37.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
37.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
37.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
37.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
37.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)

37.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
37.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
37.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
37.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
37.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
37.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
37.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
37.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
37.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
37.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
37.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
37.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
37.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
37.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
37.56			
37.57			
37.58			
37.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
37.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
37.61	-C(O)C(CH ₃) ₂ O(Ph)	-C(O)CH(C ₂ H ₅)O(Ph)	-C(O)CH ₂ OCH ₂ Ph
37.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
37.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
37.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
37.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)

37.66			
-------	---	--	--










Table 38

Formula III : A = -B(OH)₂ ; X = -CN ; R³ = table below ; R¹¹ = -CH₂CH₂Ph.

5

	.1	.2	.3
38.1	-C(O)Ph	-C(O)ClI ₂ Ph	-C(O)CH ₂ CH ₂ Ph
38.2	-C(O)CH ₂ OPh	-C(O)ClI ₂ NHPh	-C(O)CH ₂ SPh
38.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
38.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
38.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
38.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
38.7	-C(O)naphth-1-yl	-C(O)ClI ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
38.8	-C(O)naphth-2-yl	-C(O)ClI ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
38.9	-C(O)o-biphenyl	-C(O)ClI ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
38.10	-C(O)m-biphenyl	-C(O)ClI ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
38.12	-C(O)p-biphenyl	-C(O)ClI ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
38.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
38.14	-C(O)m-PhOPh	-C(O)ClI ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
38.15	-C(O)p-PhOPh	-C(O)ClI ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
38.16	-C(O)o-PhNHPh	-C(O)ClI ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
38.17	-C(O)m-PhNHPh	-C(O)ClI ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
38.18	-C(O)p-PhNHPh	-C(O)ClI ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
38.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
38.20	-C(O)m-PhSPh	-C(O)ClI ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
38.21	-C(O)p-PhSPh	-C(O)ClI ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
38.22	-C(O)o-PhCH ₂ SPh	-C(O)ClI ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
38.23	-C(O)m-PhCH ₂ SPh	-C(O)ClI ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
38.24	-C(O)p-PhCH ₂ SPh	-C(O)ClI ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
38.25	-C(O)adamantyl	-C(O)ClI ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
38.26	-C(O)cyclopentyl	-C(O)ClI ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
38.27	-C(O)cyclohexyl	-C(O)ClI ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
38.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NI(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
38.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NI(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
38.30	-C(O)pyridin-2-yl	-C(O)ClI ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
38.31	-C(O)pyridin-3-yl	-C(O)ClI ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
38.32	-C(O)pyridin-4-yl	-C(O)ClI ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
38.33	-C(O)furan-2-yl	-C(O)ClI ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
38.34	-C(O)furan-3-yl	-C(O)ClI ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
38.35	-C(O)thiophen-2-yl	-C(O)ClI ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
38.36	-C(O)thiophen-2-yl	-C(O)ClI ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
38.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
38.38	-C(O)oxazo-2-yl	-C(O)ClI ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)

240

38.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
38.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
38.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
38.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
38.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
38.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
38.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
38.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
38.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
38.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
38.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
38.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
38.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
38.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2.2-(Ph ₂)
38.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
38.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
38.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
38.56			
38.57			
38.58			
38.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
38.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
38.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
38.62	-C(O)CH ₂ O(α-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
38.63	-C(O)CH ₂ O(α-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)











38.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
38.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
38.66			

Table 39

Formula III: A = -B(OH)₂; X = -CH₂NH₂; R³ = table below; R¹¹ = CH₃

	1	2	3
39.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
39.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
39.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
39.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
39.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
39.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
39.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
39.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
39.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
39.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
39.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
39.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
39.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
39.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
39.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
39.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
39.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
39.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
39.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
39.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
39.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
39.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
39.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
39.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
39.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
39.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
39.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
39.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
39.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
39.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
39.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
39.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)

39.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
39.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
39.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
39.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
39.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
39.39	-C(O)thiazo-2-yl	-C(O)CH ₂ (thiazo-2-yl)	-C(O)CH ₂ CH ₂ (thiazo-2-yl)
39.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
39.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
39.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
39.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
39.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
39.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
39.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
39.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
39.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
39.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
39.50	-C(O)C(CH ₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
39.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
39.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
39.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
39.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
39.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
39.56			
39.57			
39.58			











39.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
39.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
39.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
39.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
39.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
39.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
39.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
39.66			

Table 40

Formula III : A = -B(OH)₂; X = CH₂NH₂; R³ = table below; R¹¹ = -CH₂CH₂Ph.

	.1	.2	.3
40.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
40.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
40.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
40.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
40.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
40.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
40.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
40.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
40.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
40.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
40.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
40.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
40.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
40.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
40.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
40.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
40.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
40.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
40.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
40.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
40.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
40.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
40.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
40.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
40.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
40.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
40.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
40.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
40.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
40.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
40.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
40.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
40.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
40.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
40.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
40.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
40.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
40.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
40.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
40.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)

245










40.42	-C(O)benzothiophen-2-yl	-C(O)Cl ₁₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
40.43	-C(O)thiophen-2-yl	-C(O)Cl ₁₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
40.44	-C(O)benzimidazo-2-yl	-C(O)Cl ₁₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
40.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
40.46	-C(O)benzothiazo-2-yl	-C(O)Cl ₁₂ (benzothiazo-2-yl)	-C(O)Cl ₁₂ CH ₂ (benzothiazo-2-yl)
40.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
40.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
40.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
40.50	-C(O)C(Cl ₁₃) ₂ NHSO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
40.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
40.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2.2-(Ph ₂)
40.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxo)indolin-3-yl
40.54	-C(O)Cl ₁₂ (<i>N</i> -benzimidazol-2-one)	-C(O)Cl ₁₂ (<i>N</i> -benzoxazol-2-one)	-C(O)Cl ₁₂ (<i>N</i> -benzothiazol-2-one)
40.55	-C(O)Cl ₁₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)Cl ₁₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
40.56			
40.57			
40.58			
40.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
40.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(Cl ₁₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
40.61	-C(O)C(CH ₃) ₂ OPh	-C(O)C(CH ₃) ₂ OCH ₂ Ph	-C(O)CH ₂ OCH ₂ Ph
40.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
40.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
40.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
40.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)

40.66			
-------	--	--	--

Table 41

5 Formula III : A = -B(pinanediol) ; X = -CN ; R³ = table below ; R¹¹ = CH₃

	1	2	3
41.1	-C(O)Ph	-C(O)Cl ₂ Ph	-C(O)CH ₂ CH ₂ Ph
41.2	-C(O)Cl ₂ OPh	-C(O)Cl ₂ NHPh	-C(O)CH ₂ SPh
41.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
41.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
41.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
41.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
41.7	-C(O)naphth-1-yl	-C(O)Cl ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
41.8	-C(O)naphth-2-yl	-C(O)Cl ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
41.9	-C(O)o-biphenyl	-C(O)Cl ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
41.10	-C(O)m-biphenyl	-C(O)Cl ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
41.11	-C(O)p-biphenyl	-C(O)Cl ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
41.12	-C(O)o-PhOPh	-C(O)Cl ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
41.13	-C(O)m-PhOPh	-C(O)Cl ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
41.14	-C(O)p-PhOPh	-C(O)Cl ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
41.15	-C(O)o-PhNHPh	-C(O)Cl ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
41.16	-C(O)m-PhNHPh	-C(O)Cl ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
41.17	-C(O)p-PhNHPh	-C(O)Cl ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
41.18	-C(O)o-PhSPh	-C(O)Cl ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
41.19	-C(O)m-PhSPh	-C(O)Cl ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
41.20	-C(O)p-PhSPh	-C(O)Cl ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
41.21	-C(O)o-PhC ₂ H ₅	-C(O)Cl ₂ (o-PhC ₂ H ₅)	-C(O)CH ₂ CH ₂ (o-PhC ₂ H ₅)
41.22	-C(O)m-PhC ₂ H ₅	-C(O)Cl ₂ (m-PhC ₂ H ₅)	-C(O)CH ₂ CH ₂ (m-PhC ₂ H ₅)
41.23	-C(O)p-PhC ₂ H ₅	-C(O)Cl ₂ (p-PhC ₂ H ₅)	-C(O)CH ₂ CH ₂ (p-PhC ₂ H ₅)
41.24	-C(O)adamantyl	-C(O)Cl ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
41.25	-C(O)cyclopentyl	-C(O)Cl ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
41.26	-C(O)cyclohexyl	-C(O)Cl ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
41.27	-C(O)CH ₂ O(cyclopentyl)	-C(O)Cl ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
41.28	-C(O)CH ₂ O(cyclohexyl)	-C(O)Cl ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
41.29	-C(O)pyridin-2-yl	-C(O)Cl ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
41.30	-C(O)pyridin-3-yl	-C(O)Cl ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
41.31	-C(O)pyridin-4-yl	-C(O)Cl ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
41.32	-C(O)furan-2-yl	-C(O)Cl ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
41.33	-C(O)furan-3-yl	-C(O)Cl ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
41.34	-C(O)thiophen-2-yl	-C(O)Cl ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)










41.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
41.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
41.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
41.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
41.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
41.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
41.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
41.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
41.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
41.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
41.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
41.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
41.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
41.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
41.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
41.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
41.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph) ₂
41.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
41.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
41.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
41.56			
41.57			
41.58			
41.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph

41.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
41.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
41.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
41.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
41.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
41.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
41.66	$ \begin{array}{c} \text{O} \\ \parallel \\ \text{OC} - \text{N} \\ \\ \text{CH}_2 \\ \\ \text{C}_6\text{H}_5 \end{array} $		

Table 42

Formula III : A = -B(pinenediol) ; X = -CN ; R³ = table below ; R¹¹ = -CH₂CH₂Ph.

	.1	.2	.3
42.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
42.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
42.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
42.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
42.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
42.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
42.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
42.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
42.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
42.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
42.11	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
42.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
42.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
42.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
42.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
42.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
42.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
42.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
42.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
42.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
42.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
42.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
42.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
42.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
42.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
42.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
42.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
42.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
42.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
42.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
42.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
42.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
42.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
42.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
42.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
42.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
42.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
42.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)

42.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
42.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
42.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
42.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
42.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
42.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
42.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
42.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
42.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
42.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
42.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
42.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
42.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
42.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ ((2-oxo)indolin-3-yl)
42.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
42.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
42.56			
42.57			
42.58			
42.59	-C(O)N(C ₁₁ H ₂₃)CH ₂ Ph	-C(O)N(C ₂₁ H ₄₃)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
42.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
42.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph








42.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
42.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
42.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
42.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
42.66			

Table 43

Formula III : A = -B(pinandiol) ; X = -CH₂NH₂ ; R³ = table below ; R¹¹ = CH₃

	.1	.2	.3
43.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
43.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
43.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
43.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
43.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
43.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
43.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
43.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
43.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
43.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
43.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
43.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
43.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
43.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
43.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
43.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
43.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
43.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
43.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
43.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
43.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)
43.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
43.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
43.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
43.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
43.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
43.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
43.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
43.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)

43.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
43.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
43.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
43.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
43.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
43.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
43.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
43.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
43.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
43.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
43.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
43.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
43.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
43.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
43.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
43.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
43.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
43.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
43.49	-C(O) <i>N</i> -indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
43.50	-C(O)C(CH ₃) ₂ NIISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
43.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
43.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
43.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxo)indolin-3-yl
43.54	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
43.55	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
43.56			
43.57			





43.58			
43.59	-C(O)N(C ₁₁)CH ₂ Ph	-C(O)N(C ₂₁₁₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
43.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
43.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
43.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
43.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
43.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
43.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
43.66			

Table 44

Formula III : A = -B(pinanediol) : X = CH₂NI₂ : R³ = table below : R¹¹ = -CH₂CH₂Ph.

	1	2	3
44.1	-C(O)Ph	-C(O)CH ₂ Ph	-C(O)CH ₂ CH ₂ Ph
44.2	-C(O)CH ₂ OPh	-C(O)CH ₂ NHPh	-C(O)CH ₂ SPh
44.3	-C(O)o-PhOH	-C(O)m-PhOH	-C(O)p-PhOH
44.4	-C(O)o-PhCH ₂ OH	-C(O)m-PhCH ₂ OH	-C(O)p-PhCH ₂ OH
44.5	-C(O)o-PhCOOH	-C(O)m-PhCOOH	-C(O)p-PhCOOH
44.6	-C(O)o-PhCH ₂ COOH	-C(O)m-PhCH ₂ COOH	-C(O)p-PhCH ₂ COOH
44.7	-C(O)naphth-1-yl	-C(O)CH ₂ (naphth-1-yl)	-C(O)CH ₂ CH ₂ (naphth-1-yl)
44.8	-C(O)naphth-2-yl	-C(O)CH ₂ (naphth-2-yl)	-C(O)CH ₂ CH ₂ (naphth-2-yl)
44.9	-C(O)o-biphenyl	-C(O)CH ₂ (o-biphenyl)	-C(O)CH ₂ CH ₂ (o-biphenyl)
44.10	-C(O)m-biphenyl	-C(O)CH ₂ (m-biphenyl)	-C(O)CH ₂ CH ₂ (m-biphenyl)
44.12	-C(O)p-biphenyl	-C(O)CH ₂ (p-biphenyl)	-C(O)CH ₂ CH ₂ (p-biphenyl)
44.13	-C(O)o-PhOPh	-C(O)CH ₂ (o-PhOPh)	-C(O)CH ₂ CH ₂ (o-PhOPh)
44.14	-C(O)m-PhOPh	-C(O)CH ₂ (m-PhOPh)	-C(O)CH ₂ CH ₂ (m-PhOPh)
44.15	-C(O)p-PhOPh	-C(O)CH ₂ (p-PhOPh)	-C(O)CH ₂ CH ₂ (p-PhOPh)
44.16	-C(O)o-PhNHPh	-C(O)CH ₂ (o-PhNHPh)	-C(O)CH ₂ CH ₂ (o-PhNHPh)
44.17	-C(O)m-PhNHPh	-C(O)CH ₂ (m-PhNHPh)	-C(O)CH ₂ CH ₂ (m-PhNHPh)
44.18	-C(O)p-PhNHPh	-C(O)CH ₂ (p-PhNHPh)	-C(O)CH ₂ CH ₂ (p-PhNHPh)
44.19	-C(O)o-PhSPh	-C(O)CH ₂ (o-PhSPh)	-C(O)CH ₂ CH ₂ (o-PhSPh)
44.20	-C(O)m-PhSPh	-C(O)CH ₂ (m-PhSPh)	-C(O)CH ₂ CH ₂ (m-PhSPh)
44.21	-C(O)p-PhSPh	-C(O)CH ₂ (p-PhSPh)	-C(O)CH ₂ CH ₂ (p-PhSPh)
44.22	-C(O)o-PhCH ₂ SPh	-C(O)CH ₂ (o-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (o-PhCH ₂ SPh)

2541

44.23	-C(O)m-PhCH ₂ SPh	-C(O)CH ₂ (m-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (m-PhCH ₂ SPh)
44.24	-C(O)p-PhCH ₂ SPh	-C(O)CH ₂ (p-PhCH ₂ SPh)	-C(O)CH ₂ CH ₂ (p-PhCH ₂ SPh)
44.25	-C(O)adamantyl	-C(O)CH ₂ (adamantyl)	-C(O)CH ₂ CH ₂ (adamantyl)
44.26	-C(O)cyclopentyl	-C(O)CH ₂ (cyclopentyl)	-C(O)CH ₂ CH ₂ (cyclopentyl)
44.27	-C(O)cyclohexyl	-C(O)CH ₂ (cyclohexyl)	-C(O)CH ₂ CH ₂ (cyclohexyl)
44.28	-C(O)CH ₂ O(cyclopentyl)	-C(O)CH ₂ NH(cyclopentyl)	-C(O)CH ₂ S(cyclopentyl)
44.29	-C(O)CH ₂ O(cyclohexyl)	-C(O)CH ₂ NH(cyclohexyl)	-C(O)CH ₂ S(cyclohexyl)
44.30	-C(O)pyridin-2-yl	-C(O)CH ₂ (pyridin-2-yl)	-C(O)CH ₂ CH ₂ (pyridin-2-yl)
44.31	-C(O)pyridin-3-yl	-C(O)CH ₂ (pyridin-3-yl)	-C(O)CH ₂ CH ₂ (pyridin-3-yl)
44.32	-C(O)pyridin-4-yl	-C(O)CH ₂ (pyridin-4-yl)	-C(O)CH ₂ CH ₂ (pyridin-4-yl)
44.33	-C(O)furan-2-yl	-C(O)CH ₂ (furan-2-yl)	-C(O)CH ₂ CH ₂ (furan-2-yl)
44.34	-C(O)furan-3-yl	-C(O)CH ₂ (furan-3-yl)	-C(O)CH ₂ CH ₂ (furan-3-yl)
44.35	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
44.36	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
44.37	-C(O)imidazo-2-yl	-C(O)CH ₂ (imidazo-2-yl)	-C(O)CH ₂ CH ₂ (imidazo-2-yl)
44.38	-C(O)oxazo-2-yl	-C(O)CH ₂ (oxazo-2-yl)	-C(O)CH ₂ CH ₂ (oxazo-2-yl)
44.39	-C(O)thioazo-2-yl	-C(O)CH ₂ (thioazo-2-yl)	-C(O)CH ₂ CH ₂ (thioazo-2-yl)
44.40	-C(O)benzofuran-2-yl	-C(O)CH ₂ (benzofuran-2-yl)	-C(O)CH ₂ CH ₂ (benzofuran-2-yl)
44.41	-C(O)benzofuran-3-yl	-C(O)CH ₂ (benzofuran-3-yl)	-C(O)CH ₂ CH ₂ (benzofuran-3-yl)
44.42	-C(O)benzothiophen-2-yl	-C(O)CH ₂ (benzothiophen-2-yl)	-C(O)CH ₂ CH ₂ (benzothiophen-2-yl)
44.43	-C(O)thiophen-2-yl	-C(O)CH ₂ (thiophen-2-yl)	-C(O)CH ₂ CH ₂ (thiophen-2-yl)
44.44	-C(O)benzimidazo-2-yl	-C(O)CH ₂ (benzimidazo-2-yl)	-C(O)CH ₂ CH ₂ (benzimidazo-2-yl)
44.45	-C(O)benzoxazo-2-yl	-C(O)CH ₂ (benzoxazo-2-yl)	-C(O)CH ₂ CH ₂ (benzoxazo-2-yl)
44.46	-C(O)benzothiazo-2-yl	-C(O)CH ₂ (benzothiazo-2-yl)	-C(O)CH ₂ CH ₂ (benzothiazo-2-yl)
44.47	-C(O)o-Ph(P(O)Ph ₃)	-C(O)m-Ph(P(O)Ph ₃)	-C(O)p-Ph(P(O)Ph ₃)
44.48	-C(O)Ph-2-(fluoren-9-yl)	-C(O)Ph-3-(fluoren-9-yl)	-C(O)Ph-4-(fluoren-9-yl)
44.49	-C(O)N-indolin-2-one	-C(O)indolin-2-yl	-C(O)indol-2-yl
44.50	-C(O)C(CH ₃) ₂ NHISO ₂ (naphth-2-yl)	-C(O)cyclopentyl-2-(Ph)	-C(O)cyclohexyl-2-(Ph)
44.51	-C(O)pyrrolidin-3-yl-4-(Ph)	-C(O)tetrahydrofuran-3-yl-4-(Ph)	-C(O)tetrahydrothiophen-3-yl-4-(Ph)
44.52	-C(O)tetrahydronaphth-1-yl	-C(O)tetrahydronaphth-2-yl	-C(O)cyclopropyl-2,2-(Ph ₂)
44.53	-C(O)tetrahydroisoquinolin-1-yl	-C(O)tetrahydroisoquinolin-3-yl	-C(O)CH ₂ (2-oxoindolin-3-yl)
44.54	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
44.55	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)

44.56			
44.57			
44.58			
44.59	-C(O)N(CH ₃)CH ₂ Ph	-C(O)N(C ₂ H ₅)CH ₂ Ph	-C(O)N(C ₃ H ₇)CH ₂ Ph
44.60	-C(O)pyridin-3-yl-5-(Ph)	-C(O)Ph-3-(CH ₂ (thiophen-2-yl))	-C(O)Ph-3-(CH ₂ Ph)
44.61	-C(O)C(CH ₃) ₂ OPh	-C(O)CH(C ₂ H ₅)OPh	-C(O)CH ₂ OCH ₂ Ph
44.62	-C(O)CH ₂ O(o-PhCH ₂ OH)	-C(O)CH ₂ O(m-PhCH ₂ OH)	-C(O)CH ₂ O(p-PhCH ₂ OH)
44.63	-C(O)CH ₂ O(o-PhCOOH)	-C(O)CH ₂ O(m-PhCOOH)	-C(O)CH ₂ O(p-PhCOOH)
44.64	-C(O)CH ₂ O(o-PhCOOCH ₃)	-C(O)CH ₂ O(m-PhCOOCH ₃)	-C(O)CH ₂ O(p-PhCOOCH ₃)
44.65	-C(O)CH ₂ O(o-PhCH ₂ COOH)	-C(O)CH ₂ O(m-PhCH ₂ COOH)	-C(O)CH ₂ O(p-PhCH ₂ COOH)
44.66			

Table 45

Formula IV : A = -B(OH)₂ ; X = -CN ; Y = table below.

	1	2	3
45.1	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
45.2	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
45.3			








45.4			
45.5			
45.6			

Table 46

Formula IV : A = -B(OH)₂ : X = -CH₂NHCH₂ : Y = table below.











	1	2	3
46.1	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
46.2	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
46.3			
46.4			
46.5			
46.6			

Table 47

Formula IV : A = -B(pinandediol) ; X = -CN ; Y = table below.











	1	2	3
47.1	-C(O)CH ₂ (<i>N</i> -benzimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzoxazol-2-one)	-C(O)CH ₂ (<i>N</i> -benzothiazol-2-one)
47.2	-C(O)CH ₂ (<i>N</i> -dihydroimidazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrooxazol-2-one)	-C(O)CH ₂ (<i>N</i> -dihydrothiazol-2-one)
47.3			
47.4			
47.5			
47.6			

Table 48

Formula IV : A = -B(pinenediol) ; X = -CH₂NI₁2 ; Y = table below.











	1	2	3
48.1	-C(O)CH ₂ (N-benzimidazol-2-one)	-C(O)CH ₂ (N-benzoxazol-2-one)	-C(O)CH ₂ (N-benzothiazol-2-one)
48.2	-C(O)CH ₂ (N-dihydroimidazol-2-one)	-C(O)CH ₂ (N-dihydrooxazol-2-one)	-C(O)CH ₂ (N-dihydrothiazol-2-one)
48.3			
48.4			
48.5			
48.6			

Table 49

Formula I: A = -B(pinenediol); X = See Table below; R³ = hydrocinnamoyl; R¹¹ = -CH₂CH₂Ph

Example No.	.1	.2	.3
49.1	-NH ₂	-NHCH(=NH)H	-CH ₂ NHC(=NH)NH ₂
49.2	-NHC(=NH)NH ₂	-CH ₂ NH ₂	

Table 50

Formula I: A = -B(pinenediol); X = See Table below; R³ = hydrocinnamoyl; R¹¹ = -N(CH₃)₂.

Example No.	.1	.2	.3
50.1	-NH ₂	-NHCH(=NH)H	-CH ₂ NH ₂
50.2	-CH ₂ NHC(=NH)NH ₂	-NHC(=NH)NH ₂	

Table 51

Formula I: A = -B(pinenediol); X = -CH₂NH₂; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
51.1	-CH ₂ (m-PhCF ₃)	-CH ₂ (m-PhCH ₃)	

Table 52

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
52.1	-CH ₂ (m-PhCF ₃)	-CH ₂ (m-PhCH ₃)	

Table 53

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = hydrocinnamoyl;
R¹¹ = See Table below

Example No.	.1	.2	.3
53.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl
53.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
53.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-(2,2-dimethyl-2-(3,5-dimethyl)-phenyl)ethyl
53.4	-2-(3,5-dimethyl)phenyl ethyl	-cyclopropyl	-cyclohexyl

Table 54

Formula I: A = -B(pinenediol); X = -CH₂NH₂; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
54.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl

54.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
54.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-[2,2-dimethyl-2-(3,5-dimethyl)-phenyl]ethyl
54.4	-2-(3,5-dimethyl)phenyl ethyl	-cyclopropyl	-cyclohexyl

Table 55

Formula I: A = -B(OH)₂; X = -NHC(=NH)NH₂; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
55.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl
55.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
55.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-[2,2-dimethyl-2-(3,5-dimethyl)-phenyl]ethyl
55.4	-2-(3,5-dimethyl)phenyl ethyl	-cyclopropyl	-cyclohexyl

Table 56

Formula I: A = -B(pinanediol); X = -NHC(=NH)NH₂; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
56.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl
56.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
56.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-(2,2-dimethyl-2-(3,5-dimethyl)-phenyl)ethyl
56.4	-2-(3,5-dimethyl)phenyl ethyl	-cyclopropyl	-cyclohexyl

Table 57

Formula I: A = -B(OH)₂; X = -NHC(=NH)H; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
57.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl
57.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
57.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-(2,2-dimethyl-2-(3,5-dimethyl)-phenyl)ethyl

57.4	-2-(3,5-dimethyl)phenylethyl	-cyclopropyl	-cyclohexyl
------	------------------------------	--------------	-------------

Table 58

Formula I: A = -B(pinanediol); X = -NHC(=NH)H; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
58.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl
58.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
58.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-(2,2-dimethyl-2-(3,5-dimethyl)-phenyl)ethyl
58.4	-2-(3,5-dimethyl)phenylethyl	-cyclopropyl	-cyclohexyl

Table 59

Formula I: A = -B(OH)₂; X = -NH₂; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
59.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl

59.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
59.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-[2,2-dimethyl-2-(3,5-dimethyl)-phenyl]ethyl
59.4	-2-(3,5-dimethyl)phenylethyl	-cyclopropyl	-cyclohexyl

Table 60

Formula I: A = -B(pinenediol); X = -NH₂; R³ = hydrocinnamoyl; R¹¹ = See Table below

Example No.	.1	.2	.3
60.1	-(2,2-dimethyl-2-phenyl)ethyl	-(2,2-ethanediyl-2-phenyl)ethyl	-(2,2-diethyl-2-phenyl)ethyl
60.2	-N-phenyl-N-methyl	-N-benzyl-N-methyl	-C(=O)CH ₂ CH ₂ CO ₂ H
60.3	-C(=O)CH ₂ CH ₂ -CO ₂ CH ₃	-(2,2-butanediyl-2-phenyl)ethyl	-[2,2-dimethyl-2-(3,5-dimethyl)-phenyl]ethyl
60.4	-2-(3,5-dimethyl)phenylethyl	-cyclopropyl	-cyclohexyl

Table 61

Formula I: A = See Table below; X = -CH₂NH₂; R³ = hydrocinnamoyl; R¹¹ = -CH₃

Example No.	.1	.2	.3
61.1	-C(=O)CO ₂ H	-C(=O)OCH ₂ CH ₂ -NHCbz	-C(=O)OCH ₂ CH ₂ -NH ₂
61.2	-C(=O)OCH ₃ HCL	-C(=O)OCH ₃ free base	-C(=O)CH ₃
61.3	-CH ₂ OH	-CH ₂ OH; X = -CH ₂ NHCbz	-C(=O)OH; X = -CH ₂ NHCbz
61.4	-C(OH)(OCH ₃)-C(=O)OCH ₃	-C(=O)NHNH ₂	

Table 62

Formula I: A = -B(pinane-1,2-diol); X = See Table below; R³ = 2-(2-cyanothiophenyl)-benzoyl; R¹¹ = -CH₃

Example No.	.1	.2	.3
62.1	-Br	-CH ₂ Br	-SC(=NH)NH ₂
62.2	-N ₃	-CH ₂ SC(=NH)NH ₂	-CH ₂ N ₃
62.3	-NH ₂	-CH ₂ NHC(=NH)NH ₂	-NHC(=NH)NH ₂
62.4	-NHC(=NH)H	-CH ₂ NHC(=NH)H	-CH ₂ NH ₂
62.4	-SCN		

Table 63

Formula I: A = -B(pinane-1,2-diol); X = See Table below; R³ = 2-(thiophenyl)benzoyl; R¹¹ = -CH₃

Example No.	.1	.2	.3
63.1	-Br	-CH ₂ Br	-SC(=NH)NH ₂
63.2	-N ₃	-CH ₂ SC(=NH)NH ₂	-CH ₂ N ₃

63.3	-NH ₂	-CH ₂ NHC(=NH)NH ₂	-NHC(=NH)NH ₂
63.4	-NHC(=NH)H	-CH ₂ NHC(=NH)H	-CH ₂ NH ₂
63.5	-SCN		

Table 64

Formula I: A = -B(pinenediol); X = -CH₂NH₂; R³ = See Table below; R¹¹ = -CH₃

Example No.	.1	.2	.3
64.1	2-(benzyl)-benzyl	2-(benzyl)-benzyl; R ¹¹ = -C(=O)CH	2-(pyrrol-1-ylmethyl)benzyl
64.2	2-(2-methylbenzyl)-benzovl	3-(3-trifluoromethylbenzyl)-benzovl	3-(3-chlorobenzyl)-benzovl
64.3	2-(2-cyano-benzyl)benzovl		

Table 65

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = See Table below; R¹¹ = -CH₃

Example No.	.1	.2	.3
65.1	2-(benzyl)-benzyl	2-(benzyl)-benzyl; R ¹¹ = -C(=O)CH	2-(pyrrol-1-ylmethyl)benzyl
65.2	2-(2-methylbenzyl)-benzovl	3-(3-trifluoromethylbenzyl)-benzovl	3-(3-chlorobenzyl)-benzovl

65.3	2-(2-cyano- benzyl)benzyl		
------	------------------------------	--	--

Table 66

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = See Table below;
 R¹¹ = -N(CH₃)CH₂Ph

Example No.	.1	.2	.3
66.1	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ CH ₃
66.2	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ CH ₃
66.3	-C(=O)CH ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ NH- S(O) ₂ CH ₃	-C(=O)CH ₂ CH ₂ - CO ₂ CH ₃
66.4	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ CH ₃	-C(=O)CH ₂ N- (CH ₃)S(O) ₂ CH ₃	

Table 67

Formula I: A = -B(pinenediol); X = -CH₂NH₂; R³ = See Table below; R¹¹ = -N(CH₃)CH₂Ph

Example No.	.1	.2	.3
67.1	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ CH ₃
67.2	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ CH ₃
67.3	-C(=O)CH ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ NH- S(O) ₂ CH ₃	-C(=O)CH ₂ CH ₂ - CO ₂ CH ₃

67.4	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ CH ₃	-C(=O)CH ₂ N- (CH ₃)S(O) ₂ CH ₃	
------	--	---	--

Table 68

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = See Table below;
R¹¹ = -CH₂CH₂Ph

Example No.	.1	.2	.3
68.1	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ CH ₃
68.2	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ CH ₃
68.3	-C(=O)CH ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ NH- S(O) ₂ CH ₃	-C(=O)CH ₂ CH ₂ - CO ₂ CH ₃
68.4	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ CH ₃	-C(=O)CH ₂ N- (CH ₃)S(O) ₂ CH ₃	

Table 69

Formula I: A = -B(pinanediol); X = -CH₂NH₂; R³ = See Table below; R¹¹ = -CH₂CH₂Ph

Example No.	.1	.2	.3
69.1	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ C- (CH ₃) ₂ CH ₂ CO ₂ CH ₃
69.2	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)CH ₂ CO ₂ H	-C(=O)CH- (NHBOC)- CH ₂ CH ₂ CO ₂ CH ₃
69.3	-C(=O)CH ₂ CH ₂ CO ₂ H	-C(=O)CH ₂ NH- S(O) ₂ CH ₃	-C(=O)CH ₂ CH ₂ - CO ₂ CH ₃

69.4	-C(=O)CH ₂ CH ₂ - CH ₂ CO ₂ CH ₃	-C(=O)CH ₂ N- (CH ₃)S(O) ₂ CH ₃	
------	--	---	--

Table 70

Formula I: A = See Table below; X = -CH₂NH₂; R³ = 2-(benzyl)benzoyl; R¹¹ = -CH₃

Example No.	.1	.2	.3
70.1	-C(=O)CO ₂ H	-C(=O)OCH ₂ CH ₂ - NHCbz	-C(=O)OCH ₂ CH ₂ - NH ₂
70.2	-C(=O)OCH ₃ HCL	-C(=O)OCH ₃ free base	-C(=O)CH ₃
70.3	-CH ₂ OH	-CH ₂ OH; X = -CH ₂ NHCbz	-C(=O)OH; X = -CH ₂ NHCbz
70.4	-C(OH)(OCH ₃)- C(=O)OCH ₃	-C(=O)NHNH ₂	

Table 71

Formula I: A = See Table below; X = -CH₂NH₂; R³ = 2-(2-trifluoromethylbenzyl)benzoyl; R¹¹ = -CH₃

Example No.	.1	.2	.3
71.1	-C(=O)CO ₂ H	-C(=O)OCH ₂ CH ₂ - NHCbz	-C(=O)OCH ₂ CH ₂ - NH ₂
71.2	-C(=O)OCH ₃ HCL	-C(=O)OCH ₃ free base	-C(=O)CH ₃
71.3	-CH ₂ OH	-CH ₂ OH; X = -CH ₂ NHCbz	-C(=O)OH; X = -CH ₂ NHCbz
71.4	-C(OH)(OCH ₃)- C(=O)OCH ₃	-C(=O)NHNH ₂	

Table 72

Formula I: A = -B(OH)₂; X = See Table below; R³ = hydrocinnamoyl; R¹¹ = -N(CH₃)₂

Example No.	.1	.2	.3
72.1	-NH ₂	-NHCH(=NH)H	-CH ₂ NH ₂
72.2	-CH ₂ NHC(=NH)NH ₂	-NHC(=NH)NH ₂	

Table 73

Formula I: A = -B(pinanediol); X = -CH₂NH₂; R³ = -C(=O)CH₂CH₂CO₂H; R¹¹ = See Table below

Example No.	.1	.2	.3
73.1	-CH ₂ (m-PhCF ₃)	-CH ₂ (m-PhCH ₃)	

Table 74

Formula I: A = -B(pinanediol); X = -NHC(=NH)NH₂; R³ = See Table below; R¹¹ = -CH₃

Example No.	.1	.2	.3
74.1	2-(benzyl)-benzyl	2-(benzyl)-benzyl; R ¹¹ = -C(=O)CH	2-(pyrrol-1-ylmethyl)benzyl
74.2	2-(2-methylbenzyl)-benzovl	3-(3-trifluoromethylbenzyl)-benzovl	3-(3-chlorobenzyl)-benzovl

74.3	2-(2-cyano-benzyl)benzoyl		
------	---------------------------	--	--

Table 75

Formula I: A = -B(OH)₂; X = -NHC(=NH)NH₂; R³ = See Table below; R¹¹ = -CH₃

Example No.	.1	.2	.3
75.1	2-(benzyl)-benzyl	2-(benzyl)-benzyl; R ¹¹ = -C(=O)CH	2-(pyrrol-1-ylmethyl)benzyl
75.2	2-(2-methylbenzyl)-benzoyl	3-(3-trifluoromethylbenzyl)-benzoyl	3-(3-chlorobenzyl)-benzoyl
75.3	2-(2-cyano-benzyl)benzoyl		

Table 76

Formula I: A = -B(OH)₂; X = -CH₂NHC(=NH)H; R³ = See Table below; R¹¹ = -cyclopropyl

Example No.	.1	.2	.3
76.1	hydrocinnamoyl	-C(=O)CH ₂ OPh	-C(=O)CH ₂ SPh

Table 77

Formula I: A = -B(pinenediol); X = -CH₂NHC(=NH)H; R³ = See Table below; R¹¹ = -cyclopropyl

Example	.1	.2	.3
No.			
77.1	hvdrocinnamovl	-C(=O)CH ₂ OPh	-C(=O)CH ₂ SPh

Table 78

Formula I: A = -B(OH)₂; X = -CH₂NH₂; R³ = See Table below;
R¹¹ = -cyclopropyl

Example	.1	.2	.3
No.			
78.1	hydrocinnamovl	-C(=O)CH ₂ OPh	-C(=O)CH ₂ SPh

Table 79

Formula I: A = -B(pinanediol); X = -CH₂NH₂; R³ = See Table below;
R¹¹ = -cyclopropyl

Example	.1	.2	.3
No.			
79.1	hvdrocinnamovl	-C(=O)CH ₂ OPh	-C(=O)CH ₂ SPh

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
 (i) APPLICANT: Galemme, et al.
 (ii) TITLE OF INVENTION: ELECTROPHILIC PEPTIDE ANALOGS
 AS INHIBITORS OF TRYPSIN LIKE ENZYMES
 (iii) NUMBER OF SEQUENCES: 3
 (iv) CORRESPONDENCE ADDRESS:
 (A) ADDRESSEE: THE DUPONT MERCK PHARMACEUTICAL
 COMPANY
 (B) STREET: 1007 MARKET STREET
 LEGAL DEPARTMENT
 (C) CITY: WILMINGTON
 (D) STATE: DE
 (E) COUNTRY: U.S.A.

(F) ZIP: 19898

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.50 INCH DISK
 (B) COMPUTER: APPLE MACINTOSH
 (C) OPERATING SYSTEM: APPLE MACINTOSH
 (D) SOFTWARE: MICROSOFT WORD

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: N/A
 (B) FILING DATE: HERewith
 (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: REINERT, NORBERT F.
 (B) REGISTRATION NUMBER: 18,926
 (C) REFERENCE/DOCKET NUMBER: DM-6666

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 302-892-8867
 (B) TELEFAX: 302-892-8536

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14
 (B) TYPE: amino acid
 (C) TOPOLOGY: linear

(ii) MOLECULAR TYPE: peptide

(vi) ORIGINAL SOURCE: synthetic

(ix) FEATURE:

(D) OTHER INFORMATION: thrombin inhibitor

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Leu Ser Asn Leu Ser Asn Leu Ser Asn Leu Ser Asn
 1 5 10

Gly

- (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14
 (B) TYPE: amino acid
 (C) TOPOLOGY: linear
(ii) MOLECULAR TYPE: peptide
(vi) ORIGINAL SOURCE: synthetic
(ix) FEATURE:
 (D) OTHER INFORMATION: thrombin inhibitor
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu Ser Asn Leu Ser Asn Leu Ser Asn Leu Ser Asn
1 5 10

Gly

- (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14
 (B) TYPE: amino acid
 (C) TOPOLOGY: linear
(ii) MOLECULAR TYPE: peptide
(vi) ORIGINAL SOURCE: synthetic
(ix) FEATURE:
 (D) OTHER INFORMATION: thrombin inhibitor
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Leu Ser Asn Leu Ser Asn Leu Ser Asn Leu Ser Asn
1 5 10

Gly

275

Utility

The compounds which are described in the present invention represent a novel class of potent, reversible inhibitors of trypsin-like enzymes. Trypsin-like enzymes are a group of proteases which hydrolyzed peptide bonds at basic residues liberating either a C-terminal arginyl or lysyl residue. Among these are enzymes of the blood coagulation and fibrinolytic system required for hemostasis. They are Factors II, X, VII, IX, XII, kallikrein, tissue plasminogen activators, urokinase-like plasminogen activator, and plasmin. Enzymes of the complement system, acrosin (required for fertilization), pancreatic trypsin are also in this group. Elevated levels of proteolysis by these proteases can result in disease states. For example, consumptive coagulopathy, a condition marked by a decrease in the blood levels of enzymes of both the coagulation system, the fibrinolytic system and accompanying protease inhibitors is often fatal. Intervention by a synthetic inhibitor would clearly be valuable. More specifically, proteolysis by thrombin is required for blood clotting. Inhibition of thrombin results in an effective inhibitor of blood clotting. The importance of an effective inhibitor of thrombin is underscored by the observation that conventional anticoagulants such as heparin (and its complex with the protein inhibitor, antithrombin III) are ineffective in blocking arterial thrombosis associated with myocardial infarctions and other clotting disorders. However, a low molecular weight thrombin inhibitor, containing a different functionality, was effective in blocking arterial thrombosis (Hanson and Harker, *Proc. Natl. Acad. Sci. U.S.A.* **85**, 3184 (1988)). Therefore, we have chosen to demonstrate utility of compounds in the inhibition of thrombin, both as in

buffered solutions and in plasma. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as
5 anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes.

Compounds of the present invention are expected to be effective in the control of aberrant proteolysis and a number of accompanying disease states such as
10 inflammation, pancreatitis, and hereditary angioedema.

The effectiveness of compounds of the present invention as inhibitors of blood coagulation proteases was determined using purified human proteases and synthetic substrates following procedures similar to
15 those described in Kettner et al. (1990).

For these assays, the rate of enzymatic (thrombin, Factor Xa, and Factor VIIa) hydrolysis of chromogenic substrates (S2238 (H-D-Phe-Pip-Arg-pNA), S2222, and S2288, respectively; Kabi Pharmacia, Franklin, OH) was
20 measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nm. A decrease in the rate of
25 absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, K_i .

Thrombin and Xa determinations were made in 0.10 M
30 sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5 % PEG 8000. VIIa determinations were made in 0.05 M tris buffer, pH 7.6, containing 0.10 M NaCl, 4 mM CaCl_2 , and 0.1% bovine serum albumin. The Michaelis constant, K_m , for substrate hydrolysis was
35 determined at 25 °C using the method of Lineweaver and Burk.

Values of K_i were determined by allowing 0.2 - 0.5 nM human thrombin or human factor Xa (Enzyme Research Laboratories, South Bend, IN) , or 50 nM human factor VIIa (BiosPacific, Emeryville, CA) react with the substrate (0.20 mM - 1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate K_i values.

$$\frac{v_o - v_s}{v_s} = \frac{I}{K_i (1 + S/K_m)}$$

where:

- v_o is the velocity of the control in the absence of inhibitor;
- v_s is the velocity in the presence of inhibitor;
- I is the concentration of inhibitor;
- K_i is the dissociation constant of the enzyme-inhibitor complex;
- S is the concentration of substrate;
- K_m is the Michaelis constant.

Using the methodology described above, representative compounds of this invention were evaluated and found to exhibit a K_i of less 500 μ M thereby confirming the utility of compounds of the invention as effective inhibitors of human blood coagulation proteases. The results of these assays are summarized in Table 80, where +++ indicates a $K_i < 500$ nM; ++ indicates a $K_i < 50,000$ nM; and + indicates a $K_i 500,000 < \text{nM}$; - indicates inactive.

Table 80. K_i values for inhibition of Serine Proteases by compounds of the present invention.

Ex No.	Thrombin	Factor Xa	Factor VIIa	IC50 Thrombin time
49.1.1	+++	++	inactive	NT
49.1.2	+++	NT	NT	+++
49.1.3	+++	+++	NT	+++
49.2.1	+++	+++	NT	++
50.1.1	NT	NT	NT	NT
50.1.2	+++	NT	NT	+++
50.1.3	+++	NT	NT	NT
51.1.1	+++	+++	++	NT
51.1.2	+++	NT	NT	NT
52.1.1	+++	+++	++	NT
52.1.2	+++	+++	++	+++
53.1.1	+++	+++	+++	+++
53.1.2	+++	+++	+++	+++
53.2.1	+++	NT	NT	++
53.2.2	+++	+++	+++	NT
53.4.3	+++	++	+++	NT
54.1.1	+++	NT	NT	NT
54.1.2	+++	++	+++	+++
54.1.3	+++	++	+++	NT
54.2.1	+++	NT	NT	++
54.2.2	+++	NT	NT	++
54.2.3	+++	++	++	NT
54.3.1	+++	++	++	NT
54.3.2	+++	++	+++	NT
54.3.3	NT	++	+++	NT
54.4.1	NT	++	++	NT
54.4.2	+++	++	+++	+++
54.4.3	+++	++	+++	++
55.1.1	+++	+++	+++	NT
56.1.1	+++	+++	+++	NT
56.1.2	+++	+++	+++	NT
56.3.3	+++	+++	+++	NT
56.4.1	NT	NT	NT	NT


57.1.1	+++	+++	+++	NT
57.1.2	+++	+++	+++	NT
57.4.2	+++	++	NT	+++
58.1.1	+++	+++	+++	NT
58.3.3	NT	NT	NT	NT
58.4.1	NT	NT	NT	NT
58.4.2	++	NT	NT	NT
59.1.1	+++	++	+++	NT
59.4.2	+++	++	NT	+++
60.1.1	+++	++	NT	NT
60.3.3	+++	++	++	NT
60.4.1	+++	++	++	NT
60.4.2	+++	NT	NT	NT
61.1.1	+++	++	++	NT
61.1.2	++	Inactive	Inactive	NT
61.1.3	++	++	Inactive	NT
61.2.1	++	++	++	NT
61.2.2	++	Inactive	Inactive	NT
61.2.3	NT	Inactive	Inactive	NT
61.3.1	++	Inactive	Inactive	NT
61.3.2	++	Inactive	Inactive	NT
61.3.3	++	++	inactive	NT
61.4.1	+++	++	++	++
62.1.1	++	++	++	NT
62.1.2	++	++	++	NT
62.1.3	+++	+++	+++	NT
62.2.1	++	++	++	NT
62.2.2	+++	+++	++	NT
62.2.3	++	++	++	NT
62.3.1	++	++	++	NT
62.3.2	+++	+++	++	NT
62.3.3	+++	+++	+++	NT
62.4.1	+++	+++	+++	NT
62.4.2	+++	+++	++	NT
62.4.3	+++	+++	++	++

63.1.3	+++	+++	++	NT
63.3.1	+++	++	inactive	NT
63.4.1	+++	+++	++	+++
63.4.2	+++	+++	++	++
63.5.1	++	++	inactive	NT
64.1.1	+++	++	++	Inactive
64.1.2	+++	++	+++	NT
64.1.3	+++	NT	NT	++
64.2.2	+++	+++	++	NT
64.2.3	+++	+++	+++	NT
65.1.3	+++	NT	NT	++
66.1.1	+++	+++	++	++
66.1.2	+++	NT	++	NT
66.1.3	+++	NT	++	NT
66.3.2	+++	+++	+++	+++
67.1.2	+++	++	++	NT
67.1.3	+++	+++	++	NT
67.3.2	+++	NT	NT	NT
68.2.1	+++	++	++	NT
68.3.1	+++	++	++	NT
68.3.3	+++	++	++	++
68.4.1	+++	+++	++	++
68.4.2	+++	NT	NT	NT
69.1.1	+++	+++	++	++
69.2.1	+++	NT	+++	NT
69.2.2	+++	NT	+++	NT
69.2.3	+++	NT	++	NT
69.3.2	+++	+++	+++	+++
69.4.1	+++	++	++	NT
69.4.2	+++	NT	NT	NT
70.4.2	++	++	inactive	NT
71.4.2	++	NT	NT	NT
72.1.3	+++	NT	NT	+++
73.1.2	+++	+++	++	NT
75.3.1	NT	NT	+++	NT

76.1.1	+++	NT	NT	NT
77.1.1	+++	NT	NT	NT
78.1.2	+++	NT	NT	+++
78.1.3	+++	NT	NT	+++
79.1.2	+++	NT	NT	+++
79.1.3	+++	NT	NT	+++

WHAT IS CLAIMED IS:


1. A compound of formula (I):



or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein:

R¹ is

- a) -(C₁-C₁₂ alkyl)-X,
- b) -(C₁-C₁₂ alkenyl)-X, or
- c)




X is

- a) halogen,
- b) -CN,
- c) -NO₂,
- d) -CF₃,
- e) -NH₂,
- f) -NHR²,
- g) -NHC(=NH)R²,
- h) -NHC(=NH)NHOH,
- i) -NHC(=NH)NHNH₂,
- j) -NHC(=NH)NHCN,
- k) -NHC(=NH)NHR²,
- l) -NHC(=NH)NHCOR²,

283


- k) $-C(=NH)NHR^2$,
 l) $-C(=NH)NHCOR^2$,
 m) $-C(=O)NHR^2$,
 n) $-CO_2R^2$,
 5 o) $-OR^2$,
 p) $-OCF_3$,
 q) $-S(O)_rR^2$,
 r) $-SC(=NH)NHR^2$, or
 s) $-SC(=NH)NHC(=O)R^2$;
- 10 R^2 is
- a) hydrogen, or
 b) C_1-C_4 alkyl;
- 15 R^3 is
- a) $-C(=O)-aryl$,
 b) $-C(=O)-(CH_2)_p-CR^6R^7-(CH_2)_q-aryl$,
 c) $-C(=O)-(C_2-C_5 \text{ alkenyl})-aryl$,
 d) $-C(=O)-W-CR^8R^9-aryl$, with the proviso that W
 20 cannot be a bivalent oxygen atom,
 e) $-C(=O)-CR^8R^9-W-(CH_2)_r-aryl$, with the proviso
 that W cannot be $-NR^4-$ or $-NC(=O)R^4-$,
 f) $-C(=O)-heteroaryl$,
 g) $-C(=O)-(CH_2)_p-CR^6R^7-(CH_2)_q-heteroaryl$,
 25 h) $-C(=O)-(C_2-C_5 \text{ alkenyl})-heteroaryl$,
 i) $-C(=O)-W-CR^8R^9-heteroaryl$,
 j) $-C(=O)-CR^8R^9-W-(CH_2)_r-heteroaryl$, with the
 proviso that W cannot be $-NR^4-$ or $-NC(=O)R^4-$,
 k) $-C(=O)-heterocycle$,
 30 l) $-C(=O)-(CH_2)_p-CR^6R^7-(CH_2)_q-heterocycle$,
 m) $-C(=O)-(C_2-C_5 \text{ alkenyl})-heterocycle$,
 n) $-C(=O)-W-CR^8R^9-heterocycle$,
 o) $-C(=O)-CR^8R^9-W-(CH_2)_r-heterocycle$, with the
 proviso that W cannot be $-NR^4-$ or $-NCOR^4-$,
 35 p) $-C(=O)-(CH_2)_t-adamantyl$.

- q) $-\text{C}(=\text{O})-(\text{CH}_2)_t-(\text{C}_5\text{-C}_7 \text{ cycloalkyl})$,
 r) $-\text{C}(=\text{O})-(\text{CH}_2)_t-\text{W}-(\text{C}_5\text{-C}_7 \text{ cycloalkyl})$,
 s)



5 $(\text{CH}_2)_t\text{-aryl}$, wherein aryl is limited to phenyl,


t)




10

$(\text{CH}_2)_p\text{-W}-(\text{CH}_2)_q\text{-aryl}$, wherein aryl is limited to phenyl,

u)




v)



15


285

w)



5


x)




with the proviso that R^{13} cannot be $-N(C_1-C_4 \text{ alkyl})_2$ when A is $-C(=O)R^{14}$,

10

y)




z)




15

aa)




bb)




5

cc)





dd)




10


ee)



5




hh)




10

ii)


288



- jj) $-(C(=O)-(CR^8R^9)-NR^{11'})_v-R^{11}$;
 5 kk) $-(C(=O)-(CR^8R^9)-NR^{11'})_v-C(=O)R^{11}$;
 ll) $-(C(=O)-(CR^8R^9)-NR^{11'})_v-C(=S)R^{11}$;
 mm)




nn)




10

- oo) $-C(=O)-(CR^8R^9)-NHS(O)_rR^8$;
 pp)



15

qq)



R^4 and R^5 are independently selected at each occurrence from the group consisting of:

- a) hydrogen,
- b) C₁-C₄ alkyl,
- c) -(C₁-C₄ alkyl)-aryl, or
- d) C₅-C₇ cycloalkyl;

5

R⁶, R⁷, R⁸ and R⁹ are independently selected at each occurrence from the group consisting of:

- a) hydrogen,
- b) C₁-C₄ alkyl,
- 10 c) C₁-C₄ alkoxy,
- d) aryl,
- e) -(C₁-C₄ alkyl)-aryl,
- f) -(C₁-C₄ alkyl)-heterocycle,
- g) -O-aryl,
- 15 h) -(CH₂)_p-CO₂R⁴,
- i) R⁶ and R⁷ can be taken together to form a (C₂-C₇) alkyl, or
- j) R⁸ and R⁹ can be taken together to form a (C₂-C₇) alkyl;

20

R¹⁰ is:


- phenyl, wherein phenyl is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₇-C₁₅ alkylaryl, C₇-C₁₅ alkoxyaryl, methylenedioxy, -NO₂, -CF₃, -SH, -S(O)_r-(C₁-C₄ alkyl), CN, -OH, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -NHCOR⁴, -(CH₂)_p-CO₂R⁴;

25

30 R¹¹ is:


- a) C₁-C₄ alkyl,
- b) C₃-C₆ cycloalkyl,
- c) -OR⁴,
- d) -NR¹⁵R¹⁶,
- 35 e) -NC(=O)R¹⁵R¹⁶,
- f) -NR¹⁵C(=O)OR⁴,

- g) aryl,
 h) -(C₁-C₄ alkyl)-aryl,
 i) heteroaryl,
 j) -(C₁-C₄ alkyl)-heteroaryl,
 5 k) -(C₁-C₄ alkyl)-CO₂R⁴,
 l) heterocycle,
 m) -(C₁-C₄ alkyl)heterocycle,
 n)




10


o)



p)




q)



15

, or


r)



291


R^3 and R^{11} , when taken together to form a ring bonded to the nitrogen:

a)




5

b)





10



c)



d)




5



10





R^4 and R^{11} can also be taken together to form $-(CH_2)_2-$;

5 $R^{11'}$ is independently selected at each occurrence from the group consisting of:

- a) hydrogen;
- b) C_1-C_4 alkyl
- c) $-OR^4$
- 10 d) $-NR^{15}R^{16}$
- e) $-NC(=O)R^{15}R^{16}$
- f) $-NR^{15}C(=O)OR^4$
- g) aryl,
- h) $-(C_1-C_4 \text{ alkyl})\text{-aryl}$,
- 15 i) heteroaryl,
- j) $-(C_1-C_4 \text{ alkyl})\text{-heteroaryl}$,
- k) $-(C_1-C_4 \text{ alkyl})\text{-CO}_2R^4$,
- l) heterocycle,
- m) $-(C_1-C_4 \text{ alkyl})\text{heterocycle}$,

20

R^{13} is independently selected at each occurrence from the group consisting of:

- a) hydrogen
- 25 b) halogen,
- c) C_1-C_4 alkyl,
- d) C_1-C_4 alkoxy,
- e) methylenedioxy,
- f) $-NO_2$,
- 30 g) $-CF_3$,

- h) -SH,
- i) $-S(O)_r-(C_1-C_4 \text{ alkyl})$,
- j) -CN,
- k) -OH,
- 5 l) $-NH_2$,
- m) $-NH(C_1-C_4 \text{ alkyl})$,
- n) $-N(C_1-C_4 \text{ alkyl})_2$,
- o) $-NHC(=O)R^4$, or
- p) $-(CH_2)_p-CO_2R^4$;

10

 R^{14} is:

- a) $-CF_3$,
- b) $-CHF_2$,
- c) $-CH_2F$,
- 15 d) $-CH_2Cl$,
- e) $-C(=O)OR^4$,
- f) $-C(=O)NR^{15}R^{16}$,
- g) $-C(=O)R^4$,
- h) $-C(=O)COOR^4$,
- 20 i) $-C(=O)C(=O)NR^{15}R^{16}$,
- j) $-C(=O)C(=O)R^4$,
- k) $-CY^3Y^4COOR^4$,
- l) $-CY^3Y^4C(=O)NR^{15}R^{16}$, or
- m) $-CY^3Y^4C(=O)R^4$;

25

R^{15} and R^{16} are independently selected at each occurrence from the group consisting of:


- a) hydrogen,
- b) C_1-C_4 alkyl,
- 30 c) $-(C_1-C_4 \text{ alkyl})\text{-aryl}$,
- d) C_5-C_7 cycloalkyl, or
- e) phenyl, unsubstituted or substituted by R^{13} ;

R^{15} and R^{16} taken together to form a ring can also include:


35

- a)

295



b)

5 R¹⁷ is:

- a) hydrogen,
- b) C₁-C₄ alkyl,
- c) aryl,
- d) -(C₁-C₄ alkyl)-aryl, or
- 10 e) C₅-C₇ cycloalkyl;

R¹⁸ is:

- a) hydrogen,
- b) -(C₁-C₅) alkyl, or
- 15 c) -(C₁-C₅) haloalkyl,
- d) -(C₁-C₅) alkoxy;

R¹⁹ is:

- a) hydrogen,
- 20 b) -(C₁-C₅) alkyl,
- c) halo, or
- d) -(C₁-C₅) haloalkyl,
- e) -NO₂,
- f) -NR⁴R⁵,
- 25 g) -CN,
- h) -(C₁-C₅) alkoxy;

R²⁰ is

- a) hydrogen; or
- 30 b) -N² with amine protecting;

A is:

- a) $-BY^1Y^2$, or
- b) $-C(=O)R^{14}$,
- c) $C(OH)R^{14}R^{18}$;

5

W is

- a) $-O-$,
- b) $-S(O)_r-$,
- c) $-NR^4-$, or
- d) $-NC(=O)R^4-$;

10

y^1 and y^2 are

- a) $-OH$,
- b) $-F$,
- c) $-NR^4R^5$,
- d) C_1-C_8 alkoxy, or

15

when taken together y^1 and y^2 form:

- e) a cyclic boron ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O,
- f) a cyclic boron amide where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O,
- g) a cyclic boron amide-ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O;

20

25

30

y^3 and y^4 are

- a) $-OH$ or
- b) $-F$;

35 n is 0 or 1;

p is 0 to 3;

q is 0 to 4;
r is 0 to 2;
t is 1 to 3;
v is 1 to 17;

5

wherein aryl is defined as phenyl, fluorenyl, biphenyl and naphthyl, which may be unsubstituted or include optional substitution with one to three substituents;

- 10 heteroaryl is 2-, or 3-, or 4-pyridyl; 2-or 3-furyl; 2-or 3-benzofuranyl; 2-, or 3-thiophenyl; 2- or 3-benzo[b]thiophenyl; 2-, or 3-, or 4-quinolinyl; 1-, or 3-, or 4-isoquinolinyl; 2- or 3-pyrrolyl; 1- or 2- or 3- indolyl; 2-, or 4-, or 5-oxazolyl; 2-benzoxazolyl ;
15 2- or 4- or 5-imidazolyl; 1- or 2- benzimidazolyl; 2- or 4- or 5-thiazolyl; 2-benzothiazolyl; 3- or 4- or 5-isoxazolyl; 3- or 4- or 5-pyrazolyl; 3- or 4- or 5-isothiazolyl; 3- or 4-pyridazinyl; 2- or 4- or 5-pyrimidinyl; 2-pyrazinyl; 2-triazinyl; 3- or 4-
20 cinnolinyl; 1-phthalazinyl; 2- or 4-quinazolinyl; or 2-quinoxaliny ring; said ring(s) may be unsubstituted or include optional substitution with one to three substituents.

- 25 heterocycle is tetrahydroisoquinoline, tetrahydroquinoline, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, morpholino; said ring(s) may be unsubstituted or include optional substitution with one to three
30 substituents.

- the substituents that may be attached to the aryl, heteroaryl and heterocycle ring(s) may be independently selected at each occurrence from the group consisting
35 of:
halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, methylenedioxy,

-NO₂, -CF₃, -SH, -S(O)_r-(C₁-C₄ alkyl), CN, -OH, -NH₂,
 -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -NHC(=O)R⁴, -(CH₂)_p-
 CO₂R⁴, phenyl which may be unsubstituted or substituted
 with R¹³.

5

2. A compound of claim 1 wherein:

A is -BY¹Y²;

10

heteroaryl is 2-, 3-, or 4-pyridyl; 2-, or 3-furyl; 2-,
 or 3-thiophenyl; 2-, 3-, or 4-quinolinyl; or 1-, 3-, or
 4-isoquinolinyl which may be unsubstituted or include
 optional substitution with one to three substituents;

15

heterocycle is 1-, 3-, or 4-tetrahydroisoquinolinyl, 2-
 or 3-pyrrolidinyl, and 2-, 3- or 4-piperidinyl which
 may be unsubstituted or include optional substitution
 with one to three substituents.

20

3. A compound of claim 2 selected from the group
 consisting of:

Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn-C10H16 HCl

25 Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn(CH=NH)-
 C10H16 HCl

Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn(CH=NH)-OH
 HCl

30 Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroArg(CH₃)-C10H16
 HCl

Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroLys-C10H16 HCl

Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroLys-OH HCl

Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroOrn-C10H16 HCl

35 Hydrocinnamoyl-[N-(N(CH₃)₂)-Gly]-boroOrn(CH=NH)-C10H16
 HCl

Methanesulfonyl-Sar-[N-(Phenethyl)-Gly]-boroLys-C10H16

- HCl
- Methanesulfonyl-Sar-[N-(Phenethyl)-Gly]-boroLys-OH HCl
- Methanesulfonyl-Gly-[N-(Phenethyl)-Gly]-boroLys-C10H16
HCl
- 5 Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-
boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-
boroLys-OH HCl
- Hydrocinnamoyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-
10 C10H16 HCl
- Hydrocinnamoyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-
OH HCl
- Succinyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-C10H16
HCl
- 15 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
boroLys-OH HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-
boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-
20 boroLys-OH HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-
boroOrn(CH=NH)-OH HCl
- Hydrocinnamoyl-[N-(2,2-(Diethyl)-Phenethyl)-Gly]-
boroLys-C10H16 HCl
- 25 Hydrocinnamoyl-Sar-Lys[C(=O)-C(=O)-OH]
(2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH₂]₃-Br]-
C10H16
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH₂]₄-
Br]-C10H16
- 30 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroIrg-C10H16 HBr
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH₂]₃-N₃]-
C10H16
- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-borohomoIrg-C10H16
HBr
- 35 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroGly[CH₂]₄-
N₃]-C10H16

- (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroOrn-C10H16 HCl
 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-borohomoArg-C10H16
 HCl
 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroArg-C10H16 HCl
 5 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroOrn(CH=NH)-
 C10H16 HCl
 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroLys(CH=NH)-
 C10H16 HCl
 2-Benzyl-(N-Benzyl)-Sar-boroLys-C10H16 HCl
 10 2-Thiophenyl-Benzoyl-Sar-boroLys(CH=NH)-C10H16
 2-(Thiophenyl)-Benzoyl-Sar-boroIrg-C10H16 HBr
 2-(Thiophenyl)-Benzoyl-Sar-boroOrn-C10H16 HCl
 2-(Thiophenyl)-Benzoyl-Sar-boroOrn(CH=NH)-C10H16 HCl
 Pinanediol N-{N-methyl-N-[2-(Thiophenyl)-Benzoyl]Sar}-
 15 1-amido-5-thiocyanatobutane boronate
 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroLys-C10H16 HCl
 Acetyl-Gly[N-(2-(Benzyl)-Benzyl)]-boroLys-C10H16 HCl
 Pinanediol N-{N-methyl-N-[2-(pyrrol-1-ylmethyl)-
 Benzyl]glycyl}-1-amido-5-aminopentaneboronate,
 20 hydrochloride salt
 N-{N-methyl-N-[2-(pyrrol-1-ylmethyl)-Benzyl]glycyl}-1-
 amido-5-aminopentaneboronic acid, hydrochloride
 salt 2-(2-(Trifluoromethyl)-Benzyl)-Benzoyl-Sar-
 Lys-C(=O)-NHNH2 2 HCl
 25 2-(Benzyl)-Benzoyl-Sar-Lys-C(=O)-NHNH2 2 HCl
 [3-(Trifluoromethyl)-Benzyl]-Benzoyl-Sar-boroLys-C10H16
 HCl
 3-(3-(Chloro)-Benzyl)-Benzoyl-Sar-boroLys-C10H16 HCl
 Hydrocinnamoyl-Sar-Lys(Z)-C(=O)-O-(CH2)2-NH(Z)
 30 Hydrocinnamoyl-Sar-Lys-C(=O)-O-(CH2)2-NH2 2 HCl
 Hydrocinnamoyl-Sar-Lys(Z)-C(=O)-OCH3
 Hydrocinnamoyl-Sar-Lys-C(=O)-OCH3 HCl
 Hydrocinnamoyl-Sar-Lys-C(=O)-CH3 HCl
 Hydrocinnamoyl-Sar-Lys(Z)-H
 35 Hydrocinnamoyl-Sar-NHCH(CH2OH)(CH2)4-NH(Z)
 Hydrocinnamoyl-Sar-NHCH(CH2OH)(CH2)4-NH2

- Hydrocinnamoyl-Sar-Lys[CH(OH)(OCH₃)-C(=O)-OCH₃] HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn-C10H16 HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys-OH HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn(CH=NH)-OH
 5 HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroOrn(CH=NH)-
 C10H16 HCl
 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys(CH=NH)-
 C10H16 HCl
 10 Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys(CH=NH)-OH
 HCl
 Phenoxyacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl
 Thiophenacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl
 Phenoxyacetyl-[N-(Cyclopropyl)-Gly]-boroLys-OH HCl
 15 Thiophenacetyl-[N-(Cyclopropyl)-Gly]-boroLys-OH HCl
 Hydrocinnamoyl-[N-(N-(Methyl)-Phenyl)-Gly]-boroLys-
 C10H16 HCl
 Hydrocinnamoyl-[N-(N-(Methyl)-Phenyl)-Gly]-boroLys-OH
 HCl
 20 Hydrocinnamoyl-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-
 C10H16 HCl
 Glutaryl-[N-(Phenethyl)-Gly]-boroLys-OH HCl
 Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-
 C10H16
 25 Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-
 boroLys-C10H16 HCl
 Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-OH
 Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-
 boroLys-OH HCl
 30 Boc-Asp-[N-(Phenethyl)-Gly]-boroLys-C10H16
 Boc-Glu-[N-(Phenethyl)-Gly]-boroLys-C10H16
 Boc-Glu(OCH₃)-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl
 Boc-Glu-[N-(Phenethyl)-Gly]-boroLys-OH
 Hydrocinnamoyl-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-OH
 35 HCl
 Methanesulfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-

- boroLys-C10H16 HCl
 Methanesulfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-
 boroLys-OH HCl
 Hydrocinnamoyl-[N-(Succinyl)-Gly]-boroLys-C10H16
 5 Hydrocinnamoyl-[N-(Methyl Succinyl)-Gly]-boroLys-C10H16
 HCl
 Succinyl-[N-(Phenethyl)-Gly]-boroLys-OH
 Methyl Succinyl-[N-(Phenethyl)-Gly]-boroLys-OH HCl
 Glutaryl-[N-(Phenethyl)-Gly]-boroLys-C10H16
 10 Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl
 Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys-OH HCl
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂CH₂Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(CH₃)₂Ph)]-Gly-boroLys-OH
 [N-(-C(O)(CH₂)₂Ph)-N-(CH₂C(ethanediyl)Ph)]-Gly-boroLys-
 15 OH
 Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-
 boroArg-C10H16 HCl
 Hydrocinnamoyl-[N-(2-(Cyclopentyl)-Phenethyl)-Gly]-
 boroLys-C10H16 HCl
 20 (2-(2-Cyano)-Thiophenyl)-Benzoyl-Sar-boroArg-OH HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 boroLys-C10H16 HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 boroOrn-C10H16 HCl
 25 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 boroLys-OH HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 boroArg-C10H16 HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 30 boroOrn(CH=NH)-C10H16 HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 boroArg-OH HCl
 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 boroOrn(CH=NH)-OH HCl
 35 Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-
 boroOrn-C10H16 HCl

- Hydrocinnamoyl-{N-(2,2-(Dimethyl)-Phenethyl)-Gly}-
boroLys-ClOH16 HCl
- Hydrocinnamoyl-{N-[2-(3,5-dimethylphenyl)-ethyl]-Gly}-
boroOrn-ClOH16 HCl
- 5 Hydrocinnamoyl-{N-[2-(3,5-dimethylphenyl)-ethyl]-Gly}-
boroLys-ClOH16 HCl
- Hydrocinnamoyl-{N-[2,2-(Dimethyl)-2-(3,5-
dimethylphenyl)-ethyl]-Gly}-boroArg-ClOH16 HCl
- Hydrocinnamoyl-{N-[2,2-(Dimethyl)-2-(3,5-
10 dimethylphenyl)-ethyl]-Gly}-boroOrn(CH=NH)-ClOH16
HCl
- Hydrocinnamoyl-{N-[2-(3,5-dimethylphenyl)-ethyl]-Gly}-
boroArg-ClOH16 HCl
- Hydrocinnamoyl-{N-[2-(3,5-dimethylphenyl)-ethyl]-Gly}-
15 boroOrn(CH=NH)-ClOH16 HCl
- Hydrocinnamoyl-[N-(Cyclohexyl)-Gly]-boroLys-ClOH16 HCl
- Hydrocinnamoyl-[N-(Cyclopropyl)-Gly]-boroLys-ClOH16 HCl
- Hydrocinnamoyl-[N-(Cyclohexyl)-Gly]-boroLys-OH HCl
- 20 4. A pharmaceutical composition comprising a
pharmaceutically suitable carrier and a therapeutically
effective amount of a compound of claim 1.
5. A pharmaceutical composition comprising a
25 pharmaceutically suitable carrier and a therapeutically
effective amount of a compound of claim 2.
6. A pharmaceutical composition comprising a
pharmaceutically suitable carrier and a therapeutically
30 effective amount of a compound of claim 3.
7. A method of treating a physiological
disorder in a warm blooded animal catalyzed by trypsin-
like enzymes comprising administering to an animal in
35 need such treatment an effective amount of a compound
of claim 1.

304

8. A method of treating a physiological disorder in a warm blooded animal catalyzed by trypsin-like enzymes comprising administering to an animal in
5 need such treatment an effective amount of a compound of claim 2.

9. A method of treating a physiological disorder in a warm blooded animal catalyzed by trypsin-
10 like enzymes comprising administering to an animal in need such treatment an effective amount of a compound of claim 3.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/11280

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/69; C07F 5/02, 5/04

US CL :514/64; 546/13; 548/110; 558/5,288,298; 562/7

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/64; 546/13; 548/110; 558/5,288,298; 562/7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

Database Searched: REGISTRY (Structure-based Search)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5,187,157 (KETTNER ET AL.) 16 FEBRUARY 1993, see columns 3, line 13-column 4, line 21.	1-9
A	US, A, 4,537,773 (SHENVI) 27 AUGUST 1985, see entire document.	1-9
A	US, A, 5,169,841 (KLEEMAN ET AL.) 08 DECEMBER 1992, see entire document.	1-9

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 DECEMBER 1994

Date of mailing of the international search report

10 JAN 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL G. AMBROSE

Telephone No. (703) 308-1235